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Summary 
Sepsis is not only the leading cause of death in non-coronary intensive care units 
(ICUs) but also one of the most common causes of morbidity and mortality for all 
hospitalised patients. Globally, 20 to 30 million patients are estimated to be afflicted 
every year with an astonishing hospital mortality rates between 30 and 60%. There is 
no current therapy for sepsis other than anti-infectives and supportive care. These 
approaches only give the body time to recover, but do not treat the cause of the 
problem.  
In this study we seek to discover the effects of the virulence factor from a bacterium, 
Yersinia pestis V antigen on LPS-induced responses. Y. pestis, the causative agent of 
the three main plague pandemics has been responsible for over 200 million deaths. 
The bacterium has been so successful because it encodes several virulence factors, 
one of which is V antigen.  
Our results demonstrate a modulatory role of Y. pestis V antigen on bacterial 
infections. Using monocytic and macrophage cells we have shown that V antigen can 
reduce the expression of pattern recognition receptors (PRRs) of the innate immune 
system, causing the modulation of the cellular response directed towards LPS bacterial 
pathogen-associated molecular patterns (PAMPs). We also tested different fractions of 
Y. pestis in order to identify the functional domain of responsible for this 
immunomodulation. Our results demonstrated that this functional domain in found 
within the amino acids 135-275 of V antigen.  
Of a greater magnitude, our in vivo data show an impressive 80% reduction in mortality 
in a mouse model of sepsis when mice are treated with V antigen in comparison to 
those that were not. This protein should unquestionably be further investigated as a 
possible therapeutic intervention for sepsis. 
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1.1. Sepsis 
Sepsis is one of the oldest and most puzzling conditions in medical history. Sepsis 
(σηψις), which is the original Greek word for the “decomposition of animal or vegetable 
organic matter in the presence of bacteria” was described by Hippocrates as the 
process by which flesh rots, generating foul odours and wound putrefaction (Majno, 
1991). The term sepsis is found in the Corpus Hippocraticum, but its earliest 
appearance is in Homer’s poems, where sepsis is derived of the verb form sepo 
(σηπω), meaning “I rot”. Aristoteles, Plutarch and Galen use sepsis in the same sense 
as Hippocrates. For 2,700 years the word “sepsis” has essentially maintained its core 
meaning (Geroulanos and Douka, 2006). 
Understanding of this condition took a great leap forward when the schools of 
Hippocrates (460-370 BC) and Galenos (Galen of Pergamum; AD 129-199) concluded 
that a poison was the dominant cause.  
 
Figure 1.1: Thirteen century fresco of Hippocrates (right) and Galenos (left). These two masters 
dominated European medical education and practice until the seventeenth century. The text on 
the paper in front of Galenos reads “Mundi presentis seres manet ex elementis”, meaning “The 
present world’s connection persists on the basis of the elements”. The text on the paper in front 
of Hippocrates reads “Ex his formantur que sunt quecu(m)q(ue) chreantur”, meaning “Of these 
(all) is formed which exists and which will be created” (Beutler and Rietschel, 2003). 
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Experiments preformed by Albrecht von Haller (1708-1777) and François Magendie 
(1783-1855) supported the hypothesis that poison was present in putrid matter. They 
showed that intravenous application of decomposed fish or meat to experimental 
animals caused symptoms of illness. It was Louis Pasteur (1822-1895) that 
conclusively linked the decay of organic matter to the presence of bacteria and 
microorganisms. He recognised that microbes were not only necessary, but sufficient, 
to cause an infectious disease (Beutler and Rietschel, 2003). In spite of this, the 
presence of bacteria did not entirely explain the pathogenesis of sepsis. Many patients 
with sepsis died despite the successful eradication of pathogens with the use of 
modern antibiotics. This lead researchers to suggest that it was the host, not the 
bacteria, that drove the pathogenesis of sepsis (Cerra, 1985). 
1.1.1. Definitions 
Systemic inflammatory response to infection has long been surrounded by confusion. 
Several terms have been used interchangeably: septicaemia, sepsis, sepsis syndrome 
and septic shock. In clinical practice, sepsis is a particularly unsettled term used in 
describing the body’s systemic response to infection. In 1991, The American College of 
Chest Physicians and the Society of Critical Care Medicine held a Consensus 
Conference with the aim of publishing the definitions of sepsis syndromes to clarify the 
terminology used to describe the body’s systemic response to infection (Bone et al., 
1992). The panel defined sepsis as a systemic inflammatory response to infection 
noting that sepsis could occur in response to multiple infectious causes. This lead to 
the proposal of the phrase systemic inflammatory response syndrome (SIRS) which 
describes a systemic inflammatory response, independent of its cause. The term 
septicaemia was deemed both unnecessary and unhelpful which lead to its elimination 
from current usage. The panel coined the terms “severe sepsis” to describe when 
sepsis is associated with organ dysfunction, and “septic shock” for sepsis complicated 
by hypotension that is refractory to fluid resuscitation (Bone et al., 1992). 
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Bacteraemia  The presence of viable bacteria in the blood 
SIRS 
The systemic inflammatory response to a variety of severe clinical 
insults which is manifested by two or more of the following conditions: 
1. Temperature >38ºC or <36ºC 
2. Heart rate >90 beats per minute 
3. Respiratory rate >20 breaths per minute or PaCO2 <32 mm Hg 
4. White blood cell count >12,000/cu mm, <4,000/cu mm, or >10% 
immature (band) forms. 
Sepsis The systemic inflammatory response (SIRS) as a result of infection. 
Severe sepsis 
Sepsis associated with organ dysfunction, hypoperfusion, or 
hypotension.  
Septic shock 
Sepsis-induced with hypotension despite adequate fluid resuscitation 
along with the presence of perfusion abnormalities that may include, but 
are not limited to, lactic acidosis, oliguria, or an acute alteration in 
mental status.  
Table 1.1: Definitions of bacteraemia, SIRS, sepsis, severe sepsis and septic shock (Bone et 
al., 1992). 
 
In 2001, a second panel, the International Sepsis Definitions Conference, revisited the 
1992 sepsis guidelines. Based on this conference a consensus document was 
developed (Levy et al., 2003). This document concluded that there was not enough 
evidence to support a change to the previous definitions aside from expanding the list 
of signs and symptoms of sepsis to reflect the clinical bedside experience. 
 
 
 
5 
 
 
 
 
 
 
 
 
 
Figure 1.2: The relationship between infection, SIRS, sepsis, severe sepsis and septic shock. 
Adapted from Bone et al. (1992). 
 
1.1.2. Incidence and causes 
The epidemiology of sepsis, severe sepsis and septic shock is not well known due to 
the absence of population based prospective cohort studies. Most of the studies on the 
epidemiology of sepsis are based on hospital discharge diagnoses. In 1990, the 
Centers for Disease and Control (CDC), based on data from the National Hospital 
Discharge Survey, estimated that in the United States there were 450,000 cases of 
sepsis per year (Centers for Disease, 1990). In 1995, based on the International 
Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes, 
Angus et al., in a large observational cohort study (n=6,621,559) identified 751,000 
cases of severe sepsis annually, representing an estimate of 3 cases per 1,000 
population and 2.26 cases per 100 hospital discharges (Angus et al., 2001). Using the 
National Hospital Discharge Survey database, Martin and co-workers identified 
10,319,418 cases of sepsis from an estimated 750 million hospitalizations in the United 
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States over a 22-year period, with an increase of frequency from 82.7 cases per 
100,000 population in 1979 to 240.4 cases per 100,000 population in 2000, meaning 
there was an annualized increase in the incidence of sepsis of 8.7% (Martin et al., 
2003). 
In European intensive care units, a Sepsis Occurrence in Acutely Ill Patients (SOPA) 
study collected data on all patients admitted to the intense care units (ICUs) during a 
two week period. A total of 3,147 adult patients were enrolled and 1,177 (37.4%) were 
diagnosed with sepsis (Vincent et al., 2006). 
Padkin and colleagues investigated the occurrence of severe sepsis in the first 24 
hours of admission in 91 general ICUs in England, Wales and Northern Ireland 
between 1995 and 2000. They found that from 56,673 adult admissions to ICUs 15,362 
(27.1%) had severe sepsis in the first 24 hours (Padkin et al., 2003). Using the 
Intensive Care National Audit & Research Centre (ICNARC) Case Mix Programme 
Database, Harrison et al. (2006) evaluated the admissions with severe sepsis occurring 
at any time within 24 hours of admissions to ICUs in England, Wales and Northern 
Ireland, between 1995 and 2005. From 342,860 admissions, 92,672 admissions (27%) 
were identified as having severe sepsis in the first 24 hours following admission. 
Harrison and co-workers also identified that the percentage of admission with severe 
sepsis during the first 24 hours increased from 23.5% in 1996 to 28.7% in 2004. This 
represents an estimated 31,000 annual admissions to all 240 adult general critical care 
units in England, Wales and Northern Ireland (Harrison et al., 2006). 
Severe sepsis can arise as a result of both public-acquired and health care-linked 
infections. Respiratory tract infections are the most common site of infection both in 
severe sepsis and in septic shock, followed by genitourinary and intraabdominal 
infections (Angus et al., 2001, Esper et al., 2006, Mayr et al., 2010, Vincent et al., 
2009). Blood cultures from patients with severe sepsis and septic shock are positive in 
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only one third of cases. This might occur due to the increase in empiric antibiotic 
treatment. In positive blood cultures, the most common Gram-positive microorganisms 
present are Staphylococcus aureus and Streptococcus pneumonia, whereas 
Escherichia coli, Klebsiella spp. and Pseudomonas aeruginosa are the more prevalent 
Gram-negative isolates (Angus et al., 2001). Martin et al. (2003) in an epidemiology 
study of sepsis from 1979 through 2000, showed that Gram-positive bacteria became 
the predominant organisms causing sepsis in comparison to Gram-negative infections. 
In spite of this, in a more recent study conducted by Vincent and colleagues (2009) 
involving 14,414 patients in 1265 ICUs from 75 countries, 62% of the positive isolates 
were Gram-negative organisms, 47% were Gram-positive and 19% were fungi (Vincent 
et al., 2009).  
Age, race and sex also influence the incidence of severe sepsis. The incidence of 
severe sepsis and septic shock is higher in infants and elderly persons than in other 
age groups, with a sharp increase in incidence in elderly people (Angus et al., 2001, 
Dombrovskiy et al., 2007, Harrison et al., 2006, Martin et al., 2003, Padkin et al., 2003, 
Vincent et al., 2006, Wang et al., 2007). Epidemiologic studies have shown a higher 
incidence of severe sepsis and septic shock in black people (Martin et al., 2003, Mayr 
et al., 2010). Several reports have also shown that men are more likely to develop 
sepsis than women (Angus et al., 2001, Bateman et al., 2010, Martin et al., 2003, 
Padkin et al., 2003, Vincent et al., 2006). 
1.1.3. Morbidity and Mortality 
Sepsis is not only the leading cause of death in non-coronary ICUs but also one of the 
most common causes of morbidity and mortality for all hospitalised patients (Alberti et 
al., 2003, Martin et al., 2003). Deaths related to severe sepsis exceed the number of 
persons with other diseases which are more likely to catch the public attention, such as 
breast cancer and AIDS (Moss, 2005). Angus et al. (2001) and Martin et al. (2003) 
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reported that the mortality rate in the United States due to sepsis was approximately 
30%, whereas Vincent and colleagues (2006) European ICU study show that the 
overall ICU and hospital mortality rates were 18.5 and 24.1%, respectively. The 
EPISEPSIS study group conducted a nationwide survey of patients with severe sepsis 
in 206 French ICUs over two consecutive weeks (Brun-Buisson et al., 2004). The 30-
day mortality rate was 35%. With regards to England, Wales and Northern Ireland, 
Padkin et al. (2003) showed that of the ICU admissions with severe sepsis, 35% died 
before ICU discharge and 47% died during their hospital stay, whereas Harrison and 
colleagues (2006) epidemiology study revealed that there was a 45% hospital mortality 
in 2004. A more recent study showed that in 2010 alone, 5.1% of deaths in England 
were associated with sepsis (McPherson et al., 2013).  
1.1.4. Cost of care 
Besides being among the leading causes in critically ill patients, sepsis and septic 
shock constitute an enormous economic burden. In the United States the annual cost is 
estimated at $16,7 billion, where the average length of stay and cost per case were 
19.6 days and $22,100 (Angus et al., 2001), and between 1997 and 2008, the inflation-
adjusted aggregate costs for treating patients hospitalized for this condition increased 
annually, on average, 11.9% (Hall et al., 2011).  
ICU costs relative to patients with septic shock have been analysed by Edbrooke et al. 
in 213 patients in the UK (Edbrooke et al., 1999). The median total cost of care for all 
septic patients was $10,623, a cost ratio of 6:1 compared with the cost care for non-
septic patients of $1,667. The finds of an analysis of 385 patients with severe sepsis 
from three German ICUs, show that the average costs were €23,297 per patient and 
€1,318 per day (Moerer et al., 2002). In both the UK and German studies the length of 
stay and personal costs of septic patients was significantly higher compared to non-
septic patients.  
9 
 
1.1.5. Clinical features 
The clinical manifestations of sepsis are very unpredictable, depending on the primary 
site of infection, the causative organism, the pattern of acute organ dysfunction, the 
patient underlying medical history and the gap before initiation of treatment. The signs 
of both infection and organ dysfunction can be trivial, therefore Levy and colleagues 
(2003) provided a list of warning signs of developing sepsis (Table 1.2). This list aims 
to codify the physical and laboratory findings that aid a clinician to determine whether 
or not a patient is developing sepsis. Acute organ dysfunction primarily affects the 
respiratory and cardiovascular systems. Respiratory compromise is manifested as the 
acute respiratory distress syndrome (ARDS), which is defined as hypoxemia with 
bilateral infiltrates with no cardiac evidence (Dellinger et al., 2013, Force et al., 2012). 
Cardiovascular compromise is manifested mostly as hypotension or an elevated blood 
lactate concentration (Dellinger et al., 2013).  
 
Sepsis (documented or suspected infection plus ≥1 of the following) 
General variables 
Fever (core temperature >38.3ºC) 
Hypothermia (core temperature, <36ºC) 
Heart rate (>90 beats per minute or >2 SD above the normal value for age) 
Tachypnea 
Altered mental status 
Significant edema or positive fluid balance (>20ml/kg over 24 hours) 
Hyperglycemia (plasma glucose >120 mg/dl or 7.7mmol/L) in the absence of diabetes 
Inflammatory variables 
Leukocytosis (white-cell count >12,000/mm3) 
Leukopenia (white-cell count <4000/mm3) 
Normal white-cell count with >10% immature forms 
Plasma C-reactive protein >2 SD above the normal value 
Plasma procalcitonin >2 SD above the normal value 
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Hemodynamic variables 
Arterial hypotention (systolic pressure <90 mmHg, mean arterial pressure <70, or 
decrease in systolic pressure of >40 mmHg in adults or <2 SD below normal for age). 
Mixed venous oxygen saturation >70% 
Cardiac index >3.5 litters/min/square meter of body-surface area) 
Organ dysfunction variables 
Arterial hypoxemia (ratio of the partial pressure of arterial oxygen to the fraction of 
inspired oxygen <300). 
Acute oliguria (urine output <0.5ml/kg/hr or 45ml/hr for at least 2 hours) 
Creatinine increase >0.5mg/dL 
Coagulation abnormalities (international normalized ratio >1.5 or activated partial-
thromboplastin time >60 seconds) 
Ileus (absent bowel sounds) 
Thrombocytopenia (platelet count <100,00/mm3) 
Hyperbilirubinemia (plasma total bilirubin >4mg/dL or 70mmol/L) 
Tissue perfusion variables 
Hyperlactatemia (>1 mmol/L) 
Decreased capillary refill or mottling 
Severe sepsis (sepsis plus organ dysfunction) 
Septic shock (sepsis plus either hypotention (refractory to intravenous fluids) or 
hyperlactatemia 
Table 1.2: Diagnostic criteria for sepsis, severe sepsis and septic shock. Adapted from Levy et 
al. (2003). 
 
1.1.6. Treatment 
Significant improvements in patient outcomes may have resulted from advances in 
training, better surveillance and monitoring, prompt diagnosis and treatment of the 
underlying infection. However, the reality is that the case-fatality rates for severe sepsis 
and septic shock remains very high with those who survive often having impaired 
physical and neurocognitive functioning, mood disorders, and a low quality of life 
(Angus et al., 2003).  
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The development of clinical practice guidelines was produced in order to improve the 
management of severe sepsis and septic shock. The Surviving Sepsis Campaign 
Guidelines for Management of Severe Sepsis and Septic Shock were first published in 
2004 (Dellinger et al., 2004), revised in 2008 (Dellinger et al., 2008), and revised again 
and republished in 2013 (Dellinger et al., 2013). The basic elements for the treatment 
of sepsis and septic shock has not changed much since 1960s: rapid administration of 
empirical antibiotics that target all likely pathogens, the use of fluid resuscitation and 
vasopressors to reverse hypotension and maintain tissue perfusion, and if possible, 
prompt removal or drainage of the source of the infection (Dellinger et al., 2013, 
Suffredini and Munford, 2011). 
Apart from guidelines, sepsis bundles were created in order to ensure all steps of care 
are consistently delivered. The Surviving Sepsis Campaign and the Institute of 
Healthcare Improvement worked together to assemble two sepsis bundles, the 3-h 
resuscitation and 6-h management bundles, which represent a number of treatment 
goals to be achieved in a set period of time and function as a measurable quality 
indicators (Figure 1.3). The Surviving Sepsis Campaign guidelines and bundles have 
led to a sustained and quality improvement in sepsis care, and have been associated 
with reduced mortality (Levy et al., 2010). 
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Figure 1.3: Surviving Sepsis Campaign 3 and 6 hour bundles. In cooperation with the Institute 
of Healthcare Improvement the Surviving Sepsis campaign suggested the implementation of a 
core set of recommendations in order to improve quality in sepsis care. Adapted from Dellinger 
et al. (2013) 
 
1.2. The immune system 
The human body is permanently exposed to invasive microorganisms that compromise 
health and ultimately life. These pathogens seek an opportunity to enter the body 
through epithelial surfaces such as the skin, respiratory tract, gastro-intestinal tract and 
genitourinary tract. When these pathogens are successful in entering the body they 
need to be identified and dealt fast and effectively. This process is performed by the 
immune system which consists of two distinct, but closely linked processes: innate 
immunity and adaptive (also known as acquired) immunity. 
1.2.1. Innate immune system 
The innate immune system provides early host defence against infections. It does so, 
primarily through anatomical barriers, such as the skin and internal epithelial layers, the 
peristaltic movement of the gastrointestinal tract and the oscillation of cilia found in the 
respiratory tract. Additionally, lysozyme found in tears, saliva and nasal secretion act 
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as antibacterial substances. The more intricate function of the innate immune system 
involves germline-encoded receptors that detect invading pathogens resulting on the 
activation of inflammation. This theory was proposed 25 years ago by Charles 
Janeway, in the now famous paper “Approaching the Asymptote: Revolution and 
Evolution in Immunology” (Janeway, 1989). In this publication he coined two terms that 
would revolutionise the way we view the innate immune system. The first was pattern 
recognition receptors (PRRs), a class of immune-sensor molecules that are capable of 
recognising infectious agents. The second term was used to describe the ligands they 
recognise, pathogen-associated molecular patterns (PAMPs). These are highly 
conserved structures and are recognised by the innate immune system as foreign to 
the body. PAMPs are essential for the survival and proliferation, so their detection is 
essential in order to trigger an appropriate immune response.  
The detection of infectious agents is made by the so called “trinity of innate sensors” 
which include Toll-like receptors (TLRs), NOD-like receptors (NLRs) and RIG-I-like 
receptors (RLRs). The recognition of PAMPs by one of these families of PRRs results 
in the activation of signalling cascades that induce the secretion of inflammatory 
cytokines, chemokines and type-I interferons (IFN) in order to eradicate pathogens, 
stimulate tissue repair and activate an adaptive immune response (Kumar et al., 2011). 
1.2.2. Adaptive immune system 
Unlike the innate immune system, which is the primary barrier to infectious agents and 
which acts immediately, the adaptive immune system mediates a delayed response to 
foreign antigen. This branch of the immune system is crucial for the control of 
pathogens that escape removal by the innate immune response and essential in the 
development of immunological memory. This procedure operates via generation of 
antigen specific B and T-cell receptors through a process of gene rearrangement which 
have specificity for a PAMP expressed by the invading microorganism. One of the most 
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cunning methods the adaptive immune system has towards the eradication of 
pathogens is the production of plasma cells and memory cells. When a B-cell comes 
into contact with an antigen it proliferates and generates plasma cells, which release 
antibodies relevant to the antigen recognised in order clear it, whilst memory cells are 
produced in order to prepare the body for future challenges of the same pathogen. If 
the body is exposed to a second challenge of the same pathogen, the immune 
response is much faster compared to the initial challenge and consequently the 
eradication of the infectious agent is also much faster (Hoebe et al., 2004, Iwasaki and 
Medzhitov, 2010). 
1.2.3. Dysfunctional immune responses 
Under normal circumstances the immune system can distinguish self from foreign 
molecular components. Many of the diseases that afflict mankind are a consequence of 
a failure of this precise mechanism, where a dysfunctional innate and/or adaptive 
immune system recognises self antigens as foreign. This is referred to as an 
autoimmune disease and both the innate and adaptive immunity are now seen as 
accountable for this detrimental outcome. Septic shock is the purest example of host 
injury mediated by a systemic innate immune activation. Other examples include 
rheumatoid arthritis and systemic lupus erythematosus which are also correlated with 
the over-production of inflammatory cytokines (TNF-α and type-I IFN, respectively) 
(Beutler, 2004, Hoebe et al., 2004). 
1.3. Pattern recognition receptors 
Germ-line encoded pattern-recognition receptors (PRRs) of the innate immune system 
can be divided into three distinct groups: Toll-like receptors (TLRs), nucleotide-binding 
domain leucine-rich repeat-containing (NBD-LRR) proteins (NLRs) and retinoic acid-
inducible gene (RIG)-I-like receptors (RLRs). 
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1.3.1. Toll-like receptors 
Toll-like receptors (TLRs) are the most widely studied PRRs and considered to be 
essential in pathogen recognition. There are thirteen mammalian TLRs, ten of which 
are found in humans and twelve of which are found in mice. TLRs were first identified 
in 1985 by Dr. Nüsslein-Volhard and co-workers, when they screened Drosophila 
melanogaster for embryonic polarity genes. They found a receptor that was involved in 
the production of the dorsal-ventral axis in embryos, and dubbed it Toll. Developing 
Drosophila embryos could not establish a proper dorsal-ventral pattern and appeared 
“toll” (“weird” in German colloquial speech) (Anderson et al., 1985). In 1991, Gay et al. 
found that the cytoplasmic domain of Toll was related to that of the human interlukin-1 
receptor (IL-1R). The amino acid sequence of the Toll receptor in the Drosophila and 
the IL-1R was identical throughout most of the domain, where 135 amino acids were 
identical. In this publication, the extracytoplasmic section of the Toll protein, made of 
leucine-rich repeat proteins (LRRs) was also described in this publication (Gay and 
Keith, 1991). The link between Toll and its pivotal role in triggering an immune 
response was only made in 1996. Lemaitre and colleagues found that Toll-deficient 
adult Drosophila infected with Aspergillus fumigates, a pathogen for insects, died after 
2-3 days - half the time compared to the wild-type population. This study demonstrated 
that Toll was essential for Drosophila to mount an immune response against the fungus 
(Lemaitre et al., 1996). 
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Figure 1.4: Scanning electron micrograph of germinating hyphes of Aspergillus fumigates on a 
dead Drosophila melanogaster adult (200x magnification) (Lemaitre et al., 1996). 
 
In 1997, Medzhitov and Janeway cloned and characterized the first human Toll 
homologue, hToll, which shared homology with the Drosophila Toll (dToll) over the 
entire length of the protein chains (Medzhitov et al., 1997). A year later, there were two 
major discoveries in the TLR field. Firstly, Rock et al. coined the term Toll-like receptors 
(TLRs) and described 5 homologues of Toll (TLRs 1-5) (Rock et al., 1998). Secondly, 
Poltorak et al. discovered that TLR4 is the receptor for bacterial lipopolysaccharide 
(LPS), a component found on the outer membrane of Gram-negative bacteria, which 
finally cemented the idea of TLRs being able to recognise infectious agents (Poltorak et 
al., 1998). The discovery of the remaining known TLRs came in quick succession. 
Takeuchi et al. (1999) discovered TLR6, followed by TLRs 7, 8, 9 (in 2000) and 10 (in 
2001) (Chuang and Ulevitch, 2001, Chuang and Ulevitch, 2000). 
1.3.1.1. Toll-like receptor structure 
TLRs are type I membrane glycoproteins, which possess three domains: an 
extracellular leucine rich repeats (LRRs), a transmembrane domain and a cytoplasmic 
TIR domain (Figure 1.5). The extracellular domain of the TLR family proteins contain 
between 16 and 28 LRRs and they all share a common structural motif 
17 
 
“xLxxLxxLxLxx”, 20-30 amino acids long. This domain contains a β-strand and an α-
helix linked by hoops, which are thought to grant the LRR a unique horseshoe 
architecture. The LRRs are thought to create the binding site for PAMPs. The 
cytoplasmic domain of TLRs is called Toll/IL-1 receptor (TIR) domain due to its 
similarity to the IL-1 receptor. This domain consists of approximately 200 amino acids. 
Within the TIR domain there are three highly conserved regions (Box 1, 2 and 3) which 
are required for the interaction and recruitment of intracellular proteins that participate 
in the signalling pathways of TLRs (Carpenter and O'Neill, 2009, Jin and Lee, 2008, 
Kumar et al., 2011). 
 
 
 
 
 
 
 
 
 
 
Figure 1.5: Toll-like receptor family basic structure. The extracellular domain consists of 16-28 
leucein rich repeats (LRRs) at the N-terminus, followed by a transmembrane domain. The 
cytoplasmic domain consists of the Toll/IL-1 receptor (TIR) domain at the C-terminus. The LRRs 
form a horseshoe-like structure that creates the binding site for PAMP. The TIR domain 
possesses three highly conserved regions: box 1 is considered the signature sequence of the 
family, whereas box 2 and 3 contain amino acids critical for signalling. 
         Box 2 
         Box 1 
         Box 3 
Extracelular region 
Cytoplasmic region 
LRRs 
TIR domain 
Transmembrane domain 
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1.3.1.2. Individual Toll-like receptors 
So far, ten functional TLRs have been discovered in humans and twelve functional 
TLRs have been found in mice. TLR1-9 are conserved in both human and mice but 
TLR10 is not functional in mice. This is due to a retrovirus insertion, which substituted 
the C-terminal half of the receptor for an unrelated and non-productive sequence in the 
Tlr10 gene. Mice do express TLR11, TLR12 and TLR13, but these have been lost in 
the human genome, with the Tlr11 gene having a stop codon that results in a lack of 
production of the receptor. The function of TLR10 in humans, and TLR12 and TLR13 in 
mice remains unknown (Beutler, 2004, Kawai and Akira, 2009, Kawai and Akira, 2010, 
Kumar et al., 2011). 
TLR1, 2, 4, 5, 6 and 11 are all present on the cell surface, with their LRR domain facing 
out of the cell, whereas TLR3, 7, 8 and 9 are exclusively expressed within the 
endosomal membrane, with their LRR domain facing into the endosomal compartment. 
Most TLRs are believed to be homodimers, although heterodimers do exist in the case 
of TLR2/TLR1 and TLR2/TLR6. Once a PAMP binds to its respective TLR it recruits a 
single or a combination of TIR-domain-containing adaptor proteins. This results in the 
activation of the signalling cascade, which in turn results in the production of 
proinflammatory cytokines as well as type-I interferon (Kawai and Akira, 2011). 
1.3.1.2.1. Cell surface TLRs and their ligands 
TLR1, TLR2, TLR4, TLR5, TLR6 and TLR11 are expressed on the cell surface and 
recognise microbial membrane components such as lipids, lipoproteins and proteins. 
1.3.1.2.1.1. TLR1, 2 and 6 
TLR2 is capable of forming stable heterodimers with TLR1 and TLR6 or non-TLR 
molecules such as CD14, CD36 and dectin-1. This confers the ability of TLR2, in 
conjunction with bound heterodimers, to recognize a wide range of PAMPs from 
19 
 
bacteria, parasites, fungi and viruses. These include lipoproteins and lipopeptides, 
lipoteichoic acid (LTA) and peptidoglycan from Gram-positive bacteria, 
lipoarabinomannan from mycobacteria, zymosan from fungi and viral components such 
as haemaglutinin protein from the measles virus (Akira et al., 2006, Kawai and Akira, 
2011). In particular, the TLR2/TLR1 heterodimer recognises triacylated lipopeptides as 
its main PAMP, and on the other hand, the TLR2/TLR6 heterodimer recognises 
diacylated lipopeptides (Kawai and Akira, 2010). 
In 2007, the crystal structure of the human TLR2/TLR1 heterodimer was discovered. 
TLR2 forms a stable heterodimer with TLR1 which, with the addition of the triacylated 
lipopeptide, Pam3CSK4, shows that the overall shape of the complex resembles the 
letter “m” (Figure 1.6). The formation of the TLR2/TLR1/Pam3CSK4 heterodimer allows 
the initiation of downstream signalling (Jin et al., 2007).  
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Figure 1.6: The structure of the human TLR2/TLR1/Pam3CSK4. This structure shows that two of 
the three hydrophobic lipid chains on Pam3CSK4 (red) are submerged in the hydrophobic 
spaces within TLR2 (blue), with the remaining hydrophobic lipid chain within TLR1 (blue). 
TLR2/TLR1/Pam3CSK4 forms an “m” shaped heterodimer. A) side view; B) top view. (Jin et al., 
2007). 
 
In 2009, Kang et al. determined the crystal structure of TLR2/TLR6 heterodimer. 
Similar to TLR1, TLR6 also forms an “m”-shaped heterodimer with TLR2 with the 
addition of the diacyl lipopeptide, Pam2CSK4 (Figure 1.7.). The stability of 
TLR2/TLR1/Pam3CSK4 complex relies upon the interaction between the amide-bound 
lipid and TLR1. On the other hand, in the TLR2/TLR6/Pam2CSK4 complex, the bridging 
role of the amide lipid chain is missing. Nevertheless, TLR2 and TLR6 are able to form 
a stable heterodimer due to the increased hydrophobic interactions between the two 
TLRs. These interactions seem to compensate for the reduced lipid chain interaction 
(Kang and Lee, 2011, Kang et al., 2009). 
A 
B 
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Figure 1.7: The structure of the mouse TLR2/TLR6/Pam2CSK4 complex. This structure shows 
the two esther-bound lipids on Pam2CSK4 (red) are inserted into hydrophobic pockets within 
TLR2 (light blue) but not within TLR6 (light green). TLR2 and TLR6 can still form stable 
heterodimers because the increased hydrophobic interaction between the two TLRs. 
TLR2/TLR6/Pam2CSK4 forms an “m” shaped heterodimer. A) side view; B) top view. (Kang et 
al., 2009). 
 
1.3.1.2.1.2. TLR4 
TLR4, a founding member of the TLR family, is responsible in the recognition of 
bacterial lipopolysaccharide (LPS), a component of the outer membrane of Gram-
negative bacteria. TLR4 detects the presence of LPS through the formation of a 
trimolecular receptor complex, involving CD14 and myeloid differentiation factor 2 (MD-
2). LPS-binding protein (LBP), a soluble protein, is the first protein to encounter 
circulating LPS. LPS and LBP bind in the serum and form the LPS-LBP complex, which 
A 
B 
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in turn bind to CD14 on the cell surface (Tobias et al., 1997). Subsequently, CD14, a 
glycosylphosphatidylinositol (GPI)-linked protein, delivers the LPS-LBP to the TLR4-
MD-2 complex (Akashi et al., 2000, Shimazu et al., 1999). In response to LPS, TLR4 
has been shown to associate with other receptor clusters such as heat shock proteins 
(Hsps), in particular Hsp70 and Hsp90; chemokine receptor (CXCR4) and leukocyte 
integrins CD11b/CD18 (Triantafilou and Triantafilou, 2004). 
TLR4 has also been shown to be involved in the recognition of respiratory syncytial 
virus (RSV) fusion proteins, mouse mammary tumour virus and Streptococcus 
pneumoniae pneumolysin (Burzyn et al., 2004, Kawai and Akira, 2010). 
The crystal structure of mouse TLR4 has been reported. Two studies, one in 2007 and 
one in 2009, published the crystal structure of mouse TLR4-MD-2 heterodimer bound 
to Eritoran (an antagonist PAMP) or lipid A (an agonist PAMP). The structural study of 
TLR4-MD-2 in complex with LPS has shown that four of four acyl chains of Eritoran 
and five of the six acyl chains of lipid A are submerged within the hydrophobic space of 
MD-2. The remaining lipid chain of lipid A is inserted into the hydrophobic space of 
TLR4. This aids the interaction between MD-2 and TLR4, resulting in the activation of 
downstream signalling for lipid A, unlike Eritoran, as it has no direct interaction with 
TLR4 (Kim et al., 2007, Park et al., 2009). 
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Figure 1.8: Structure of the TLR4-MD-2 complex. A) Structure of the mouse TLR4-MD2 
complex. The N-terminal, central, and C-terminal domains of TLR4 are coloured blue, cyan and 
green, respectively. MD-2 is shown in pink and red (Kim et al., 2007). B1) and B2) Top and side 
view, respectively, of the TLR4-MD-2-LPS homodimer complex. Lipid A component of LPS is 
shown in red and pink, MD-2 in grey and the TLR4 receptors in blue and green. Adapted from 
Park et al. (2009). 
A 
B1 
B2 
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1.3.1.2.1.3. TLR5 and mouse TLR11 
TLR5 is responsible for sensing flagellin, a protein expressed by flagellated bacteria 
(Hayashi et al., 2001). TLR5 has been shown to be expressed on the intestinal 
epithelial cells, and endothelial cells and also highly expressed in CD11c+CD11b+ 
lamina propria DCs in the small intestine (Uematsu et al., 2008).  
Mouse TLR11 is thought to be a close relative to TLR5, and is highly expressed in the 
bladder and kidneys. In 2004, Zang and colleagues showed that TLR11-deficient mice 
are prone to infection with uropathological bacterial and concluded that TLR11 plays an 
important role in preventing infections of the urogenital system. Human TLR11 non-
functional duo to a stop codon in the gene (Zhang et al., 2004). 
1.3.1.2.1.4. TLR10 
TLR10 is expressed in humans but not in mice, but little is known about the ligand and 
cascade activated by this TLR. 
1.3.1.2.2. Intracellular TLRs and their ligands 
TLR3, TLR7, TLR8 and TLR9 are localised in intracellular vesicles such as the 
endosomes membrane and the endoplasmic reticulum (ER). These endosomal TLRs 
predominantly recognise pathogenic nucleic acids, DNA, single-stranded-DNA 
(ssDNA), single- and double-stranded-RNA (ssRNA and dsRNA, respectively). 
1.3.1.2.2.1. TLR3 
TLR3 is involved in the recognition of double-stranded ribonucleic acid (dsRNA). In 
2001, experiments with TLR3-deficient mice showed that they had reduced responses 
to a synthetic analogue of dsRNA, polyinosinic-polycytidylic acid (poly(I:C)), resulting in 
a lower secretion of inflammatory cytokines (Alexopoulou et al., 2001). TLR3 can also 
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recognise single-stranded (ssRNA) produced during the replication of dsRNA viruses 
such as RSV and the West Nile virus (Groskreutz et al., 2006, Wang et al., 2004). 
Leonard et al. showed in a biochemical study that dsRNA, but not dsDNA or ssRNA, 
induces homodimerization of TLR3 (Leonard et al., 2008). Liu and co-workers 
determined the crystal structure of TLR3 bound to a dsRNA ligand. The architecture of 
the TLR3 homodimer, induced by the binding of dsRNA, is similar to the “m” shape 
dimers of the TLR2 and TLR4 complexes (Figure 1.9). Although it resembles the 
overall structure, the TLR3 homodimer has a different mechanism for recognising the 
ligand of the TLR4-MD-2, TLR2/TLR1 and TLR2/TLR6 complexes. Both the C- and N-
terminal on the lateral side of the convex surface of each TL3 dimer interact with 
dsRNA ligand (Kang and Lee, 2011, Liu et al., 2008).  
 
 
Figure 1.9: Structure of the TLR3 homodimer associated with double-stranded RNA (dsRNA). 
TLR3 homodimer in light blue, dsRNA in green and orange. The C- and N-terminal RNA 
interaction sites with TLR3 are marked in arrows. A) side view; B) top view. Adapted from (Kang 
and Lee, 2011). 
 
 
 
A B 
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1.3.1.2.2.2. TLR7 and TLR8 
TLR7 and TLR8 are phylogenetically very similar and are responsible for the detection 
of viral ssRNA. These receptors were originally proposed to be responsible in sensing 
imidaziquiniline (imiquimod and resiquimod (R-848)) and guanine analogs. Murine 
experiments showed that TLR7-deficient mice did not show any inflammatory cytokine 
production when challenged with imidazoquinolines (Hemmi et al., 2002). TLR7 and 
TLR8 can also recognise ssRNA from RNA viruses including influenza A virus and 
human immunodeficiency virus (HIV) (Kawai and Akira, 2009). 
1.3.1.2.2.3. TLR9 
TLR9 detects foreign deoxyribonucleic acid (DNA). In 2000, Hemmi et al. showed that 
TLR9 knock-out mice were unable to detect 2’-deoxyribo(cytidine-phospate-guanosine) 
(CpG) DNA motifs that are found in DNA bacteria and DNA viruses (Hemmi et al., 
2000). The sugar back-bone of DNA (2’-deoxyribose) is enough to bind and activate 
TLR9. This is important to distinguish between “self” DNA, when it has a 
phosphodiester (PD) backbone, and unnatural, or foreign DNA, when it has a 
phorothionate (PS) backbone (Haas et al., 2008). TLR9 has also been linked to detect 
crystal hemozoin from parasites (Coban et al., 2010).  
1.3.1.3. TLR ligands 
TLRs are one of the most important PRRs groups discovered to date. These receptors 
homo and hetero-dimerize in order to recognise a broad spectrum of PAMPs derived 
from microbial pathogens such as viruses, bacteria, fungi and parasites (Table 1.3). 
This broad recognition of PAMPs by the different TLRs triggers the release of 
inflammatory cytokines that orchestrate a rapid and effective pathogen removal. TLRs 
1, 2, 4, 5, 6 and 11 are cell surface bound whilst TLRs 3, 7, 8, 9 are located in the 
endosomal membrane. 
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Receptor Ligand Source of ligand 
TLR1 Triacyl lipopeptides Bacteria and mycobacteria 
TLR2 Lipoprotein/lipopeptides 
Peptidoglycan 
Lipoteichoic acid 
Lipoarabinomannan 
Phospholipomannan 
GPI-mucin 
Envelope glycoproteins 
Porins 
Zymosan 
Β-Glycan 
Heat-shock protein 70 
 
Various pathogens 
Gram-positive bacteria 
Gram-positive bactéria 
Mycobacteria 
Candida albicans 
Protozoa 
Viruses (e.g., HSV, measles virus) 
Neisseria 
Fungi 
Fungi 
Host 
TLR3 dsRNA Viruses 
TLR4 Lipopolysaccharide (LPS) 
Mannan 
Fusion proteins 
Envelope glycoproteins 
Glycoinositolphospholipids 
Heat-shock protein 60, 70 
Fibrinogen 
 
Gram-negative bacteria 
Candida 
RSV 
Mammary-tumor virus 
Trypanosoma 
Host 
Host 
TLR5 Flagellin Flagellated bacteria 
TLR6 Diacyl lipopeptides 
Lipoteichoic acid 
Zymosan 
 
Mycoplasma 
Gram-positive bacteria 
Fungi 
TLR7 ssRNA 
Imidazoquinoline 
 
RNA viruses 
Synthetic compounds 
TLR8 ssRNA 
Imidazoquinoline 
 
RNA viruses 
Synthetic compounds 
TLR9 CpG motifs 
Hemozoin 
Bacteria and Viruses 
Plasmodium falcuparum 
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hTLR10 Not determined Not determined 
mTLR11 Not determined 
Profilin-like molecule 
Uropathogenic bacteria 
Toxoplasma gondii 
 
mTLR12 Not determined Not determined 
mTLR13 Not determined Not determined 
Table 1.3: Toll-like receptors, the ligands they recognise and their source (Akira et al., 2006, 
Kawai and Akira, 2009, Kawai and Akira, 2011, Kumar et al., 2011, Mogensen, 2009).  
 
1.3.1.3.1. Lipopolysaccharide 
Bacteria are unicellular prokaryote microorganisms consisting of many members of 
various shapes and sizes. Although diverse, all PAMPs from bacteria can be 
recognised by the different TLRs. Lipopolysaccharide (LPS) is an important structural 
component found on the outer membrane of Gram-negative bacteria which consists of 
a hydrophobic domain known as lipid A (endotoxin), a non-repeating core 
oligosaccharide region, and a distal O-specific chain (O-antigen) polysaccharide 
(Figure 1.10) (Beutler and Rietschel, 2003). Lipid A, the hydrophobic anchor of LPS, is 
a glucosamine-based phospholipid that constitutes the outer monolayer of the outer 
membranes of Gram-negative bacteria. In a single E. coli cell there are around 106 lipid 
A residues, and because they have a conserved architecture, they are detected at 
picomolar levels by TLR4 (Galloway and Raetz, 1990). The hydrophilic polysaccharide 
unit is composed by a core region and an O-specific chain. The core oligosaccharides 
contains an inner (lipid A proximal) and an outer core. The outer core provides an 
attachment site for the O-specific chain, whereas the inner core contains residues of 
Kdo (3-deoxy-D-manno-oct-2-ulosonic acid) and L-glycero-D-mannoheptose (L,D-Hep) 
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oligosaccharide and can contain phosphates, amino acids and sugars such as 2-keto-
3-deoxyoctulsonic acid. In comparison to the core region, the O-specific chain is 
structurally more variable, which gives rise to the different Gram-negative bacterial 
strains. For example, in E. coli strains there are around 170 different O-specific chain 
structures (Raetz and Whitfield, 2002). 
 
 
 
 
 
 
Figure 1.10: A Gram-negative cell wall. A) electron micrograph of E. coli; B) location of 
lipopolysaccharide (LPS), outer membrane, peptidoglycan and inner membrane in the bacteria 
cell wall; C) schematic diagram of the toxic centre of the Gram-negative lipopolysaccharide 
(LPS); D) the lipid A component. GlcN: D-glucosamine; Hep: L-glycero-D-manno-heptose; Kdo: 
2-keto-3-deoxy-octulosonic acid; P: phosphate. Adapted from Beutler and Rietschel (2003). 
A) E. coli B) Cell-wall organization 
C) Architecture of lipopolysaccharide 
D) Structure of lipid A 
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1.3.1.4. CD14 
Even though TLRs are the key detectors of invading pathogens, they require adapter 
molecules for the effective activation in response to the different PAMPs. The efficacy 
of TLR4 activation is greatly enhanced by CD14, a 55 kDa glycosylphosphatidylinositol 
(GPI)-anchored protein, and one of the first adapter molecules to be identified as a co-
receptor for LPS (Wright et al., 1990).  
The crystal structure of CD14 has been determined to a 2.5 Å resolution. It was shown 
that the CD14 monomer contains thirteen β strands where eleven of them (β3-13) 
overlap with conserved leucine-rich repeats (LRRs). CD14 exists as a dimer in solution 
as well as in the crystallographic asymmetric unit (Figure 1.11). Its horseshoe-like 
structure and the number of conserved LRRs is close to those in TLR4, which shows 
close similarities with between the adaptor molecule and the TLR family (Kim et al., 
2005). 
 
Figure 1.11: Overall structure of the CD14 dimer. Two monomers of CD14 in the crystal are 
coloured gray and cyan. Disulfide bridges are shown in orange. Adapted from Kim et al. (2005). 
 
31 
 
The main role of CD14 in LPS recognition was demonstrated by Haziot et al. (1996) in 
CD14-knockout mice. The group demonstrated that CD14-deficient mice were 10,000-
fold less sensitive to LPS compared to control mice. 
The recognition of LPS through TLR4 involves a series of steps which start from the 
binding of LPS by LPS-binding protein (LBP) which transfers the bound LPS to CD14, 
which in turn facilitates the transfer of LPS to the TLR4 which activates the signalling 
pathway (Kawai and Akira, 2011). 
1.3.1.5. TLR signalling 
As soon as a particular PAMP has been recognised by its respective TLR, it dimerises, 
often forming homodimers or, in the case of TLR1, 2 and 6, a heterodimer. The TLR 
dimer undergoes a conformational change which results in the recruitment and 
activation of intracellular TIR domains, which activates downstream signalling, which 
subsequently activates transcription factors. These transcription factors are then 
translocated to the nucleus where they cause an up-regulation of genes that are 
responsible for the inflammatory and antiviral response.  
TLR signalling is divided into two different pathways: the myeloid differentiation primary 
gene-88 (MyD88)-dependant and MyD88-independent pathway (Figure 1.12). MyD88 
adaptor molecule is utilised by all the TLRs, except TLR3, in order to induce 
downstream signalling. TLR3 utilises a second pathway, the MyD88-independent 
pathway, i.e. the TRIF-dependent pathway. TLR4 can signal in a MyD88-dependant 
and independent manner. TLR signalling requires other adaptor molecules which 
accurately transduce the signal, including four in particular: MyD88, TIR domain-
containing adaptor-inducing interferon-β (TRIF), TRIF-related adaptor molecule 
(TRAM) and TIR-domain containing adaptor protein (TIRAP, also known as MAL 
(MyD88-adaptor like)). These adaptor molecules, like all the TLRs, contain and interact 
through a Toll-interleukin 1 receptor (IL-1R) homology domain (TIR domain) (Kawai 
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and Akira, 2010). MyD88, is used by all the TLRs, with the exception of TLR3, and 
activates the transcription factor nuclear factor kappa-light-chain-enhancer of activated 
B cells (NF-κB) and mitogen-activated protein kinases (MAPKs) in order to produce 
inflammatory cytokines. On the other pathway, TRIF is used by TLR3 and TLR4 in 
order to activate the transcription factors NF-κB and interferon regulatory factor 3 
(IRF3), which consequently leads to the production of inflammatory cytokines and type-
I interferon. The adaptor molecules TRAM and TIRAP recruit TRIF to TLR4 and MyD88 
to TLR2 and TLR4, respectively. Consequently, TLR downstream signalling can be 
categorised as either MyD88-dependent, responsible for the production of inflammatory 
cytokines, or MyD88-independent (TRIF-dependent) pathways, which induces the 
production of both type-I IFN and inflammatory cytokines (Kawai and Akira, 2011). 
1.3.1.5.1. MyD88-dependent pathway 
After MyD88 is activated by TLRs it recruits the IL-1R-associated kinase (IRAK) family 
protein kinases IRAK4, IRAK1, IRAK2 and IRAKM. MyD88 recruits IRAK4 through a 
death domain (DD)-DD association, which in turn associates with IRAK1 and IRAK2 
causing IRAK-1 phosphorylation and activation. This results in the interaction of IRAK1 
with tumor necrosis factor (TNF) receptor-associated factor 6 (TRAF6), forming the 
IRAK-1-TRAF-6 complex (Kawagoe et al., 2008). IRAKMs main function is to block the 
formation of this complex (Kobayashi et al., 2002). IRAK1 bound to TRAF6 dissociates 
from the complex and binds with transforming growth factor-B-activated kinase 1 
(TAK1) and the TAK1 binding proteins 2 and 3 (TAB2 and TAB3). This complex 
activates TAK1, which phosphorylates the IκB-kinase (IKK) complex which is made up 
of NEMO (NF-κB essential modulator, also known as IKK-γ) IKK-α and IKK-β. IκB is 
then phosphorylated and undergoes proteosomal degradation, causing the release of 
NF-κB which can then translocate to the nucleus where it induces gene transcription of 
proinflammatory cytokines (Kawai and Akira, 2009, Kawai and Akira, 2010, Kumar et 
al., 2011).  
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1.3.1.5.2. MyD88-independent pathway 
The MyD88-independent, also called TRIF-dependent pathway, induces the expression 
of type-I IFN and is activated only by TLR3 or TLR4. TRIF is bound to TLR3 through its 
TIR domain, whereas TLR4 uses TRAM, which is associated with TRIF, in order to 
activate this signalling pathway. Following this, TRIF associates with TRAF3 and 
activates the IKK complex of TRAF family member-associated NF-κB activator (TANK)-
binding kinase 1 (TBK1) and IKKε. This complex mediates direct phosphorylation of 
IFN regulatory factor 3 (IRF3) and IRF7. This phosphorylation causes IRF3 and IRF7 to 
form hetero- or homodimers, translocate to the nucleus and with the aid of coactivators 
such as CBP and p300, initiate transcription of IFN and IFN-inducible genes in order to 
induce type-I IFN expression. TRIF-dependent pathway can also activate NF-κB. This 
occurs when the TLR4 TRIF recruits TRAF6 as well as receptor-interacting protein 1 
(RIP-1) and TNF receptor (TNFR)-associated death domain (TRADD), which forms a 
complex in conjunction with TRAF6 after RIP-1 is polyubiquinated. These two 
molecules activate TAK1, which consequently activate the NF-κB pathway (described 
previously in 1.3.5.1) (Kawai and Akira, 2010, Mogensen, 2009). 
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Figure 1.12. Toll-like receptor signalling pathways. TLR4 is able to activate both MyD88-
dependent (shown on the left) and – independent (TRIF-dependent) (shown on the right) 
pathways. The MyD88-dependent pathway is responsible for the activation of NF-κB which 
consequently controls the induction of proinflammatory cytokines. On the other hand, the MyD-
88-independent pathway activates IRF3/7 in order to induce type-I IFN expression. Adapted 
from (Mogensen, 2009). 
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1.3.2. NOD-like receptors 
Nod-like receptors (NLRs) form part of the ‘trinity of pathogens sensors’ - a term coined 
by Creagh and O'Neill (2006), combined with the TLRs and RLRs. There are 22 
different NLRs members known in the human genome and many more in mice. NLRs 
are located in the cytosol and share a unique domain architecture consisting of a 
central nucleotide-binding and oligomerisation (NACHT) domain, which is located 
between C-terminal leucine-rich repeats (LRRs) and N-terminal caspase recruitment 
(CARD) or pyrin (PYD) domains. The LRR domain is thought to be the ligand binding 
domain as well as having an autoregulation, whereas CARD and PYD domains are 
involved in homotypic protein-protein interactions necessary for downstream signalling 
(Figure 1.14). The N-terminal domain has been used to separate the NLR family into 
three subgroups: the nucleotide-binding oligomerisation domain (NOD) (NOD1-2, 
NOD3/NLRC3, NOD4/NLRC5, NOD5/NLRX1 and CIITA); the NLRPs (NLRP1-14, also 
known as NALPs); and NLRC4 (also known as IPAF) (Schroder and Tschopp, 2010, 
Stutz et al., 2009). Functionally NLRs can be separated on their ability to form a 
complex known as the inflammasome. 
1.3.2.1. Inflammasome  
The term inflammasome was first used in 2002 by Martinon and colleagues, due to its 
similarity to the apoptosome and its ability to cause inflammation. The inflammasomes 
are a group of multimeric protein complexes that consist of an activated receptor 
molecule, apoptosis-associated speck-like protein containing CARD (ASC) and pro-
caspase-1. The formation of the inflammasome complex is triggered by a variety of 
substances derived from infections, tissue damage or metabolic dysfunctions (Martinon 
et al., 2002). Ultimately, the arrangement of the inflammasome complex triggers the 
activation of pro-caspase-1, which proteolytically activates the pro-inflammatory 
cytokines IL-1β and IL-18. 
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The inflammasomes are arranged with an inflammasome sensor molecule that is 
connected to pro-caspase-1 via ASC. ASC is common to all inflammasomes and it 
contains two death fold domains: one pyrin (PYD) and one CARD domain. In their 
inactive state, NLR is kept inactive and once it binds to its specific ligand, a 
conformational change occurs which enables the NLR to bind to ASC through a PYD-
PYD homotypic interaction. This interaction triggers ASC to bring monomers of pro-
caspase-1 into close proximity, via CARD-CARD homotypic interactions, which initiates 
the activation of caspase-1 self-cleavage and the formation its active form. The main 
role of caspase-1 is to activate pro-IL-1β and pro-IL-18. This is the second step in the 
conversion of pro-IL-1β into its bioactive cytokine IL-1β, as it requires a priming signal. 
This signal is induced by the activation of NF-κB, which is promoted by TLR recognition 
of their ligands. On the other hand, pro-IL-18 does not need a priming signal as it is 
constitutively expressed and its expression is increased after cellular activation (Davis 
et al., 2011, Latz et al., 2013, Stutz et al., 2009). 
A number of inflammasome sensor molecules can activate caspase-1 and lead to IL-1β 
production, suggesting roles in inflammasome formation. These include NLRP1 (NOD-, 
LRR- and pyrin domain-containing 1), NLRP3, NLRP6, NLRP7 NLRP12, NLRC4 
(NOD-, LRR- and CARD-containing 4, or IPAF), NOD2. Two other non-NLRs have 
been described as inducing the formation of inflammasome: the PYTHIN (pyrin and 
HIN domain-containing protein) family members absent in melanoma 2 (AIM2) and 
IFN-γ-inducible protein 16 (IFI16) (Hornung and Latz, 2010, Latz et al., 2013). Although 
for some of these NLRs it is only suggested that they form inflammasomes, others, 
such as NLRP1 and NLPR3 have been widely documented to form inflammasomes. 
1.3.2.1.1. NLPR1 inflammasome 
From the NLR family, NLRP1 was the first to be shown to form an inflammasome 
(Martinon et al., 2002). NLRP1 contains an N-terminal CARD that anchors a CARD 
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domain, a central NACHT nucleotide-binding domain, LRR domain, a function-to-find 
domain (FIIND) and a C-terminal CARD. This structural layout is exclusive to NLRP1. 
NLRP1 can directly activate caspase-1 without recruiting ASC, although the bypass of 
ASC greatly declines the formation of the inflammasome complex and the processing 
of IL-1β (Faustin et al., 2007, Proell et al., 2013). It still remains unclear the method by 
which NLRP1 recruits ASC, as the mouse NLRP1 ortholog do not have PYD domains. 
It has been speculated that a CARD-CARD homotypic interaction between NLR and 
ASC recruits a first layer of ASC, resulting in the interaction with a second layer of ASC 
through interaction via PYR-PYR homotypic domain (Latz et al., 2013). NLRP1 has 
been shown to sense the bacterial lethal toxin (LT) from Bacillus anthracis (Boyden and 
Dietrich, 2006). In addition, NLRP1 has been shown to directly bind to its ligand 
muramyl dipeptide, which is enough to activate the assembly of the inflammasome 
complex. However, NLRP1 seems to need the interaction of NOD2, another receptor 
for muramyl dipeptide, suggesting that NOD2 is an important component on the 
assembly of the NLRP1 inflammasome (Hsu et al., 2008). 
1.3.2.1.2. NLRP3 inflammasome 
The NLRP3 inflammasome is the best characterised inflammasome. Unlike NLRP1, 
the NLRP3 has a typical tripartite structure organisation: an N-terminal pyrin domain, a 
central NACHT domain and a C-terminal LRR domain. The NACHT domain has 
ATPase activity and upon stimulation causes the receptor to oligomerise and recruit 
ASC via its pyrin domain. NLRP3 lacks a CARD domain therefore it can only recruit 
pro-caspase-1 via the adaptor molecule ASC (Davis et al., 2011).  
There are a plethora of triggers that activate NLRP3 including crystalline material, 
peptide aggregates, viral and bacterial PAMPs as well as damage-associated 
molecular patterns (DAMPs). NLRP3 has been shown to be activated by whole 
pathogens such as the fungi Candida albicans and Saccharomyces cerevisiae, the 
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Sendai virus, adenovirus and influenza virus (Schroder and Tschopp, 2010). NLRP3 
has also been found to be activated by host-derived molecules such as extracellular 
ATP that are sensed by the P2X7 receptor due to cell death (Mariathasan et al., 2006). 
The NLRP3 inflammasome also activates in response to fibrillar amyloid-β undergoing 
phagocytosis by microgilia. The secretion of the proinflammatory cytokine IL-1β in 
response to fibrillar amyloid-β, which has a key role in the pathogenesis of Alzheimer’s 
disease, may play an integral role in the development of this disease (Halle et al., 
2008). With regards to the activation of NLRP3 inflammasome as a response to 
bacterial PAMPs, Kayagaki and co-workers (2011) showed that the activation of 
caspase-1 and IL-1β production, after the recognition of Gram-negative bacteria, relies 
on the inflammatory pro-caspase-11 in mice (human orthologues pro-caspase 4), 
which in turn results in a non-canonical NLRP3 inflammasome activation. This non-
canonical activation is due to the requirement of three signals, instead of the standard 
two found in the IL-1β generation (see section 1.3.2.1), in response to Gram-negative 
bacteria. The first signal, which is found in the conventional model, is induced by the 
activation of NF-κB, which is promoted by TLR recognition of bacteria, which results on 
an up-regulation of NLRP3 and pro-IL-1β. The second signal involves two parts: the 
first is that the bacterial mRNA from live bacteria activates NLRP3; and the second is 
that the MyD88-independent pathway mediates the secretion of type-I IFNs, which in 
turn induce pro-caspase-11 expression and activation (Figure 1.13) (Kayagaki et al., 
2011, Latz et al., 2013). 
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Figure 1.13. Canonical and non-canonical activation of IL-1β. NLRP3 needs supplementary co-
factors for the induction of the bioactive form of IL-1β in response to Gram-negative bacteria. To 
successfully induce the production of IL-1β it is required a three step checkpoint. The first being 
the activation of TLR4 through TRIF which induces the secretion of type-I IFNs. The second is 
the activation of NLRP3 via live bacterial mRNA. The third step is via the MyD88-independent 
pathway which mediates the secretion of type-I IFNs, which in turn induce pro-caspase-11 
expression and activation. Question marks show speculative pathways. Adapted from Latz et al. 
(2013). 
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1.3.2.1.3. NLRP12 
There are some inflammasome sensors whose ability to form inflammasomes is as of 
yet undetermined. Although this is the case for NLRP12 (also known as Monarch-1 or 
PYPAF7), other functions have been described for this inflammasome sensor since its 
discovery in 2002 (Wang et al., 2002). NLRP12 has been shown to be a positive 
regulator of dendritic cells and neutrophils migration, where NLRP12 knockout mice 
showed a significant reduction in the capacity of both these cell types to migrate to 
draining lymph nodes (Arthur et al., 2010). NLRP12 has also been shown to be a 
negative regulator of non-canonical NF-κB signalling. The canonical pathway, as 
mentioned before, is activated through the IκB-kinase (IKK) complex which is made up 
of NEMO, IKK-α and IKK-β. IκB is then phosphorylated and undergoes proteosomal 
degradation, causing the release of NF-κB which induces the production of 
proinflammatory cytokines. On the other hand, the non-canonical pathway is 
dependent on the NF-κB-inducing kinase (NIK) which activates IKKα, and in turn leads 
to a nuclear accumulation of p52-containing NF-κB that induces the production of 
proinflammatory cytokines. Lich et al. (2007), showed that in in vitro analysis of 
monocytes that NLRP12 is a negative regulator of NF-κB. It was suggested that this 
NLR protein has the ability to associate with NIK, which suppresses non-canonical NF-
κB activation (Lich et al., 2007). In 2012, experiments with NLRP12-deficient mice 
demonstrated that these were very susceptible to inflammation. The authors concluded 
that NLRP12 functions as a NF-κB negative regulator through its interaction with NIK 
and TRAF3. This shows that this inflammasome sensor is important in regulating 
inflammatory responses (Allen et al., 2012).  
1.3.2.2. NOD1 and NOD2 
Nucleotide-binding oligomerisation domain-containing protein 1 (NOD1) and NOD2 
play a major role in regulating NF-κB and MAP kinases, NOD1 being one of the very 
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first NLRs to be described (Inohara et al., 1999). NOD1 and NOD2 recognise 
fragments of peptidoglycan, a major component of bacterial cell walls. NOD1 
recognises γ-D-glutamyl-meso-diaminopimelic acid (iE-DAP) (Chamaillard et al., 2003), 
whereas NOD2 detects, like NLRP1, muramyl dipeptide (MDP) (Girardin et al., 2003). 
NOD1 is thought to be responsible for the detection of Gram-negative bacteria, as iE-
DAP is only found in Gram-negative peptidoglycan. On the contrary, NOD2 is a more 
general detector, as MDP is found in both Gram-negative and Gram-positive bacteria. 
Both these proteins also recognise various other pathogens from Escherichia coli, 
Chlamydia pneumonia and Pseudomas aeruginosa, detected by NOD1, to 
Streptococcus pneumonia, Mycobacterium tuberculosis and Salmonella typhimurium, 
by NOD2 (Kufer et al., 2006, Kumar et al., 2011). 
The structure of NOD1 and NOD2 consists of a C-terminal LRR, a central nucleotide 
binding oligomerization domain, and an N-terminal domain containing either one 
(NOD1) or two (NOD2) CARDs. Upon ligand binding, NOD1 and NOD2 initiate 
oligomerization which leads to the recruitment of the adaptor molecule RIP2 via their 
respective CARD domains by homophilic interactions. NEMO is recruited to RIP2, 
which causes the phosphorylation of IKKβ releasing NF-κB to induce transcription of 
inflammatory cytokines (Figure 1.15). RIP2 can also recruit TRAF3 which leads to the 
activation of TBK1 and IKKε. This causes IRF3 and IRF7 to form hetero- or 
homodimers, translocate to the nucleus in order to induce type-I IFN expression 
(Kersse et al., 2011). 
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Figure 1.14. Structure of NOD-like receptors (NLRs). NLRs have three distinct domains: C-
terminal leucine-rich repeats (LRRs), a central oligomerization domain (NACHT) and an N-
terminal CARD or/and PYD domain. Most NLRs also contain a NACHT-associated domain 
(NAD) C-terminal of the NACHT domain. Adapted from Martinon et al. (2009). 
 
Figure 1.15. NOD1 and NOD2 proteins detect peptidoglycan (PGN) from Gram-negative 
(NOD1) and both Gram-negative and –positive (NOD2) bacteria. NOD1 and NOD2 recognise 
iE-DAP and MDP, respectively, and through the adaptor molecule RIP2 activate NF-κB which 
induces the transcription of proinflammatory cytokines. Adapted from Akira et al. (2006). 
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1.4. The innate immune response in sepsis 
Sepsis is a clinical disorder that is an often-fatal systemic inflammatory response to a 
microbial infection. This medical condition is paradoxical, seeing as the mechanism 
that has been designed to protect the host against bacterial infection is the main source 
of injury and damage to the host. Bacterial products, such as lipopolysaccharide (LPS) 
form Gram-negative bacteria, which are recognised by the host leading to an 
oversecretion of cytokines that seem to be damaging to the host. 
The pathophysiology of sepsis seems be a product of a multi-system disorder, where 
septic patients seem to have an uncontrolled initiation of coagulation, fibrinolysis and 
inflammation (Figure 1.16). If these cascades are not reversed, the development of 
sepsis is expected, resulting in multi-organ failure and likelihood of death. 
The onset of sepsis triggers the hosts inflammatory response which in turn induces the 
production of inflammatory mediators, such as TNF-α and IL-1β, which have 
detrimental effects on the vascular endothelium. These pro-inflammatory cytokines 
induce the expression of tissue factor (TF), which promotes the coagulation cascade. 
TF interacts with factor VIIa, forming the complex VIIa-TF that activates factors X and 
IX. Ultimately the coagulation cascade leads to the formation of fibrin aggregates and, 
with incorporated platelets, form stable clots that play a major part on the initiation of 
sepsis. Multiple organ failure is thought to be directly related to this coagulation 
cascade, which manifests as disseminated intravascular coagulation (DIC), and 
microvascular thrombosis (Levi and Ten Cate, 1999). 
Another system that becomes uncontrolled due to the onset of sepsis is the fibrinolysis 
cascade. This system is used to remove clots, and unlike the coagulation cascade, 
which becomes overexpressed during sepsis, fibrinolysis becomes suppressed. In 
health, plasmin is the main effector molecule of fibrinolysis. Plasmin production is 
induced when tissue plasminogen activation factor (t-PA) triggers the conversion of 
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plasminogen to plasmin, which in turn is able to degrade fibrin and the clots. The 
fibrinolysis cascade is tightly controlled by two inhibitors: the plasminogen activator 
inhibitor (PAI)-1, which is produced by endothelial cells and platelets in order to inhibit 
t-PA; and the thrombin-activatable fibrinolysis inhibitor (TAFI). Septic patients have this 
system compromised, where as a result of bacterial components, the levels of PAI-1 
and TAFI are increased. The suppression of this system also decreases the levels of 
protein C, which is an inhibitor of PAI-1 and t-PA. (Bajzar et al., 1996, Hotchkiss and 
Karl, 2003).  
 
Figure 1.16. Uncontrolled cascades of inflammation, coagulation and fibrinolysis. A) LBP-LPS 
complexes bind to CD14 and MD2 and are transferred to the TLR4 homodimer; B) Production 
of pro-inflammatory cytokines; C) Proinflammatory cytokines lead to the initiation of the 
coagulation cascade; D) Proinflammatory cytokines also inhibit the function of t-PA, a key 
effector of fibrinolysis as well as E) thrombomodulin which activates protein C pathway. The 
combination of the uncontrolled cascades results in loss of homeostasis and DIC. Adapted from 
Triantafilou and Triantafilou (2006). 
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The combination from the uncontrolled cascades of inflammation, coagulation and 
fibriolysis, seen in patients with sepsis, result in a loss of homeostasis. As the body 
attempts to regain internal equilibrium, most endogenous modulators that are acting 
towards the normalisation of the body are consumed and depleted. This results in 
continuous endothelium injury resulting in a broad organ failure and eventually leading 
to death. Thus, the search for new therapeutic interventions for sepsis continues and 
the innate immunity field has been a key target for this purpose. 
1.4.1. Therapeutics 
Patients with severe sepsis and septic shock manifest striking heterogeneity including 
age, underlying diseases, diverse microbial etiology, local infection site and genetic 
makeup. This problem remains a major hurdle which makes the discovery of new 
therapies for severe sepsis and septic shock especially difficult. Over the past 4 
decades, the situation for septic patients has improved significantly, and yet this 
improvement is almost solely due to advances in the supportive care given to critically 
ill patients and the use of antimicrobial agents (Suffredini and Munford, 2011).  
One of first clinical trials of the sepsis hypothesis was published in 1976 by William 
Schumer. In this study 172 patients with septic shock were either treated with steroid or 
saline: 43 received dexamethasone (DMP), 43 received methylprednisolone (MPS), 
and 86 received saline. William Schumer reported that administration of a high dose of 
steroids could reduce mortality from 38.4% to 10.4% (Schumer, 1976). Forty years 
later, the use of high doses of steroids has been mostly abandoned, whilst the efficacy 
of lower doses still remains uncertain (Marshall, 2014, Minneci et al., 2009, Suffredini 
and Munford, 2011). 
Hundreds of millions of dollars have been spent in more than 100 Phase II and Phase 
III clinical trials, with over 30,000 patients, to test and develop new immunomodulating 
agents, anti-inflammatory agents and anti-endotoxin agents (Marshall, 2014, Opal et 
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al., 2014). The result of this effort and expenditure, with one momentary exception, has 
lead to no new treatments or drugs coming to the market. 
The molecular pathophysiology of sepsis is very diverse. Consequently, the targets for 
therapeutic interventions have had numerous approaches. Strategies have included 
selective neutralisation of bacterial products such as endotoxin; non-selective 
suppression of inflammation with the use of corticosteroids or non-steroidal anti-
inflammatory drugs (NSADs) such as Ibuprofen; the inhibition of host inflammatory 
mediators such as tumor necrosis factor (TNF), interlukin-1 (IL-1), platelet-activating 
factor (PAF), and nitric oxide (NO); the administration of proteins such as granulocyte 
colony-stimulating factor (G-CSF) and interferon γ; and the administration of 
anticoagulant molecules such as activated protein C (APC), anti factor pathway 
inhibitor (TFPI), antithrombin, thrombomodulin, or heparin (Marshall, 2014). 
1.4.1.1. Anti-endotoxin 
In the 1970s and 1980s attention focused on neutralizing Gram-negative bacterial 
endotoxin or lipopolysaccharide (LPS), and anti-endotoxin antibodies were tested in 
several trials. Promisingly, the first human trial of anti-endotoxin showed initial positive 
results, where Ziegler et al. (1982) used J5 antiserum containing polyclonal antibodies 
directed against the core glycolipid structure of LPS, but such results were never 
reproduced. Clinicians also tested 2 anti-LPS monoclonal antibodies – HA-1A, a 
human antibody; and E5, a murine antibody. HA-1A is a human monoclonal IgM 
antibody that binds specifically to the lipid A domain of LPS. Ziegler et al. (1991) 
showed improved mortality with the use of HA-1A therapy in 200 patients with proven 
Gram-negative sepsis. On the contrary, the 343 septic patients without culture proven 
Gram-negative bacteria showed no treatment benefit. With regards to E5, another 
monoclonal IgM anti-endotoxin antibody, showed improved mortality and the potential 
to reverse organ failure (Greenman et al., 1991). In a follow-up study, Bone et al. 
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(1995) showed that patients with suspected or proven Gram-negative sepsis treated 
with E5 had no difference in mortality. Further larger clinical trials of both HA-1A 
(McCloskey et al., 1994) and E5 (Angus et al., 2000) have failed to show any benefits.  
A novel approach to the treatment of sepsis involved the enterobacterial common 
antigen (ECA), a specific glycophospholipid surface antigen shared by all members of 
the family Enterobacteriaceae. Organisms from this family are responsible for about 
70% of proven Gram-negative infections. ECA has a close association with LPS in the 
bacterial cell wall. A human monoclonal IgM antibody, MAB-T88, directed at the 
enterobacterial common antigen was selected for its affinity and neutralisation of ECA. 
Albertson et al. (2003) evaluated the efficacy of MAB-T88 in 826 patients with sepsis in 
a prospective, randomized, double-blinded, placebo controlled, multicenter. There was 
no difference in mortality in all the patients enrolled (MAB-T88 37% vs. placebo 34%). 
A more specific endotoxin neutralizing agent, recombinant bactericidal/permeability-
increasing protein (rBPI21), seemed to prevent morbidity from meningococcal sepsis 
when tested in children. rBPI21 is a recombinant 21-kDa modified fragment of human 
BPI, a natural protein stored in the neutrophil granules that binds and neutralises the 
effects of LPS. Although rBPI21 appeared to prevent morbidity, it did not improve 
survival rate (Levin et al., 2000). 
In recent times, 3 novel anti-endotoxin compounds were tested in clinical trials but 
unfortunately all failed to meet their primary goals. 
In 2009, Dellinger and co-workers assessed the efficacy of a phospholipid emulsion 
(GR270773) in Gram-negative severe sepsis. This phospholipid emulsion, which binds 
and neutralizes endotoxin, was administered to 1379 patients with confirmed or 
suspected Gram-negative sever sepsis. Regrettably, this multicenter clinical trial 
stopped early because of adverse and life threatening events. Treatment with 
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phospholipid emulsion did not reduce mortality, nor did the onset of new multi organ 
failure (Dellinger et al., 2009). 
The quest to find a new therapeutic approach led clinicians to attempt to inhibit toll-like 
receptor 4 (TLR4), which is expressed on the surface on immune cells, and binds to 
LPS resulting it to initiate the release of proinflammatory cytokines. The first attempt 
was made with TAK-242, a small-molecule which functions as an inhibitor of the TLR4 
signalling pathway after TLR4 binds with LPS. Promising preliminary results, on a 
septic animal model, showed a decrease in cytokine levels. Rice et al. (2010) 
evaluated the efficacy of TAK-242 in a randomized, placebo-controlled trial of patients 
with severe sepsis shock or respiratory failure. In this trial TAK-242 failed to suppress 
cytokine levels, in particular IL-6, and showed no difference in 28-day mortality 
compared to placebo in affected patients. The second and most recent try was with 
eritoran tetrasodium (E5564), a synthetic lipid A antagonist that blocks LPS from 
binding at the cell surface MD2-TLR4 receptor. Phase 1 trial showed that eritoran 
blocked the effects of LPS and cytokine (TNF-α and IL-6) responses, and clinical 
illness in healthy volunteers (Lynn et al., 2003). In a phase 2 trial of E5564 treatment, in 
patients with high risk of death, positive results showed a lower mortality rate against 
placebo (Tidswell et al., 2010). Opal et al. (2013) performed a multinational phase 3 
trial in 197 ICUs in order to determine if eritoran would reduce sepsis-induce mortality. 
The result was negative compared with placebo. 
In recent years polymyxin B (PMX) has been a target for possible anti-endotoxin 
therapy. Polymyxin B is a polypeptide antibiotic that has the ability to bind and 
neutralise endotoxin. Intravenous injection of PMX has significant nephrotoxic and 
neurotoxic effects. However, a novel therapeutic strategy where PMX has been 
successfully adsorbed to polystyrene-derivative fibers (PMX-F) in a hemoperfusion 
medical device. Immobilized PMX does not leak out into the blood stream, removing its 
known toxic effects (Klein et al., 2014). Cruz et al. (2007) have published a systematic 
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review of 28 trials using PMX direct hemoperfusion (PMX-DHP) to treat patients with 
severe sepsis and septic shock. Although the authors commented that the analysed 
studies were of “suboptimal quality”, i.e. heterogeneity amongst the trials, the results 
appear to have a favourable outcome on mean arterial pressure, dopamine use, 
oxygenation (PaO2/FiO2) ratio and mortality. In 2009, the Early Use of Polymyxin B 
Hemoperfusion in Abdominal Sepsis (EUPHAS), a randomized trial of 64 patients in 10 
Italian ICUs, showed significant improvements in hemodynamics and organ 
dysfunction. It also reduced mortality from 53% in standard therapy to 32% in the PMX-
DHP group (Cruz et al., 2009). Although positive, these results might be skewed as the 
trial was stopped early after an interim analysis showed a mortality difference in the 
PMX-DHP group. Also, the trial was not blinded and patients were selected based on 
evidence of intra-abdominal sepsis where endotoxin levels were not measured prior 
enrolment for therapy. In light of these limitations, the EUPHAS investigators have 
called for further studies into the effectiveness of PMX-DHP (Kellum and Uchino, 
2009). The ongoing trial, Evaluating the Use of Polymyxin B Hemoperfusion in a 
Randomized controlled trial of Adults Treated for Endotoxemia and Septic shock 
(EUPHRATES), is the latest trial investigating the safety and efficacy of PMX-DHP 
based on mortality at 28-days in subjects with septic shock who have high levels of 
endotoxin and are treated with standard medical care plus use of the PMX medical 
device (Toraymyxin PMX cartridge), versus subjects who receive standard medical 
care alone. This trial began in June 2010 and is expected to be completed by July 
2016. EUPHRATES is a multi-centered, placebo-controlled and blinded trial which is 
comprised of 360 patients from 50 ICUs in the United States and Canada. In the first 
quarter of 2014, the second interim analysis recommended to continue the trial (Klein 
et al., 2014). 
 
 
50 
 
1.4.1.2. Corticosteroids 
From the hypothesis that septic shock and organ failure developed from the host 
inflammation, clinical trials turned their efforts to anti-inflammatory interventions that 
would improve outcomes. Glucocorticoids have been studied in 21 trials over 4 
decades with the objective to reduce inflammation in patients with sepsis. From 1963-
1988 a meta-analysis of 9 trials showed that short doses of high-dose of steroids 
(median dose 23,975 mg of hydrocortisone equivalents over a median of 1 day) 
increased mortality and worsened secondary infections. In contrast, 11 small trials 
conducted after 1997, which involved longer courses of lower-dose steroids (median 
dose, 1,209 mg equivalents of hydrocortisone over a median of 6 days) were 
associated with beneficial treatment effects, including improved shock reversal and 
survival (Minneci et al., 2004, Minneci et al., 2009). One of the main limitations of 
studies of low doses of steroids in septic shock is that the beneficial effects were found 
mainly in small trials. Furthermore, the Corticosteroid Therapy of Septic Shock 
(CORTICUS), the largest and most recent randomized controlled trial, was studied in a 
low-risk population (Minneci et al., 2009, Sprung et al., 2008). This multicenter trial 
reported that low doses of hydrocortisone did not improve survival or reversal of shock 
in patients with septic shock (Sprung et al., 2008). The beneficial effects of low-dose 
steroids needs to be confirmed in a large, multicenter trial of high-risk patients. Until 
this data is available, the decision to administer low-dose steroids for septic patients 
should be based on individual patients severity of illness and potential risk from steroid 
therapy (Marik et al., 2008, Minneci et al., 2009).  
1.4.1.3. Anti-inflammatory therapies 
Following the discovery of tumor necrosis factor (TNF-α) and interleukin 1 (IL-1β) it was 
believed that these pro-inflammatory cytokines are responsible for the inflammatory 
response that leads to hypotension, activation of the clotting cascade and organ 
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dysfunction, characteristics found in septic patients. Non-selective high-dose steroid 
therapy was abandoned in favour of testing agents that could selectively dampen these 
proinflammatory mediators.  
1.4.1.3.1. Anti-TNF-α therapy 
Due to its pivotal position in the inflammatory response to endotoxin-induced shock, 
controlling the levels of circulating TNF-α makes an attractive therapeutic target. 
Investigations of this therapeutic approach in patients were initiated in the 1990s, 
during which numerous strategies were developed in order to attenuate or neutralize 
excess circulating TNF-α. One of these approaches attempted to use TNF-α receptor 
constructs as soluble inhibitors of TNF-α bioactivity. There are two cell membrane-
associated TNF-α receptors, p55 and p75, when cleaved from the cell membrane and 
released into circulation bind free TNF-α, preventing it from binding to target cells, 
consequently, not activating them. A p55 TNF-α receptor fusion protein (lenercept) was 
created by fusing the extracellular domain of the receptor to the Fc region of an 
immunoglobulin. Although there were encouraging results in preclinical and Phase II 
trials, in a larger multicenter Phase III trial, lenercept showed no significant effect on 
mortality in patients with severe or early septic shock (Abraham et al., 2001a). 
Administration of a recombinant p75 fusion protein was also investigated. Although 
preliminary results in animal models, where it prevented death due to bacteraemia, 
when administered to patients with sepsis an unexpected increase in mortality was 
observed for treated patients (Fisher et al., 1996). 
Another strategy clinicians used in order to neutralize circulating TNF-α was the use of 
specific anti-TNF-α antibodies. Reinhart et al. (2001) investigated whether or not 
treatment with an anti-TNF-α monoclonal antibody, afelimomab, would improve survival 
in septic patients with IL-6 concentrations of >1000 pg/mL. This hypothesis was tested 
in a prospective, randomized placebo controlled trial, the RAMSES study. This study 
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had 446 participants (prospectively stratified from 944 patients: IL-6 levels >1000 
pg/mL - 446 patients and <1000 pg/mL – 498) with high levels of IL-6. Patients treated 
with afelimomab showed a 3.7% reduction in mortality rate but this result did not reach 
statistical significance. A later study, the MONARCS trial, tested the same monoclonal 
antibody fragment in 2,643 patients with severe sepsis and elevated IL-6 levels. Out of 
the total number of patients, 998 had elevated IL-6 levels (>1000 pg/mL). The results 
from the MONARCS trial, a phase III trial, showed that the administration of 
afelimomab lowered circulating levels of TNF-α and IL-6, and accelerated the 
resolution of organ dysfunction. This study also found a reduction in mortality of 5.8% 
in patients with elevated IL-6 levels (IL-6 levels >1000 pg/mL: afelimomab 42.8% vs. 
placebo 48.6%. IL-6 <1000 pg/mL: afelimomab 26.4% vs. placebo 27.7%), 
demonstrating that afelimomab had a greater effect in patients at high risk of mortality 
(Panacek et al., 2004). In a similar investigation, CytoFab, a polyclonal anti-TNF-α 
fragment antigen binding (Fab) IgG fragments, was evaluated for safety and 
effectiveness in 81 septic patients with either shock or two organ dysfunctions. 
Although CytoFab was effective in reducing levels of circulating TNF-α and IL-6, and in 
increase increasing ventilator-free days, it did not show a difference in mortality (Rice 
et al., 2006). Recently, CytoFab was further developed into AZD9773 (also a polyclonal 
antibody to TNF-α), and in a phase IIa in 70 patients with severe sepsis, AZD9773 was 
well tolerated, had an acceptable safety profile, and higher dose treatment successfully 
reduced TNF-α concentrations to near-undetectable levels (Morris et al., 2012). The 
evaluation of AZD9773 continued to a larger phase IIb study. This was a multicenter, 
randomized, double-blind, placebo controlled trial in 300 patients evaluating the 
efficacy of two intravenous dosing regiments of AZD9773. This phase IIb demonstrated 
that although AZD9773 decreased circulating TNF-α levels in patients with severe 
sepsis or septic shock, it had no statistically significant impact on ventilator-free days or 
mortality in comparison with the placebo group (Bernard et al., 2014). 
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1.4.1.3.2. Anti-IL-1 therapy 
IL-1 is a proinflammatory cytokine that is synthesized by monocytes, macrophages and 
neutrophils in response to TLR engagement and, with working with TNF-α, promotes 
the progression of the hyperimmune response typical of a septic patient. IL-1 gene 
transcription is normally accompanied by the transcription of the gene for IL-1 receptor 
antagonist (IL-1ra), which reversibly binds and competitively inhibits IL-1 receptors 
(Arend, 1991). This makes the modulation of IL-1ra, and subsequently IL-1, an 
attractive target for sepsis immunotherapy. Recombinant IL-1ra has been evaluated in 
three multicenter trials. Fisher et al. (1994b), in a phase II study, evaluated the use of 
human recombinant IL-1ra (rhIL-1ra) in the treatment of patients with sepsis. The 
results from this 99 patient trial showed that dose-depended administration of rhIL-1ra 
reduced mortality from 44% to 16% for treated patients. These encouraging results led 
to two subsequent phase III trials. The first, evaluated the use of rhIL-1ra in the 
treatment of 893 patients with sepsis, where there was not a statistical significant 
increase in survival for patients treated with rhIL-1ra compared with placebo (Fisher et 
al., 1994a). Secondly, Opal and colleagues published a trial in 1997 where continuous 
infusion of rhIL-1ra to patients (n=696) with severe sepsis failed to demonstrate a 
reduction in mortality. This trial was terminated after an interim analysis revealed a low 
likelihood of showing a statistical difference in their primary endpoint, 28-day mortality 
(Opal et al., 1997).  
1.4.1.3.3. Platelet-activating factor therapy 
The making of bioactive lipids from cell membrane components occurs alongside the 
transcription of pro-inflammatory cytokines. Phospholipase A2 (PLA2) catalyses the 
conversion of cell membrane phospholipids to arachidonic acid and lysophospholipds 
like platelet-activation factor (PAF). Receptors for PAF are expressed on platelets, 
neutrophils and monocytes and have been associated in priming, amplifying and 
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regulating the release of inflammatory mediators in sepsis (Dhainaut et al., 1998). 
There have been two distinct strategies to neutralize PAF: PAF receptor antagonist 
BN52021 (Ginkgolide B); and inactivating PAF activity through PAF acetylhydrolase. In 
1994, Dhainaut and co-workers evaluated the safety and efficacy of BN52021, a 
natural platelet-activating factor receptor antagonist (PAFra), in the treatment of 
patients with sepsis. Although the initial results seemed to be positive, where the 
mortality rate was 42% for the PAFra group compared to 51% in the placebo, a phase 
III trial in 609 patients showed that a 4-day administration of BN52021 failed to 
demonstrate a statistically significant reduction in mortality of patients with severe 
sepsis (Dhainaut et al., 1998, Dhainaut et al., 1994). Two other PAF receptor 
antagonists, TCV-309 and lexipafant, were tested but neither showed any improvement 
in mortality rates (Marshall, 2003). The other strategy exploits the fact that PAF is 
inactivated through the enzymatic action of PAF acetylhydrolase (PAF-AH). This 
enzyme accounts for all the PAF-inhibitory activity found in human blood. Septic 
patients have low circulating levels of PAF-AH, and a recombinant human enzyme 
(rPAF-AH, Pafase) has been tested in a phase II trial in 127 patients with severe 
sepsis. The results from this trial indicated that rPAF-AH was well tolerated and the 
mortality rate was lower in patients treated with rPAF-AH compared with patients 
receiving placebo (Schuster et al., 2003). A phase III trial in 1,425 (2522 patients 
planed but trial terminated early) patients was undertaken in order to find out if rPAF-
AH would decrease 28-dy all-cause mortality in patients with severe sepsis. Although it 
was well tolerated and not antigenic, the trial was stopped early as the results from this 
large phase III trial showed that rPAF-AH does not decrease mortality in patients with 
severe sepsis (rPAF-AH 25% vs. placebo 24%) (Opal et al., 2004). 
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1.4.1.4. Nitric oxide  
Nitric oxide (NO) has been found to have a variety of effects in the innate response to 
infection and also plays an important role in the development of vasodilatation during 
septic shock. Nitric oxide is continuously generated from L-arginine by nitric oxide 
synthase (NOS) and is found, in the healthy state, at low concentrations. Endotoxin 
and cytokines are associated with the increased production of nitric oxide, which in turn 
is associated with hypotension, decreased responsiveness to vasoconstrictors, and 
development of multiple organ dysfunction (Lopez et al., 2004). The different isoforms 
of NOS can be partially inhibited, reducing the overproduction of nitric oxide. This may 
be a beneficial intervention for septic patients. The administration of NOS inhibitors, 
such as a methylated arginine analog, L-N-monomethyl argenine (L-NMMA), or by N-
omega-nitro-L-arginine methyl ester (L-NAME), to patients with septic shock have 
shown to restore hemodynamics, increased blood pressure and a decrease in the need 
for vasopressors (Marshall, 2003). The safety and efficacy of NG-methyl-L-arginine 
hydrochloride (546C88), a NOS inhibitor, was assessed in a phase II clinical trial in 312 
patients with septic shock. The results demonstrated that patients with septic shock in 
the 546C88 treatment group showed an elevation of blood pressure, increase in 
resolution of shock, decrease in the requirement of vasopressors and a reduction in 
plasma nitrate concentrations (Bakker et al., 2004, Watson et al., 2004). A randomized, 
double-blind, placebo-controlled phase III clinical study of 546C88 was performed in 
order to assess its safety and efficacy in reducing mortality in patients with septic 
shock. Unfortunately this trial was stopped early by a data safety monitoring board, due 
to excess mortality in the 546C88 group (546C88 59% vs. placebo 49%) (Lopez et al., 
2004). An alternative approach to inhibit nitric oxide is the inhibition of guanylate cyclise 
with methylene blue. The administration of methylene blue to patients has shown little 
or no effect on cardiac output when administered in septic patients (Weingartner et al., 
1999). 
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1.4.1.5. Anticoagulant Therapy 
The onset of severe sepsis not only results in acute activation of the inflammatory 
system, but also simultaneously stimulates the coagulation system and inhibits 
fibrinolysis. From an adaptive point of view, activating coagulation and inhibiting 
fibrinolysis can be seen as an effort to isolate the infection with the intention of reducing 
its spread throughout the body. However, in the process of severe sepsis, this results 
in a counterproductive action as the infection is likely to be spread throughout the 
bloodstream and the activation of the coagulation system results in diffuse 
microvascular thrombi with widespread endothelial damage and organ dysfunction. In 
health, the activation of coagulation is tightly regulated through the activity of three 
endogenous anticoagulant pathways: the tissue-factor-pathway-inhibitor (TFPI) 
pathway, the antithrombin pathway, and the protein C pathway. Sepsis causes the 
deregulation of each of these pathways – making them prime targets in the treatment 
of sepsis (Bernard and Bernard, 2012, Marshall, 2003). 
1.4.1.5.1. Tissue factor and antithrombin 
Tissue factor (TF) is a transmembrane cell surface receptor found in endothelial cells 
which acts to initiate the coagulation pathway. TF inhibitor (TFPI) is an endogenous 
serine protease inhibitor that has been tested in septic patients in order to protect 
microvasculature endothelium from coagulation. Tifacogin (recombinant TFPI (rTFPI)) 
has been tested in three phase II studies. The most recent one, tifacogin was tested in 
210 patients and results showed that there was a reduction in circulating IL-6 levels 
and a trend toward reduction in 28-day all-cause mortality in the tifacogin group 
compared with placebo (Abraham et al., 2001b). Tifacogin was tested in the phase III 
trial, OPTIMIST (optimized phase III tifacogin in multicenter international sepsis trial), 
evaluating its efficacy in reducing mortality in patients with severe sepsis. This trial 
57 
 
failed to show any benefit in mortality, and it was associated with an increase in serious 
adverse events with bleeding in the tifacogin group (Abraham et al., 2003).  
Antithrombin III (AT III), an anticoagulant which is synthesized in the liver, was the 
subject of sepsis therapy due to the fact that AT III levels are reduced in septic 
patients. A meta-analysis of three trials, published in the 1990s, recruiting 122 patients 
showed promising results – a 22.9% reduction in 30-day all-cause mortality in patients 
treated with AT III (Eisele et al., 1998). However, an international multicenter phase III 
trial that recruited 2,314 patients was unable to show a difference in overall 28-day 
mortality (AT III 38.9% vs. placebo 38.7%). Furthermore, like tifacogin, high-dose of AT 
III was associated with an increased risk of haemorrhage (Warren et al., 2001). 
1.4.1.5.2. Activated protein C 
So far, the only drug approved for the treatment of severe sepsis was Xigris 
(drotecogin alfa, a recombinant human activated protein C (rhAPC)). It was 
investigated due to its anti-inflammatory, anti-coagulant and profibrinolytic properties. 
After one positive study in baboons (Taylor et al., 1987), the efficacy and safety of 
rhAPC for severe sepsis was evaluated in a randomized, double-blind, placebo-
controlled, multicenter phase II trial – the PROWESS study. This trial was stopped 
early for efficacy, 28-day mortality was lower in the rhAPC group. Treatment was 
associated with a 6.1% absolute reduction (24.7% rhAPC vs. 30.8% control) and 
19.4% relative risk reduction, with a relation noted between severity of disease and 
survival advantage (Bernard et al., 2001). The drug was approved by the US Food and 
Drug Administration (FDA) for use in the most severely ill septic patients with APACHE 
II scores greater than 25. APACHE II (Acute Physiology and Chronic Heath Evaluation 
II) is a severity-of-disease classification system (score from 0 to 71, where higher 
scores correspond to more severe disease and higher risk of death) and is applied 
within 24 hours of admission of a patient to an ICU. However, treatment with rhAPC 
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was reported to have no beneficial effects along with an increased incidence of serious 
bleeding complications in low-risk population. In addition, the patients in this trial who 
had an APACHE II score greater than 25, and treated with rhAPC, did not show any 
survival benefit observed in the first phase III trial (Abraham et al., 2005). Equally, a 
paediatric trial published in 2007 that evaluated 477 septic children did not find any 
beneficial effects (Nadel et al., 2007). In light of these contradictory results, authorities 
decided to request another randomized, multicenter, placebo-controlled study in order 
to re-assess the benefits noted in PROWESS. This lead to a subsequent trial, 
PROWESS-SHOCK. Regrettably, the results were not reproduced and the treatment 
was voluntarily removed from the market by the manufacturer (Ranieri et al., 2012). 
1.4.1.5.3. Thrombomodulin 
Thrombomodulin (TM), a transmembrane protein on the endothelial cell surface 
involved in the regulation of the coagulation system, is currently being targeted as a 
new therapeutic of sepsis. Recombinant human soluble thrombomodulin (rhTM) binds 
to thrombin to inactivate coagulation, and the thrombin-rhTM complex acts upstream in 
the activated protein C pathway leading to the production of activated protein C. 
Disseminated intravascular coagulation (DIC), resulting from a widespread activation of 
coagulation pathways has been linked with mortality in patients with severe sepsis. A 
control study, performed by Yamakawa et al. (2011), of 20 patients with severe sepsis-
induced DIC treated with rhTM compared to 45 controls showed improved 28-day 
morality and organ dysfunction in those treated with rhTM (rhTM group 25% vs. control 
47%). In order to determine the safety and efficacy of rhTM (ART-123) a phase IIb, 
international, multicenter, double-blind, randomized, placebo-controlled trial was 
undertaken. ART-123, a soluble recombinant human thrombomodulin, acts by reducing 
the thrombin-mediated clotting and enhances the production of activated protein. In this 
trial of 750 patients, the results showed an improved 28-day mortality rate of 3.8% 
(ART-123 group 17.8% vs. placebo group 21.6%). Furthermore, ART-123 is a safe 
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intervention in critically ill patients with sepsis and suspected DIC, and the findings of 
this trial support a phase III study (Vincent et al., 2013). 
1.4.1.3.4. Heparin 
The underlying principle behind anticoagulant treatments is that certain factors (TFPI, 
AT and APC) are found at a low levels in septic patients, therefore with the use of 
recombinant technology these levels are brought back to a normal. On the contrary, 
heparin, a naturally occurring proteoglycan in the coagulation system, does not 
replenish what sepsis patients have depleted, it binds to and activates antithrombin, 
which in turn reduces thrombin production and fibrin formation. The HETRASE study 
was performed in order to determine the effects of heparin as a treatment for sepsis. 
This randomized, double-blind, placebo-controlled, single centre clinical trial evaluated 
the length of stay and change in organ dysfunction of 319 patients with sepsis. The 
results did not demonstrate any beneficial effects, including 28-day mortality rate 
(Jaimes et al., 2009).  
1.4.1.6. Immunostimulants 
Sepsis is normally viewed as an excessive activation if the inflammatory cascade in 
response to microbial pathogens. From time to time, patients present a delayed 
hypersensitivity, increased immune cell apoptosis, reduced lymphocyte blastogenesis 
and suppression of major-histocompatibility-complex class I/II molecules, resulting in a 
immunological exhaustion (Hotchkiss and Opal, 2010). One of the main strategies in 
attempting to reverse this state of immune suppression has been the use of 
granulocyte colony-stimulating factor. The growth factors granulocyte-macrophage 
colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) 
act on myeloid cell precursors and stimulate them to develop into mature neutrophils. 
In 2003, a phase III clinical trial investigated the effect of G-CSF (filgrastim) in patients 
with sepsis. A previous phase I/II trial demonstrated that filgrastim had the ability to 
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increase neutrophils count and improve the resolution of shock, but the results from the 
phase III clinical trial showed that there was no difference in mortality (filgrastim 29% 
vs. placebo 25.5%) (Root et al., 2003). A later clinical trial evaluated the effect of early 
administration of G-CSF in patients with septic shock. The results from this study 
involving 166 septic patients demonstrated no clinical benefit (mortality rate G-CSF 
27% vs. placebo 25%) (Stephens et al., 2008). Compared to G-CSF, GM-CSF 
demonstrates broader effects and induces proliferation and differentiation of 
monocytes/macrophages, induces the release of pro inflammatory cytokines and 
induces antigen presentation (Schefold, 2011). A randomized phase II trial evaluated 
whether GM-CSF therapy would improve survival in patients with severe sepsis. This 
study showed no apparent difference in survival rate of the 19 patients at 30 days (GM-
CSF 80% vs. placebo 75%). There was also no improvement in the discharge both 
from the hospital and ICU stay (Presneill et al., 2002). In 2009, Meisel and colleagues 
tested whether GM-CSF would reverse monocyte deactivation, a trait of sepsis-induced 
immunosuppression. This was carried out by treating patients with GM-CSF, or 
placebo, and measuring the HLA-DR expression on monocytes, a biomarker of sepsis-
associated immunosuppression. The results from this trial show that patients in the 
GM-CSF group had HLA-DR expression normalized in 19/19 treated patients vs. 3/19 
control. The mortality rate also improved from 21% placebo vs. 16% in GM-CSF group, 
although it did not reach statistical significance (Meisel et al., 2009). A meta-analysis 
made by Bo and co-workers (2011) investigated the effects of G-CSF and GM-CSF 
therapy in septic patients. The authors found no evidence that supports the use of G-
CSF or GM-CSF in patients with sepsis although they suggest the accomplishment of 
large, prospective, multicenter clinical trials in order to investigate the potential of these 
immunosuppressants (Bo et al., 2011). 
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1.4.1.7. Other therapies 
1.4.1.7.1. Statins 
There are a number of ways in which statins may have the ability to affect the immune 
response in sepsis – from their ability to increase the physiologic concentrations of 
nitric oxide; the decrease in the production of proinflammatory cytokines, such as TNF-
α, IL-1 and IL-6; and antithrombic properties, decreasing the effect of the sepsis-
induced coagulation system (Janda et al., 2010). A multicenter cohort study examined 
the effect of statin use and clinical outcomes in patients with sepsis. The results from 
this study showed no differences in severe sepsis risk between statin users and non-
users for either prior statin use (30.8% vs. 30.7%) or continued use (30.2% vs. 30.8%). 
There was also no mortality benefit for prior or continued statin use (Yende et al., 
2011). 
1.4.1.7.2. Lactoferrin 
Lactoferrin, a glycoprotein belonging to the transferrin family, is best known for its 
bactericidal activities within specific granules of human neutrophils. It is also secreted 
as a protein which plays an important role in the innate mucosal defence, acting as an 
antimicrobial agent along the epithelial surfaces. Talactoferrin alfa (TLF), a 
recombinant form of human lactoferrin, has similar properties and acts as a mucosal 
barrier maintaining the gastrointestinal properties. Oral TLF has been shown, in both 
animal and preclinical studies, to protect against gut damage and to reduce 
translocation of bacteria across the gut mucosa (Guntupalli et al., 2013). A phase II 
randomized, double-blind, placebo-controlled study was carried out to evaluate the 
efficacy of TLF in patients with severe sepsis. The results from this study, which 
enrolled 190 patients (97 patients received TLF and 93 placebo), showed that the 
administration of TLF reduced 28-day all-cause mortality (TLF group 14.4% vs. placebo 
26.9%). Unfortunately, a follow-up phase II/III clinical trial with oral TLF in adult sepsis 
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was stopped early when the placebo group had a better 28-day mortality than the TLF 
group (Guntupalli et al., 2013, McCulloh and Opal, 2013). 
1.4.2. Dysregulated innate immune responses in sepsis 
A tight regulation of the innate immune system is key to keep the body alive. The loss 
of regulation or overstimulation of innate immunity can lead to detrimental and often-
fatal symptoms. Septic shock is a prime example of a condition that reflects this 
overreaction of the hosts innate immune system, where bacterial components cause 
the over secretion of cytokines, which trigger a chain of damaging cascades that cause 
this condition. In septic patients, as a result of the uncontrolled cascades of 
inflammation, coagulation and fibrinolysis, the homeostasis of the host is compromised, 
which leads to vital organ failure and vascular collapse. 
It is imperative to identify molecules that are able to modulate the innate immune 
responses, in order to reverse these often-fatal outcomes. A variety of virulence factors 
derived from bacteria has been shown to be able to modulate innate immune 
responses. The focus of this thesis is to characterise one such virulence factor from 
Yersinia pestis. 
1.5. Yersinia species 
The genus Yersinia is a member of the class Gammaproteobacteria, within the family 
Enterobacteriaceae, a heterogeneous group of Gram-negative aerobic bacilli (Hurst et 
al., 2011). This genus has undergone extensive diversification through its evolution, 
and has 11 currently recognized species, three of which are human pathogens: 
Yersinia pestis, Yersinia pseudotuberculosis and Yersinia enterocolitica. These three 
pathogenic Yersinia species differ from each other in their pathogenesis. Whilst Y. 
pestis is the aetiological agent for plague, Y. pseudotuberculosis and Y. enterocolitica 
are important causes of human diarrhoeal diseases (Duan et al., 2014, Perry and 
Fetherston, 1997). 
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Y. pseudotuberculosis is primarily an animal pathogen (domestic and farm animals and 
birds) although it can occasionally cause mesenteric adenitis in humans. More rarely 
can cause sepsis. It is likely to be transmitted to humans via food contaminated with 
infected faeces. Y. enterocolitica causes diarrhoeal disease, terminal ileitis and 
mesenteric adenitis. Infection may be complicated by the onset of sepsis or reactive 
polyarthritis. Both Y. pseudotuberculosis and Y. enterocolitica are food-borne 
pathogens and are transmitted through the faecal-oral route from domestic animals, 
such as sheep, swine, rodents, dogs, cats, birds and wild animals (Duan et al., 2014). 
Y. pestis is a non-motile, Gram-negative, facultative intracellular coccobacillus that is 
primarily found in rodents and is transmitted to humans via infected fleas, specially the 
rat flea (Xenopsylla cheopsis). Y. pestis is very closely related to the gastrointestinal 
pathogen Y. pseudotuberculosis, and it has been proposed that Y. pestis evolved 
between 1,500 and 20,000 years ago from Y. pseudotuberculosis (Achtman et al., 
1999). It grows at temperatures between 4 and 40ºC and tolerates pH 5 to 9.6, 
although its optimal growth occurs at temperatures of 28ºC to 30ºC and pH 7.2 to 7.6 
(Perry and Fetherston, 1997). Y. pestis is the cause of plague and is still endemic in 
some areas of the world. Unless quickly treated, bubonic plague can have a mortality 
rate between 50% and 90%. Diagnosis and appropriate treatment can reduce bubonic 
plague mortality to 5% to 15% (Prentice and Rahalison, 2007, Williamson, 2009). 
1.5.1. Plague 
Plague is an ancient disease and has been responsible for an estimate of 200 million 
deaths over several millennia (Perry and Fetherston, 1997). The causative agent is 
Yersinia pestis and it was first isolated by Alexandre Emile John Yersin (1863-1943) in 
1894 during the Hong Kong epidemic. Y. pestis has been linked with three pandemics. 
The first began in Pelusium, Egypt, and it is known as the Justinian plague (A.D. 541 to 
767). The second pandemic, famously known as the Black Death, occurred from 1336 
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to the early 19th century. It spread from the Caspian Sea to all of Europe, killing up to a 
third of the European population. The third pandemic Y. pestis pandemic began in the 
middle of the 19th century in the Chinese province of Yünnan and spread globally. Most 
of the millions of deaths in this pandemic were in India and China, and only in 1950 
was it finally considered over (Achtman et al., 1999, Perry and Fetherston, 1997). 
More recently, two epidemics of plague have occurred in India, between September 
and October 1994, showing that plague is not eradicated and can still be a 
contemporary problematic disease (Perry and Fetherston, 1997). Plague is one of the 
World Health Organisation (WHO) quarantinable diseases, and at least 1000 to 5000 
human cases of plague and 100 to 200 deaths are still reported to the WHO annually 
(Stenseth et al., 2008, Titball et al., 2003). 
1.5.2. Yersinia pestis virulence factors 
The success of Yersinia pestis in causing these pandemics lies with the fact that it 
possesses several plasmids that encode virulence factors that aid the survival and 
dissemination through its host. These include a 70 kb plasmid (pCD1), which is 
common to all three human pathogen Yersinia species, and two unique plasmids to Y. 
pestis, a larger 100 kb termed pMT1 and a smaller 9.6 kb plasmid termed pPCP1 (Hu 
et al., 1998). 
The pCD1 (calcium dependence) plasmid, also known as pYV, contains genes which 
encode for the type III secretion system (T3S). This system comprises of Yersinia outer 
proteins (Yops) and their chaparones, V antigen and other regulatory proteins required 
for the bacterium to inject toxic substances into mammalian cells and essential for 
virulence. In all three species of Yersinia there are an array of genes that make part of 
a multicomponent virulence regulon, known as the low-calcium response (Lcr), which is 
instrumental in regulating the expression of the virulence genes (Hu et al., 1998, Perry 
and Fetherston, 1997).  
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The pMT1 (murine toxin), also known as pFra in some strains, carries genes for the 
production of two proteins, Fraction-1 antigen (F1-antigen) and a phospholipase D 
(PlD). The 15 kDa capsular protein Fraction-1 (F1) antigen, also known as Caf1, is a 
capsule-associated protein which has antiphagocytic properties. F1-antigen is under 
the influence of the caf operon which is usually expressed at 37ºC, which regulates the 
assembly and anchoring of the F1 onto the outer membrane, where forms a large 
homopolymer (>200kDa) in a stacked circular structure composed of heptamers (Tito 
et al., 2001). Not only is F1-antigen thought to have an anti-phagocytic effect, but also 
it seems it has an important role in bacterial transmission as it aids the adhesion to 
epithelial cells (Liu et al., 2006). Phospholipase D is important in colonization of the flea 
gut and it appears to be needed to protect the bacterium from antibacterial factors in 
the flea midgut (Perry and Fetherston, 1997, Prentice and Rahalison, 2007). 
Finally the pPCP1 (pesticin, coagulase, plasminogen activator) plasmid encodes for a 
collection of proteins which aid the propagation of Y. pestis in the mammalian host. 
These proteins include pesticin, coagulase and plasminogen activator (PLA), which 
collectively appear to be important for the dissemination of Y. pestis by the breaking-
down of the physical barriers, i.e. endothelial and cell membrane, in order to achieve a 
successful transmission. PLA, a surface protease, is an essential virulence factor that 
activates plasminogen to plasmin, which cleaves fibrin clots and extracellular matrices, 
resulting in a facilitated migration of Y. pestis into mammalian endothelial cells 
(Lahteenmaki et al., 2001, Perry and Fetherston, 1997). 
1.5.3. LcrV or Virulence (V) antigen 
LcrV, also known as V antigen, is a 326-residue, 37 kDa soluble protein encoded by 
the lcrV gene in the pCD1/pYV plasmid, which is common in all three human 
pathogenic Yersinia species. V antigen was the first antigen to be associated with full 
virulence of Y. pestis, and not only plays vital role in regulating the translocation of 
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Yops, but also has anti-host functions of its own, making it a multifunctioning protein 
that is crucial for virulence, and is also required as an active and passive mediator of 
disease resistance (Fields et al., 1999, Pettersson et al., 1999). The first crystal 
structure of Y. pestis LcrV, at a 2.2 Å resolution, was determined by Derewenda et al. 
(2004). Recently, Chaudhury and colleagues (2013) refined the structure of Y. pestis 
LcrV and reported at 1.65 Å resolution (figure 1.17). 
  
 
Figure 1.17: Structure of Yersinia pestis LcrV at 1.65 Å resolution. In pale pink the N-terminal 
globular domain, in green the central coiled-coil domain and in light blue the less structured 
mixed α/β domain. Adapted from Chaudhury et al. (2013). 
 
Y. pestis LcrV was thought to be entirely intracellular, but it has been shown to be 
secreted into the extracellular medium in low-calcium environments, at 37ºC, 
regardless of cell contact. It most likely does so when it dissociates from the Yersinia 
secretion apparatus (Perry and Fetherston, 1997, Williamson and Oyston, 2013). LcrV 
also regulates the opening of type III secretion (T3S) channel called the injectisome, 
through which anti-host and cytotoxic factors can be translocated into the host cell. The 
A 
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injectisome is composed of a basal body embedded in the two bacterial membranes 
and an external needle protruding from the bacterial surface (Fields et al., 1999, 
Pettersson et al., 1999). Broz and co-workers determined the molecular architecture of 
the Y. enterocolitica LcrV injectimsome tip. They showed that the tip complex is formed 
by three to five LcrV monomers, with a pentamer being the best fit for an atomic 
structure (Broz et al., 2007). 
1.5.3.1. Immnunomodulatory activity of V antigen 
V antigen has previously shown immunosuppressive capabilities, thus making it a 
protein that is greatly researched. In 1995, Leary and colleagues showed that Y. pestis 
LcrV suppressed the production of the cytokines TNF-α and IFN-γ (Leary et al., 1995). 
Schmidt et al. used a recombinant polyhistadine LcrV (rVagHis) derived from Y. 
enterecolitica O8 to show that LcrV suppressed TNF-α in Balb/c mice, not by direct 
effect on macrophages, but with the presence of activated T-cells. It does so, not with 
LcrV-induced IL-10 expression, nor by cell-to-cell contact between macrophages and 
T-cells, but with an LcrV-induced soluble factor produced by T-cells. Neutralising anti-
IL-10 antibodies did not stop or diminish TNF-α suppression. The resulting suppression 
appears to occur due to either a decrease of transcription of TNF-α or increase of 
mRNA degradation (Schmidt et al., 1999). 
Studies carried out by Sing and colleagues have provided insights in how V antigen 
modulates innate immune responses. Their results appear to contradict the previous 
findings by showing that IL-10 is induced in response to Y. enterocolitica O8 
recombinant LcrV (rLcrV) stimulation in both in vitro models of murine peritoneal 
macrophages (from C3H/HeJ mice) and human monocytic Mono-Mac-6 cells lines. 
Despite not using T-cells in these in vitro models it was shown that IL-10 is required for 
the successful TNF-α suppression. However, they did not disprove that an alternative 
mechanism of IL-10 independent TNF-α suppression through the rLcrV-dependent 
68 
 
secretion of an unidentified soluble factor from T-cells does not occur. They further 
suggested that TLR4 is not involved in this process by stimulating mice cells with a 
non-functional TLR4 (C3H/HeJ, Balb/c LPSd) and without TLR4 (C57BL/10sCr) with V 
antigen, which still resulted in TNF-α suppression (Sing et al., 2002a). Sing et al. later 
that year demonstrated that Y. enterocolitica O8 rLcrV signals IL-10 production in a 
CD14-TLR2-dependent manner in both murine and human cells (CD14-TLR2-
contrasfected HEK 293), showing that both TLR2 and CD14 are necessary for IL-10 
induction and identifying a new ligand specificity of TLR2 (Sing et al., 2002b). 
Later on, Sharma and colleagues demonstrated that, in Balb/c mice peritoneal 
macrophages, LcrV innate immune recognition involves TLR2 as well as TLR6, but not 
TLR1 and that it results in the inhibition of transcription of some cytokines and 
chemokines (Sharma et al., 2005, Sharma et al., 2004, Sodhi et al., 2005). 
Reithmeier-Rost and co-workers (Sings group) investigated whether Y. enterocolitica 
O8 rLcrV had the same effects they had observed with wild-type C57BL/6 mice 
peritoneal macrophages in the human monocytic cell like Mono-Mac-6. They verified 
once again that TNF-α secretion was suppressed and IL-10 expression was induced in 
response to rLcrV. They expanded these findings by stimulating the human and murine 
cells by collecting and analysing samples during a 24 hour period, where they 
observed that rLcrV induced TNF-α secretion, which peaked at 3h and subsequently 
decreased until reaching baseline levels past 24h in the human cells. In addition, they 
found that rLcrV induced IL-10 secretion was detected after 6h and kept increasing, 
reaching peak after 24h. IL-10 secretion was also confirmed to be induced in a 
TLR2/CD14-dependent manner following rLcrV stimulation in human Mono-Mac-6 
cells, thereby confirming that this dependence applied to more than one type of human 
cells. An additional finding included rLcrV (TLR2 agonist) inducing auto-, homo- and 
heterotolerance, and that rLcrV induces IL-10 secretion at long range, without requiring 
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cell-to-cell contact and that rLcrV does not influence TLR2 or TLR4 expression in 
Mono-Mac-6 cells (Reithmeier-Rost et al., 2004). 
Later on, the same group wanted to verify whether Y. pestis LcrV acted the same way 
as Y. enterocolitica O8 LcrV by inducing IL-10 production in a TLR2/CD14-dependent 
manner. They infected cells of certain types and species with either Y. pestis LcrV or Y. 
enterocolitica O8 LcrV, and found that compared to Y. enterocolitica, Y. pestis LcrV 
resulted in a dramatically weaker TLR2/CD14-mediated response, meaning there was 
a lower secretion of IL-10 and TNF-α. Other findings of theirs led them to conclude that 
the presence of TLR2 does not change the final outcome of Y. pestis infection of mice 
and that since Y. pestis LcrV/TLR2 interaction is relatively weak, that TLR2-dependent 
IL-10 induction by LcrV does not contribute to virulence of Y. pestis (Reithmeier-Rost et 
al., 2007).  
1.5.3.2. Yersinia pestis V antigen protective fragments 
Previous studies have shown that, not only the entire, but also small regions of Yersinia 
pestis V antigen can provide protection against the plague. In 1997, Hill and colleagues 
tested a series of V antigen truncates in order to test their immunogenicity and 
functionality. They suggested that Y. pestis V antigen contains a number of protective 
epitopes that are located in a central region between amino acids (a.a.) 135 and 275 
(Hill et al., 1997).  
Subsequently, Vernazza et al. (2009) aimed to identify the minimum protective fraction 
of Y. pestis V antigen that could provide protection against plague. In order to do so, 
they generated small regions of the V antigen, residing between the central a.a. 135-
275 fragment, by removing unwanted parts of the structure and producing recombinant 
proteins. Based on analysis, models of a.a. 135-275 (V1), 168-275 (V2), 175-275 (V3), 
135-268 (V4), 135-262 (V5) and 135-275 Δ218-234 (V6) (Table 1.4, Figure 1.18) were 
generated and probed for the preservation of a protective epitope using a protective 
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monoclonal antibody and the protection against Y. pestis in mice was evaluated 
(Vernazza et al., 2009).  
 
Fragment Deletion type Amino acids 
V1 - 135-275 
V2 N-terminal 168-275 
V3 N-terminal 175-275 
V4 C-terminal 135-268 
V5 C-terminal 135-262 
V6 Internal 135-275 Δ218-234 
 
Table 1.4: Suggested V antigen fragments which may retain protective properties. Adapted 
from Vernazza et al. (2009). 
 
 
 
 
Figure 1.18: Ribbon-tube representation of modelled structures coloured by secondary 
structure: strands, yellow ribbon; helices, purple ribbon; loops, cyan blue. Left image: V antigen 
structure (a.a. 28-322). Right image: V antigen a.a. 135-275 region including a.a. 135-167 
(deleted in V2 fragments and shown in grey), a.a. 269-275 (deleted in V4 fragment and shown 
in orange), a.a. 263-269 (deleted in V5 fragment and shown in green). Adapted from Vernazza 
et al. (2009). 
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1.6. Project aims 
Despite the wealth of research on hunting different therapeutic interventions for sepsis, 
this medical conditions current therapy is limited to anti-infectives and supportive care. 
This project aimed to determine whether Yersinia Pestis V antigen has the ability to 
suppress sepsis associated inflammatory responses in vitro and in vivo. In order to 
elucidate this, both monocytic (THP-1) and macrophage (RAW 264.7) cells were used 
to test if Yersinia pestis V antigen is able to exhibit immunomodulatory activity that can 
treat or reverse the outcome of sepsis.  
The objectives of this project were: 
 Purify Yersinia pestis V antigen using affinity chromatography; 
 Investigate the participation of pattern recognition receptors, in particular Toll-
like receptors, Nod-like receptors and adaptor molecules, in response to LPS 
induced sepsis; 
 Determine the effect of Yersinia pestis V antigen on pattern recognition 
receptors;  
 Determine the inflammatory immune responses triggered by Yersinia pestis V 
antigen; 
 Purify and Identify the function domain of Yersinia pestis V antigen; 
 Determine the effects of Yersinia pestis V antigen fractions (V1, V3, V4 and V5) 
on innate immune signalling and cytokine secretion. 
 Use confocal microscopy to elucidate whether Yersinia pestis V antigen 
associates with pattern recognition receptors, signalling molecules and cellular 
organelles; 
 Finally, examine the ability of Yersinia pestis V antigen in suppressing sepsis 
associated inflammatory response in vivo. 
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2.1. Antibodies 
Primary antibodies Species Company 
TLR 1 Mouse Hycult 
TLR 2 Goat Santa Cruz Biotechnology 
TLR 4 Goat Santa Cruz Biotechnology 
TLR 6 Goat Santa Cruz Biotechnology 
TLR 7 Goat Santa Cruz Biotechnology 
TLR 9 Goat Santa Cruz Biotechnology 
CD14 Rabbit Santa Cruz Biotechnology 
NOD 1 Goat Santa Cruz Biotechnology 
NOD 2 Mouse Hycult 
NLRP 1 Mouse Hycult 
NLRP 3 Rabbit Santa Cruz Biotechnology 
NLRP 12 Rabbit Santa Cruz Biotechnology 
Caspase-1 p10 Rabbit Santa Cruz Biotechnology 
Caspase-1 p20 Goat Santa Cruz Biotechnology 
Phospho-IκBα  Rabbit New England BioLabs 
Yersinia pestis V antigen Mouse Abcam 
EEA1 (Endosome) Goat Santa Cruz Biotechnology 
IRF-7 Goat Santa Cruz Biotechnology 
IRF-3 Goat Santa Cruz Biotechnology 
MyD88 Rabbit Santa Cruz Biotechnology 
 
Secondary antibodies Label Company 
Goat anti-rabbit FITC Jackson ImmunoResearch 
Rabbit anti-goat FITC Dako Cytomation 
Rabbit anti-mouse FITC Dako Cytomation 
Goat anti-mouse FITC Jackson ImmunoResearch 
Goat anti-rabbit HRP Dako Cytomation 
Goat anti-rabbit Cy3 Jackson ImmunoResearch 
Rabbit anti-goat Cy5 Jackson ImmunoResearch 
Donkey anti-goat Alexa fluor 633 Invitrogen 
 
Table 2.1: Primary and secondary antibodies used in this study. Secondary antibodies were 
conjugated with either fluorescent fluorochrome (Fluorescein isothiocyanate (FITC)), 
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Horseradish Peroxidase (HRP) for enhanced chemiluminescence (ECL), Cyanine 3 (Cy3), 
Alexa fluor 546 or Alexa fluor 633. 
 
2.2. Cell lines 
2.2.1. Tissue Culture 
To ensure sterile conditions during tissue culture all procedures were performed in a 
Microflow Peroxide Class II Advanced Biological Safety Cabinet. Solutions, plasticware 
and glassware were autoclaved for tissue culture. Hood and equipment was 
decontaminated with 1% Aqueous Virkon (Antec International). A lab coat, disposable 
gloves and over-shoes were worn. Cell lines were grown at 37oC in a 5% CO2 
humidified atmosphere. 
2.2.2. Human monocytic leukemia cell line 
Human monocytic leukemia (THP-1) cells were initially cultured in 25cm2 flasks (Nunc) 
and then transferred into 80cm2 flasks (Nunc). THP-1 cells were maintained in Roswell 
Park Memorial Institute (RPMI) 1640 medium (Invitrogen) supplemented with 10% 
Foetal Calf Serum (FCS (Biosera)) and 2% MEM Non-essential Amino Acid Solution 
(100X) (Invitrogen). 
THP-1 cells were obtained from the European Collection of Animal Cell Cultures 
(ECACC). THP-1 cell line derived from the peripheral blood of a 1 year old male with 
acute monocytic leukaemia.  
THP-1 cells were passaged by re-suspending the suspension cells with fresh medium 
using a pipette. Cells were frozen in freezing medium consisting of 10% (v/v) dimethyl 
sulfoxide (DMSO) in FCS. 
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2.2.3. Mouse leukemic monocyte macrophage cell line 
Mouse leukaemic monocyte macrophage (RAW 264.7) cells were cultured in 25cm2 
flasks (Nunc) in Dulbecco’s Modified Eagle Medium (DMEM) 1000mg/L glucose 
medium (Invitrogen) supplemented with 10% FCS (Invitrogen) and 2% MEM Non-
essential Amino Acid Solution (100X) (Invitrogen).  
RAW 264.7 cells obtained from the European Collection of Animal Cell Cultures 
(ECACC). RAW 264.7 cell line derived from the ascites of a tumour induced in a male 
mouse by intraperitoneal injection of Abselon Leukaemia Virus (A-MuLV). 
The proteolytic enzyme trypsin (Sigma) was used for detaching and passaging of RAW 
264.7 cells. Cells were frozen in freezing medium consisting of 10% (v/v) DMSO in 
FCS. 
2.2.4. Cryogenic preservation 
Cryogenic preservation was used to maintain reserve cell lines. Cell lines were placed 
in cryotubes which then were placed in a -80ºC freezer for 24 hours and then into liquid 
nitrogen for long-term preservation. This step down in temperature allowed the cells to 
adjust to the liquid nitrogen. 
Healthy population of cells were harvested by pipetting for suspension and semi-
adherent cells, or by the use of the proteolytic enzyme trypsin (Sigma) for adhesive 
cells. Cells were placed in a 15ml tube (Nunc) and centrifuged at 12000RPM for 5 
minutes. The supernatant was aspirated off and the pellet was resuspended in 1.5ml of 
10% (v/v) of freezing medium dimethyl sulfoxide (DMSO) in FCS. Cells in the freezing 
medium were then transferred into cryotubes (Nunc), and placed into an insulated 
container and then into the -80ºC freezer for 24 hours. After 24 hours the cryotubes 
were placed in a liquid nitrogen storage tank (-196ºC). 
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2.3. Cell counting 
A hemocytometer is a cell counting glass microscope slide that allows one to obtain an 
approximation of the cell concentration (cells/ml) of a cell suspension. This device 
allows consistence throughout experiments when seeding cells. 
This method of cell counting works on the basis of there being an exact known volume 
in the chamber of the hemocytometer (Figure 2.1). A quartz cover glass sits precisely 
0.1mm above the chamber floor, each grid is 1x1mm, so the volume above each single 
grid is 0.1μl. By observing the chamber under the microscope it is possible to count the 
number of cells in cells/ml. 
 
 
 
 
 
 
 
Figure 2.1: Hemocytometer, used to count cells in suspension. It works on the basis of there 
being an exact known volume in the chambers of the hemocytometer. A quartz cover glass sits 
precisely 0.1mm above the chamber floor, where each grid (highlighted by the circle) is 1x1mm, 
therefore the volume above each grid is 0.1μl. Adapted from: http://www.invitrogen.com/site/us/ 
en/home/references/gibco-cell-culture-basics/cell-culture-protocols/counting-cells-in-ahemacyto 
meter.html / www.tekeven t.com/bm.pix/chamber-n-improved-brightline-with-v-06_500_30-
2.s600x600.jpg (12/08/2013). 
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The number of cells in each grid in the counting area should be recorded and placed in 
the following equation: 
                     
                          
                   
 
2.3.1. Hemocytometer protocol 
Cells were confluent when concentration was determined. Adherent cells were put in 
suspension by the use of the proteolytic enzyme trypsin whereas suspension and semi-
adherent cells were re-suspended by agitation. 
A few drops were added to the specialized Neubauer hemocytometer in order to flood 
its chambers. Cells were counted and recorded from the central and all corner grids 
were used. This data was entered into the equation in Section 2.3. 
A cover slip was placed on a Neubauer hemocytometer. Cells were thoroughly re-
suspended using a sterile Pasteur pipette and loaded on the edge of the cover slip, 
ensuring that both chambers of the Neubauer hemocytometer were flooded. The 
chambers were observed under a light microscope where cells were counted. 
2.4. Viability test 
Trypan blue is a diazo dye that is used to differentiate between live and dead cells. In 
this study, trypan blue was used as a viability test in order to determine the condition of 
cell populations before certain procedures. 
The trypan blue viability test works on the basis that live cells have undamaged cell 
membranes that are highly selective in their up-take and thus will not allow the dye to  
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be absorbed by the cell. On the other hand, dead cells whose membranes have been 
compromised allow the trypan blue to enter the cell thus becoming stained. 
 
Figure 2.2: Trypan blue viability test. Live cells with intact cell membranes have not absorbed 
the dye therefore are viable (black arrow). Dead cells (red arrow) that have disrupted cell 
membranes allow the dye to enter resulting in a dark blue staining of the cell. Adapted from 
http://www.intechopen.com/source/html/19106/media/image5.jpeg (12/08/2013). 
 
2.4.1. Trypan blue viability assay protocol 
Confluent cells were washed with sterile X1 PBS and then enough trypan blue (Sigma) 
to cover the cells was added and left for 10 minutes. The cells were then washed with 
sterile X1 PBS and analysed using a Neubauer hemocytometer (see section 2.3). 
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2.5. V antigen 
2.5.1. Recombinant LcrV plasmid (pVG110) 
The recombinant LcrV plasmid (pVG110) with a glutathione S-transferase (GST) tag 
used in this study was kindly provided by Prof. Richard Titball (Chemical and Biological 
Defence Establishment, Porton Down, Salisbury, UK) as previously described (Carr et 
al., 1999). The plasmid was transformed into E. coli BL21 cells. 
2.5.2. Fermentation of LcrV 
E. coli BL21 cells containing the recombinant plasmid pVG110 was cultured in Luria 
broth containing 100mg/ml ampicillin (Fisher Scientific). Cultures were placed in a 37ºC 
rotary incubator at 120RPM until an A600 of 0.3 was achieved; cultures were then 
induced with 1mM isopropyl-β-D-thiogalactopyranoside (IPTG) (Fisher Scientific). 
Cultures were incubated for a further 6 hours in a 37ºC rotary incubator at 120RPM. 
Cultures were then harvested at 7000RPM in a 4ºC centrifuge for 30 minutes. 
2.5.3. Purification of LcrV 
Once the broths had been centrifuged, the resulting pellets were resuspended in 5ml of 
X1 Phosphate buffered saline (PBS) and placed in 50ml tubes, the centrifuge container 
was washed out with a further 5ml X1 PBS and this was also added to the 50ml tube. 
The E. coli suspension was then frozen (-20ºC) and thawed 6 times. Tubes were 
vortexed vigorously between freezing and thawing. This ensures that the E. coli breaks 
and the recombinant protein can be collected. The tubes were then centrifuged at 
3500RPM in a 4ºC centrifuge for 30 minutes. The supernatant was placed in a sterile 
50ml tube and the resulting pellet was discarded. This process was repeated until the 
supernatant was clear. The supernatant was then purified using a Glutathione 
Sepharose (GST) purification column supplied by GE Healthcare. 
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2.5.3.1. Purification of V antigen fractions 
In order to determine which region of V antigen is modulating innate response against 
LPS, V antigen fragments were generated. V antigen fractions were cloned in E. coli 
and kindly supplied to us by Dr. Claire Vernazza, Ministry of Defence, Porton Down. In 
order to purify the V antigen fractions, the E. coli strain had to be cultured in Luria broth 
and the protein isolated using affinity chromatography. V antigen fragments were 
selected according to previous studies performed by Vernazza et al. (2009) (Table 2.2).  
 
Fragment Deletion type Amino acids 
V1 - 135-275 
V2 N-terminal 168-275 
V3 N-terminal 175-275 
V4 C-terminal 135-268 
V5 C-terminal 135-262 
V6 Internal 135-275 Δ218-234 
 
Table 2.2: V antigen fragments. In this study the V antigen fragments selected were V1, V3, V4 
and V5. Adapted from Vernazza et al. (2009). 
 
2.5.4. Glutathione sepharose (GST) protein purification 
GST tagged proteins can be purified from lysate using glutathione immobilized on a 
sepharose matrix via ligand specificity (figure 2.3). The GST tag has a high affinity for 
glutathione (GSH). Elution of bound GST fusion proteins from the column is achieved 
under mild, non-denaturing conditions (Wilson and Walker, 2005). 
Attachment of the ligand (glutathione) to the affinity phase occurs via a spacer. The 
spacer allows optimum ligand interaction with the GST tagged protein. 
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Figure 2.3: Matrix/spacer/ligand interaction. The glutathione ligand (orange) is coupled via a 
10-carbon spacer (blue) to highly cross-linked 6% agarose (pink). The spacer and ligand can be 
manipulated to suit the requirements of the separation. 
 
To elute the GST-tagged protein from the column an enzyme is used to cleave the 
GST from the protein of interest and thus leave the relatively large GST tag (~26KDa) 
bound to the affinity matrix. PreScission™ Protease (GE Healthcare) was used in this 
study. This protease is highly specific and also has a GST tag so on elution it remains 
bound to the matrix eliminating need for extra purification thus increasing the resolution 
and yield of the elute. 
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Figure 2.4: GST-tagged protein purification. The GST tag (orange) has a high affinity for 
glutathione (GSH) and binds the protein of choice (dark green) to the affinity matrix (black). 
Washing removes unwanted lysate (light green). PreScission
TM 
Protease (GE Healthcare) was 
used to cleave the GST tag from the protein leaving purified protein that does not require further 
purification. Adapted from source (Corporation, 2012). 
 
2.5.5 LcrV-GST-tagged protein purification 
The supernatant that was harvested from the LcrV fermentation was passed through a 
10ml Glutathione Sepharose (GST) purification column (GE Healthcare). The column 
was equilibrated by passing through 10ml PBS/1% Triton. 10ml crude V antigen was 
then passed in the column matrix and the column was sealed to terminate flow. The 
column was left to incubate at room temperature for 1hr. After incubation the column 
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was washed out with 20ml 1X PBS and the elution was discarded. To the column 10ml 
cleavage buffer (50mM Tris/150mM NaCl/1mM EDTA/1mM DTT/0.01% (w/v) Triton X-
100) was added. 150µl PreScission™ Protease (GE Healthcare) was then added and 
allowed to enter the matrix. The column was sealed to terminate flow. The column was 
then left to incubate for 3 hours at room temperature. After the incubation, 20ml 
cleavage buffer was used to wash out the column and the elution collected in a sterile 
bottle.  
2.5.6. Protein concentration 
In order to concentrate the purified proteins 10kDa cut off Centriprep centrifuge 
concentrators (Millipore) were utilised. Centriprep concentrators consist of two tubes, 
one housed in the other (Figure 2.5). The base of the internal tube has a permeable 
membrane that allows molecules through which are 10kDa or smaller, retaining the 
protein in the external tube. During centrifugation, the centrifugal force pushes anything 
that is ≤10kDa through the membrane into the internal tube. The sample remains in the 
exterior tube whilst the waste runs through the membrane into the internal tube, where 
it is then discarded.  
Sterile 10kDa cut off Centriprep concentrators (Millipore) were filled to the “fill line” with 
purified sample. The concentrators were then placed in the centrifuge and spun at 
2500RPM for 40 minutes at 4oC. The content of the internal tube was discarded. The 
content of the exterior tube was placed back into the original elution and any precipitate 
re-suspended. This process was repeated until approximately 1-2ml of purified and 
concentrated protein remained. Sterile X1 PBS was used to perform buffer exchange 
on the protein sample. X1 PBS was filled to the “fill line” and the Centriprep spun at 
2500RPM for 40 minutes at 4oC. This was performed three times with an end sample of 
approximately 1-2ml. Protein concentration was determined by spectrophotometry. 
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Figure 2.5: Centriprep concentrators. During centrifugation (2500RPM for 40 minutes at 4ºC) 
the centrifugal force pushes anything that is  10kDa from the sample container, through the cut 
off membrane, into the filtrate collector. Internal tube (filtrate collector) = waste. External tube 
(sample container)=concentrated sample. 
 
2.5.7. Endotoxin removal 
Bacterial endotoxin contamination has proven a big problem in research, especially in 
the field of immunology. When expressing a protein in an E. coli strain, for example, 
endotoxin from the E. coli can easily contaminate the purified product. Any cell 
stimulations performed with the contaminated protein will have a double effect of the 
protein itself and the contaminant, producing inconclusive data. To avoid this problem 
endotoxin can be removed by ultra-filtration, ion exchange chromatography, two phase 
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extraction or ligand specificity chromatography. In this study the Profos EndoTrap® 
blue 10 (Hycult Biotechnology) assay was used to remove endotoxin from purified 
protein samples, this assay utilizes ligand specificity chromatography (Hycult®Biotech, 
2011). 
Profos EndoTrap® blue is an affinity matrix that is designed to remove bacterial 
endotoxins from aqueous solutions, even at low endotoxin concentrations. Pre-packed 
columns have the EndoTrap blue ligand covalently bound to beaded agarose. The 
EndoTrap blue ligand is highly specific for bacterial endotoxin and has very low non-
specific binding, giving high sample yields free of endotoxin (Hycult®Biotech, 2011). 
2.5.7.1. Endotoxin removal protocol 
Profos EndoTrap® blue 10 assay columns (Hycult Biotechnology) were firstly 
regenerated. X3 the column volume of regeneration buffer (Hycult Biotechnology) was 
passed through the column and the elution discarded, this step was repeated. X3 the 
column volume of equilibration buffer (Hycult Biotechnology) was passed through the 
column and the elution discarded, this step was repeated. X1 the column volume of 
sample was passed into the column, the elute was collected in sterile glassware. X3 
the column volume of equilibration buffer was then passed through the column and 
collected in the same sterile glassware. Endotoxin free sample was re-concentrated in 
sterile Centriprep concentrators (Section 2.5.6) to a final volume of 1-2ml. 
2.5.8. Endotoxin detection 
The HyCult LAL Chromogenic Endotoxin Quantitation Kit was used in order to measure 
the amount of endotoxin in the purified protein sample using the Limulus Amebocyte 
Lysate (LAL) assay. The LAL method for measuring endotoxin is based on the 
interaction of endotoxins with the proenzyme Factor C found in circulating amebocytes 
of the horseshoe crab Limulus polyphemus. The proteolytic activity of this proenzyme 
is activated in the presence of LPS. The Chromogenic Limulus Amebocyte Lysate 
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assay measures endotoxin levels by measuring the activity of this protease in the 
presence of a synthetic peptide substrate that releases p-nitroaniline (pNA) after 
proteolysis, producing a yellow colour that can be measured by reading the 
absorbance at 405nm (Hycult®Biotech, 2011). 
To accurately measure endotoxin levels in a sample, the LAL assay uses an endotoxin 
standard of known concentration that is derived from E. coli strain O111:B4. This 
standard is provided with each kit and is used to create a standard curve. The 
endotoxin concentration is determined by extrapolating the absorbance of an unknown 
sample against this standard curve, similar to ELISA or total protein quantitation 
assays. Minimum concentration of LPS which can be measured is 0.01 EU/ml (1 EU = 
100pg LPS).  
Following endotoxin removal using the Endotrap columns, all purified recombinant 
proteins were tested for the presence of endotoxin using the LAL assay. It was shown 
that there were no detectable endotoxin in the purified samples. 
2.5.9. Determination of protein concentration 
After the Endotrap step and concentrating the sample, a UV spectrometer was used to 
determine the concentration of the sample by use of the formula shown below. The 
theory behind this formula is that the amino acid residues tyrosine and tryptophan 
within a protein show maximum absorption at a 280nm wavelength. While the 
proportion of these residues within a protein do vary and so do the extinction 
coefficients for the proteins, most proteins have an extinction coefficient within the 
range of 0.4-1.5. Following one of the Beer-Lambert law’s equations (           
                                                                      a fair 
approximation of the protein concentration of a solution in a quartz cuvette with 1cm 
length can be calculated. However, there can often be contamination of nucleic acids 
which have an absorbance 10 times that of protein at this wavelength so even a small 
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amount of nucleic acids can greatly influence absorbance. The formula corrects for this 
possibility (up to 20% contamination with nucleic acids) by also measuring the sample’s 
absorption at 260nm wavelength, the maximum absorbance of nucleic acids, 
multiplying that by a ratio determined by early researchers and subtracting that value 
from the one obtained from the absorbance at 280nm (Boyer, 2006, Wilson and 
Walker, 2005). 
A UV spectrophotometer was used to determine the absorbance of the purified and 
concentrated V antigen solution at 260nm and 280nm. Then, concentration was 
calculated using the following formula: 
                                          
 
2.6. Cell stimulations 
Throughout this study all cell stimulations were carried out in their respective mediums 
(Section 2.2) and incubated at 37ºC in a 5% CO2 humidified atmosphere. 1,000,000 
cells per sample were stimulated during the course of this study. Ligand concentrations 
were kept constant throughout this study (Table 2.3). 
Ligand Concentration 
Lipopolysaccharide (LPS) 100ng/ml 
V antigen 50μg/ml 
V1 50μg/ml 
V3 50μg/ml 
V4 50μg/ml 
V5 50μg/ml 
 
Table 2.3: Ligand concentrations used in this study. All concentrations were kept constant 
throughout.  
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2.6.1. 25cm2 flask stimulation 
Human monocytic leukemia (THP-1) cells were cultured in 80cm2 flasks (Nunc) and 
stimulated in flasks with a surface area of 25cm2 (Nunc). Sterile conditions were 
practiced throughout. THP-1 cells were counted using a hemocytometer (Section 2.3). 
The cell to volume ratio was rectified to 1,000,000 cells/ml. The cells were then 
stimulated. 
Mouse leukaemic monocyte macrophage (RAW 264.7) cells were stimulated in flasks 
with a surface area of 25cm2 (Nunc). Sterile conditions were practiced throughout. The 
growth medium was aspirated off and the cells were washed with 3ml of fresh medium. 
2ml of medium was then added to the flask. The cells were then stimulated. 
2.6.2. Lab-TekTM slide stimulation 
For confocal microscopy mouse leukaemic monocyte macrophage (RAW 264.7) cells 
were grown and stimulated on 8 well glass slides (Nunc Lab-TekTM Chamber SlideTM 
System). The growth medium was aspirated off and the cells were washed with 400μl 
of fresh medium. 150μl of growth medium was then added to each well. The cells were 
then stimulated. 
2.7. Immunofluorescence 
Immunofluorescence is a technique whereby specific molecules are labelled and 
visualised with fluorescent antibodies. Immunofluorescent labelling can be utilised to 
find the relative abundance and localisation of a chosen antigen. Fluorochromes that 
emit light of a set wavelength are conjugated to antibodies. Fluorescence is emitted 
from fluorochromes that become excited when exposed to a laser beam which results 
on the emission of light at a certain wavelength, which in turn can be imaged and/or 
quantified by a number of techniques. The development of fluorescent labelling as a 
research tool has proven invaluable. 
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Fluorescence is emitted from fluorochromes that become excited when exposed to a 
laser beam of the correct wavelength. Electrons in the fluorochrome move into a higher 
energy state when a photon from the laser is absorbed. The atoms are said to change 
from their “ground state” to an “excited state”. The emitted light is detected and can be 
used to quantify and determine the localisation of a chosen antigen. 
There are a number of different fluorochromes available which have different excitation 
and emission wavelengths. Such availability of fluorochromes coupled with high 
specificity antibodies allows multiple labelling of molecules and/or structures in a single 
sample at any one time. The table below shows the different fluorochromes used 
throughout this study (Table 2.4). 
 
Fluorochrome Excitation λ Emission λ Colour 
Fluorescein isothiocyanate (FITC) 495nm 519nm Green 
Phycoerythrin (PE) 547nm 572nm Yellow 
Cy3 553nm 556nm Red 
Cy5 650nm 667nm Blue 
Alexa fluor 633 632nm 647nm Red 
Table 2.4: Fluorochrome excitation, emission and observed colour of fluorochromes used in this 
study. 
 
Immunofluorescence can be carried out through two main tests – direct and indirect. 
2.7.1. Direct immunofluorescence 
Direct immunofluorescence involves the direct binding of a fluorochrome conjugated 
primary antibody/ligand to the antigen of interest (Figure 2.6). A specific antigen will be 
detected by the antibody, and the fluorophore it is attached to can be subsequently 
detected via microscopy or flow cytometry.  
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Figure 2.6: Direct immunofluorescence. Direct binding of fluorescein isothiocyanate (FITC) 
fluorochrome conjugated antibody to a target antigen. On excitation the labelled antibody emits 
fluorescence that can be detected and quantified. 
 
When using direct immunofluorescence to label a protein in low abundance a weak 
signal may be achieved. To surpass this indirect immunofluorescence labelling can be 
used. 
2.7.2. Indirect immunofluorescence 
Indirect immunofluorescence differs from direct immunofluorescence in that it involves 
two compatible antibodies: an unlabelled primary antibody specific for the antigen of 
interest; and a fluorescently conjugated secondary antibody specific for the primary 
antibody (Figure 2.7). The structure of an antibody makes this possible, as it has two 
regions: a Fc region (fragment crystallisable region) and a Fab region (fragment 
antigen-binding region). The Fab region contains variable sections that determine 
which antigen is bound, whilst the Fc region is constant in a class of the same species. 
Antibodies can be designed in such a way that they contain the same Fc region but 
different Fab regions. In this way, primary antibodies with the same Fc region can be 
used to detect various antigens (due to differing Fab regions), and still be detected by a 
Antigen 
FITC labelled 
antibody 
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single fluorescently-conjugated secondary antibody specific for the Fc region of the 
primary antibody.  
 
 
 
 
 
 
 
 
 
 
Figure 2.7: Indirect Immunofluorescence. Indirect immunofluorescence involves the binding of 
an unlabelled primary antibody to a chosen receptor, then the further binding of a fluorescein 
isothiocyanate (FITC) conjugated secondary antibody to the primary antibody. On excitation the 
labelled secondary antibody emits fluorescence that can be detected and quantified. 
 
The primary and secondary antibody binding is species-specific. If a goat TLR4 primary 
antibody was used for example, an anti-goat fluorochrome conjugated secondary 
antibody will have to be used with this, such as a rabbit anti-goat antibody. 
Indirect immunofluorescence has the advantage of being more sensitive than direct 
immunofluorescence because more than one secondary antibody can bind to any one 
primary antibody, thus giving a stronger signal. 
 
 
Unlabelled 
primary antibody 
FITC labelled 
secondary 
antibody 
Antigen 
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2.8. Flow cytometry 
Flow cytometry is a powerful technique used to analyse cellular characteristics of 
individual cells in a heterogeneous population. In this study, fluorescently labelled 
cells/cytokines were analysed using a Becton Dickinson (BD) Fluorescent Activated 
Cell Sorting (FACSCaliburTM) system with software supplied by Cell Quest (Figure 2.8). 
 
 
Figure 2.8: Becton Dickinson Fluorescent Activated Cell Sorter (FACSCalibur
TM
). The flow 
cytometer can quantify and distinguish between cells according to their fluorescence and 
physiological structure. http://medschool.creighton.edu/fileadmin/user/medicine/images/teachRe 
searchPatient/Research/Flow_Cytometry_Core_Files/Images/Calibur2.jpg (07/11/2013). 
 
Fluorescently labelled cells that pass through the FACS are each individually exposed 
to a laser with a single wavelength of light. Fluorescein isothiocyanate (FITC) 
conjugated antibodies were used in this study to label specific receptors. The resulting 
emitted light from the sample passes through a number of different detectors and 
analysed through the software supplied. Cytokines are labelled in much the same way 
using a cytometric bead array (CBA) kit allowing the determination of their 
concentration in a sample.  
2.8.1. FACS System 
FACS analysis can be divided into three main stages: fluidics, optics and signalling 
processing. 
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2.8.1.1. FACS fluidics 
FACS analysis requires the cells to be individually analysed. When the cytometer is set 
to acquire, cells in a sample run through the chamber at a very high speed in a single 
file. This is achieved by the fluidics system of the FACS machine via a process known 
as hydrodynamic focusing (Figure 2.9). Hydrodynamic focusing is achieved when the 
sample of cells from a central core injector merges with a flowing stream of sheath fluid 
(saline solution) in an outer core, which is flowing at a much higher velocity in the same 
direction.  
 
Figure 2.9: Hydrodynamic focusing of a sample by the fluidics system of the Fluorescence 
Activated Cell Sorter (FACS). The sample is injected from the central core into sheath fluid from 
the outer core which is flowing at a much higher velocity in the same direction. This compresses 
the cells in to flow in a single file for analysis. http://www.assay-protocol.com/uploads/Flow 
%20cytometry.JPG (13/11/2013). 
 
Hydrodynamic focusing results in the cells entering the flow cell in single file to be 
exposed to the optics system. 
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2.8.1.2. FACS optics 
As thousands of cells pass per second through the flow chamber they are subjected to 
one or more laser beams that have a programmed wavelength. When the laser strikes 
a cell, two forms of scattered light occur: forward scatter (FSC), which is the amount of 
light that is scattered in the forward direction, quantifies a cell’s size and can distinguish 
between live cells and debris, this is detected at 20º off the excitation laser bead; and 
side scatter (SSC), which is the rest of the light collected on a detector 90º from the 
laser beam, shows the granularity of a cell. Fluorescence can also be detected. Lasers 
excite the fluorophores, and the subsequent fluorescent emissions travels along the 
same tour as the SSC signal (Figure 2.10).  
 
Figure 2.10: Arrangement of filters and detectors in the Fluorescence activated cell sorter 
(FACS) optics system. Fluorescent detection and side scatter (SSC) is achieved at 90º to the 
path of excitation laser beam. Forward scatter (FSC) is detected at 20º of the excitation laser 
beam. http://static.abdserotec.com/thumbnails/signal1.jpg (13/11/2013). 
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FSC and SSC uncover the cells morphology whilst fluorochrome emission is used to 
quantify a labelled antigen. 
2.8.1.3. FACS signal processing 
Signal processing was performed by the Cell Quest software. This software has 
complete control over the FACS allowing parameter to be tailored for each experiment. 
Photons sensed by the photomultiplier (PMT) detectors (Figure 2.10) are transformed 
to voltage and then relayed to the software. The combined information from the 
detectors is quantified, saved and displayed on the screen. 
2.8.2. FACS application 
Fluorescently labelled cells/cytokines were analysed using a Becton Dickinson 
Fluorescent Activated Cell Sorter (FACSCaliburTM) with software supplied by Cell 
Quest. 
2.8.2.1. Pattern recognition receptor expression levels 
Indirect immunofluorescence followed by flow cytometry was used to investigate the 
expression levels of TLR1, TLR2, TLR4, TLR6, TLR7, TLR9, CD14, NOD1, NOD2, 
NLRP1, NLRP3, NLRP12 on THP-1 and RAW 264.7 cells in response to LPS, V 
antigen and its fractions V1, V3, V4 and V5. 
Confluent cells were stimulated with 100ng/ml of lipopolysaccharide (LPS) and 
incubated for 1, 2, 4 or 6 hours. Some of these cells were either pre-incubated for 1 
hour or post-incubated for 1, 2, 4 or 6 hours with 50µg/ml of V antigen, V1, V3, V4 or 
V5. 
To perform the indirect immunofluorescence assay, after the incubation period, cell 
samples in eppendorf tubes were centrifuged at 12000RPM for 5 minutes at room 
temperature, the supernatant was aspirated off and the cells were re-suspended in X1 
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phosphate buffered saline (PBS). The tubes were centrifuged for 2 minutes at 
13000RPM and the supernatant was aspirated. The cells were then fixed by adding 
300μl of 4% paraformaldehyde (PFA) (Sigma), resuspended and left to incubate at 
room temperature for 15 minutes. PFA is used as a fixative, by cross-linking proteins, 
mainly the residues of the amino acid lysine, to lend rigidity to the cells and prevent 
further biochemical reactions. Cells were then washed twice with 500μl PBS/0.02%(w/v) 
bovine serum albumin (BSA) (Sigma)/0.02%(w/v) sodium azide (NaN3) (Sigma)/0.02%(w/v) 
saponin (Sigma). BSA is used as a carrier protein to antibodies and as a general 
protein blocking agent. NaN3 prevents the internalisation of surface antigens, which 
could produce a loss of fluorescent intensity. The amphipathic nature of Saponin 
makes it act as a surfactant, enhancing the penetration of proteins through the cell 
membrane. The samples were then centrifuged and the supernatant aspirated off 
again, followed by re-suspension in 100μl PBS/0.02% BSA/0.02% NaN3/0.02% 
Saponin. To this, 2μl of primary antibody was added and incubated at room 
temperature for 4 hours and left over night at 4ºC. After incubation the cells were 
washed two times. The pellet was then re-suspended in 100μl PBS/0.02% BSA/0.02% 
NaN3/0.02% Saponin, followed by incubation with 2μl of the respective secondary 
antibody for 45 minutes in the dark (to prevent photobleaching) at room temperature. 
The cells were then washed twice in PBS/0.02% BSA/0.02% NaN3/0.02% Saponin, 
then re-suspended in 500μl X1 PBS and transferred to Falcon flow tubes and analysed 
using a Becton Dickinson Fluorescent Activated Cell Sorter (FACSCaliburTM) with 
software supplied by Cell Quest. 10,000 cells not gated were analysed for each 
sample. 
2.8.2.2. Cytokine analysis 
To quantify the inflammatory response of THP-1 and RAW 264.7 cells the presence 
and levels of released cytokines were determined. Cytokines are the messengers that 
co-ordinate inflammation and give a direct representation of cellular response.  
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In this study the Human Inflammation BDTM Cytometric Bead Array (CBA) (BD 
Biosciences) kit was used to measure cytokine concentrations. The Human 
Inflammation BDTM CBA kit is capable of detecting six cytokines that play major roles in 
the human inflammatory response. These are Interlukin-8 (IL-8), Interlukin-1β (IL-1β), 
Interlukin-6 (IL-6), Interlukin-10 (IL-10), Tumor Necrosis Factor (TNF) and Interlukin-
12p70 (IL-12p70). CBA analysis allows the fast and highly sensitive quantification of an 
array of cytokines in any one sample. 
In order to bind cytokines present in a sample the beads are coated with capture 
antibodies specific for a particular cytokine. In the Human Inflammation BDTM CBA kit 
there are six bead populations with different fluorescent intensities specific for IL8, IL-
1β, IL-6, IL-10, TNF and IL-12p70. Once the beads have bound to the respective 
cytokines a Phycoerythrin (PE)-conjugated detection antibody mix is added, this is a 
mixture of PE-conjugated antibodies specific for each bead (Figure 2.11). 
 
 
 
 
 
 
 
 
Figure 2.11: BD
TM
 Cytometric bead array (CBA) system. A) CBA beads (blue) bind cytokines 
(green) in sample. B) Phycoerythrin (PE)-conjugated detection antibody is added. C) Cytokine 
can be seen sandwiched between the bead and the PE detection antibody. 
 
The Becton Dickinson Fluorescent Activated Cell Sorter (FACSCaliburTM) was used in 
conjunction with Cell Quest software (Becton Dickinson) in order to run the samples. 
+ 
Beads 
Cytokines 
+ 
PE-conjugated 
antibody 
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CBA Analysis Software (Becton Dickinson) was used to process the raw data to 
cytokine concentration (pg/ml) using a previously calibrated curve. 
2.8.2.2.1. CBA protocol 
For each sample 20μl of bead mixture containing equal volumes of IL-8, IL-1β, IL-6, IL-
10, TNF and IL-12p70 beads was added to a Falcon flow tube. To this 20μl of sample 
was added and the mixture vortexed briefly. 20μl of phycoerythrin (PE)-conjugated 
detection antibody mixture was then added and again vortexed briefly. The samples 
incubated for 3 hours at room temperature being left in the dark (to avoid 
photobleaching), gently shaking every 30 minutes. 1ml X1 PBS was then added to 
each sample which was then centrifuged at 1200RPM for 5 minutes. The supernatant 
was poured off leaving the pellet undisturbed. 300μl wash buffer (BD Biosciences) was 
added to each tube and then vortexed very briefly. The samples were assayed using 
the Becton Dickinson Fluorescent Activated Cell Sorter (FACSCaliburTM) used in 
conjunction with Cell Quest software (Becton Dickinson). The cytokine concentration 
(pg/ml) was determined by data processing CBA Analysis Software (Becton Dickinson). 
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2.9. Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) is used for 
the separation of proteins according to their Molecular Weight (MW). This method is 
used for several different purposes such as to identify a protein, determine protein size 
and abundance, find the number of proteins present and find the purity present of a 
sample. 
The proteins in a sample will have a number of differences including length, shape, 
weight and charge. For SDS-PAGE to work correctly the proteins must be put in their 
native state, i.e. primary structure. SDS is an anionic detergent that disrupts the 
hydrogen bonds and Van der Waal’s interactions in proteins and breaks down cell 
membranes. This destroys the proteins secondary, tertiary and quaternary structures 
causing them to become linear. SDS also gives the protein a uniform negative charge 
making the protein travel to the positive pole in an electrical field. The denaturation of 
the protein into its primary state was caused by heating the sample in a buffer 
containing β-mercaptoethanol. 
The separation of the proteins occurs in the polyacrylamide gel which is made up of 
many acrylamide monomers that create a sieve like matrix where the proteins have to 
pass. The fact that the proteins are all denatured and negatively charged they will 
move in an electrical field towards the positive pole at the same rate. The cross-linked 
matrix makes it difficult for the molecules to move through the polyacrylamide gel, the 
smaller proteins have an advantage due to their size and thus move furthest the gel 
toward the positive terminal (Figure 2.12). 
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Figure 2.12: SDS-PAGE apparatus. SDS-PAGE is a technique for separating proteins in 
relation to their molecular weight. The application of voltage pulls negatively charged denatured 
proteins through the cross linked polyacrylamide gel matrix and separates them according to 
molecular weight. 
 
Pore size within the matrix can be manipulated by varying the concentration of 
Acrylamide/Bis in a gel matrix. In this study a 10% Acrylamide/Bis was used. The gel is 
made up in liquid form and so it can be easily poured into the appropriate casts to set. 
The polymerisation of the gel is caused by Ammonium Persulphate (APS) and N, N, N’, 
N’-tetramethylethylenediamine (TEMED) as they act as catalysts. Once these 
chemicals are added the gel forms cross links creating the sieve like matrix required. 
For SDS-PAGE analysis in this study the Mini-PROTEAN 3 apparatus (BioRad) was 
utilised (Figure 2.13). 
Stained SDS- 
polyacrylamide gel 
 between glass plates 
Buffer 
Loading wells 
SDS-treated samples 
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Figure 2.13: The Mini-PROTEAN 3 apparatus (BioRad) was used to run Sodium Dodecyl 
Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE). http://www.plant.uoguelph.ca/resea 
rch/homepage/raizada/Equipment/RaizadaWebEquipmentPDFs/9B.miniprotean3cellmanual.pdf 
(27/11/2013). 
 
 
2.9.1. Casting SDS-PAGE gels 
Gels were cast in 1mm width casts. Once the apparatus was set up, the resolving gel 
(1.5M Tris-HCL, 10% SDS, Acrylamide/Bis, 10% APS, TEMED and dH2O) mixture was 
made up leaving the addition of APS (Sigma) and TEMED (Sigma) until last. Once the 
APS and TEMED were added the liquid gel was immediately poured (as they catalyse 
the polymerisation of the acrylamide gel) into the cast leaving adequate room for the 
teeth of the comb. On top of this, a thin strip of isobutanol was added in order to 
remove any bubbles and ensure that the gel surface was smooth and flat. The gel was 
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left at room temperature for 45-60 minutes to polymerise. Once the resolving gel was 
set, the isobutanol was poured off and then the gel was rinsed with dH2O. The 4% 
stacking gel (0.5M Tris-HCL, 10% SDS, Acrylamide/Bis, 10% APS, TEMED and dH2O) 
mixture was made up (again, 10% APS and TEMED were added once the gel was 
ready to be poured). This was then placed on top of the set resolving gel. A 1mm ten 
teethed comb was placed in the stacking gel mixture to create wells for the samples. 
The gel was left to polymerise at room temperature for 45-60 minutes. 
Once the stacking gel had set, the comb was removed, the plates were unclipped from 
the casting stand and were placed, short plate facing inwards, into the electrophoresis 
tank (BioRad). X1 running buffer solution was added to the tank and filled between the 
plates. 
2.9.2. Sample preparation for SDS-PAGE 
To prepare the samples for running on the gel, X2 SDS-PAGE Reducing Sample Buffer 
was added to THP-1 and RAW 264.7 cells that had been incubated with LPS and 
either pre or post-incubated with V antigen or its fractions V1, V3, V4 and V5. Cells 
were left for 2 hours on the work top shaker and hen frozen at -20ºC for a minimum of 
one night. The SDS and the β-mercaptoethanol present in the reducing sample buffer 
denature the proteins disrupting secondary, tertiary and quaternary structures. The 
glycerol helps preserve the proteins at low temperatures, and weighs down the 
samples when loading them into the wells. The Tris present acts as a buffer (Tris has 
an effective pH range between 7 and 9.2). The addition of Brompthenol Blue allows the 
samples to be visualised as they pass through the gel.  
2.9.3. Running samples 
100μl of each sample was added to separate eppendorfs and boiled for 10 minutes, 
along with a molecular weight marker (2μl biotinylated SDS-PAGE broad range 
standards (BioRad) in 40μl SDS-PAGE Reducing Sample Buffer), to help denature the 
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proteins further. The standards are a mixture of biotinylated proteins with consistent 
molecular weights, allowing for accurate molecular weight determination of immune 
detected proteins. Once let to cool for approximately 5 minutes, 40μl of the samples 
(10μl of the standards) were then loaded into their respective wells in the 
polyacrylamide gel. The gel was run at a constant voltage of 200V for 45 minutes, or 
until the blue dye ran off the bottom of the gel. 
2.9.4. Coomassie blue staining of SDS-PAGE gel 
Coomassie blue stain binds non-specifically to nearly all proteins. It does so through 
Van der Waal’s force interactions with amino acids such as histadine, arginine, lysine 
and tyrosine. Coomassie blue staining is used as protein concentration determination 
(through the Bradford protein assay) or visualization of protein bands on SDS-PAGE 
gels. In this study Coomassie blue staining was used to visualize protein bands 
separated in SDS-PAGE gels. 
2.9.4.1. Coomassie blue protocol 
The SDS-PAGE gel was removed from the electrophoresis glass plates and placed in 
fixing solution overnight. The gel was then removed from the fixing solution and 
submerged in Coomassie blue stain for 60 minutes. The Coomassie blue was removed 
and the gel was washed with de-stain. Every 10 minutes the de-stain was changed 
until stained protein bands could be observed and the background was clear.  
2.10. Western blot 
Western blotting is a technique used to transfer the proteins that have been separated 
by SDS-PAGE onto a nitrocellulose membrane in the same formation as they were in 
the gel. Following SDS-PAGE the gel is removed and undergoes an electroblot where 
a sandwich of the gel (with the stacking gel removed) and the nitrocellulose transfer 
membrane (Whatman Protran) compressed in a cassette between two layers of blotting 
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paper and sponge like pads pre-soaked in transfer buffer (Figure 2.14). The gel 
transfer mechanism uses the same method as SDS-PAGE to pull proteins out of the 
polyacrylamide gel matrix and into the nitrocellulose paper. A constant current of 
210mA was applied for 60 minutes, electrophoretically transferring the proteins from 
the gel to the membrane. 
 
 
 
 
 
 
 
 
Figure 2.14: Electroblotting layout. Electroblotting is used to pull proteins from a polyacrylamide 
gel onto a nitrocellulose membrane. The direction of protein movement is from negative to 
positive (black arrow). The polyacrylamide gel and the nitrocellulose gel are sandwiched 
between 2 sponges and 4 chromatography papers. The protein is pulled out of the 
polyacrylamide gel (blue) into the nitrocellulose membrane (yellow). 
 
Once in the membrane the sample can be analysed through several methods: 
fluorescent detection, radioactive detection, colorimetric detection and 
chemiluminescence. These techniques allow one to view the position and relative 
concentration of a specific protein. 
2.10.1 Blocking and labelling the nitrocellulose membrane 
After the transfer was complete, the nitrocellulose membrane was removed and 
washed twice with X1 PBS-Tween. All washes and incubations were performed at 
room temperature on a rocking table, to ensure the membrane was fully covered and 
never left out to dry. The membrane was then blocked for 60 minutes using a blocking 
2X Chromatography paper 
Sponge D
ir
e
c
ti
o
n
 o
f 
tr
a
n
s
fe
r 
Sponge 
2X Chromatography paper 
Polyacrylamide gel 
Nitrocellulose paper 
105 
 
buffer. The blocking buffer blocks any remaining hydrophobic binding sites, preventing 
the binding of primary antibody to the membrane itself and thereby reducing 
background signal. The membrane was then washed for 60 minutes in X1 PBS-Tween 
with two rinses every 15 minutes. The membrane was then placed in a low volume 
container and was submerged in 1:1000 dilution of the primary antibody (either 
Phospho-IκBα rabbit (New England BioLabs) or Caspase p-10 rabbit (Santa Cruz 
Biotechnology) in X1 PBS-Tween. The membrane was left on rotary at room 
temperature for 4 hours and then left in the fridge overnight. The next day the 
membrane was washed for 30 minutes in X1 PBS-Tween with two rinses every 15 
minutes. The membrane was then placed in a low volume container and submerged in 
1:2000 goat anti-rabbit Horseradish Peroxidase (HRP) secondary antibody (DAKO 
Cytomation) in X1 PBS-Tween. The membrane was left on rotary at room temperature 
for 45 minutes. With regards to the standards the membrane was incubated for 30 
minutes with Streptavidin-HRP conjugate (GE Healthcare) at a 1:1500 dilution. The 
membrane was then washed for 3 hours in X1 PBS-Tween with two rinses every 15 
minutes. This ensured all excess antibodies had been removed before visualising the 
bands using enhanced chemiluminescence. 
2.11. Enhanced chemiluminescence 
The emission of light as a result of the dissipation of energy form a substance in an 
excited state, caused by a chemical reaction, is called chemiluminescence. Enhanced 
chemiluminescence is a very sensitive and fast procedure which utilises light emitted 
from an enzymatic reaction to image a protein of choice. The exposure of a luminal 
based substrate (ECL reagents) to the HRP label causes a light emitting reaction that 
can be visualized using a high performance chemiluminescence film (Figure 2.15.). 
Detection of the bands was performed in a dark room, to avoid exposing the 
chemiluminescence film to light. Excess PBS-Tween was drained from the membrane 
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before placing it (protein side up) on a Saran wrap. ECL western blotting reagents 1 
and 2 were mixed in a 1:1 ratio (2ml total per membrane) added to the membrane, and 
incubated at room temperature for 1 minute. Excess reagent was dabbed off, the 
membrane was transferred to a fresh piece of Saran wrap, turned over (protein side 
down), and wrapped up ensuring that it was smooth and there was no bubbles. The 
membrane was then placed in a developing cassette where a sheet of high 
performance chemiluminescence film (HyperfilmTM from GE Healthcare) was placed on 
top of the membrane. The developing cassette was closed and an initial exposure of 2 
minutes was performed. The film was developed, fixed and analysed. Depending on 
the intensity and clarity of the bands seen, the exposure time was optimised where a 
new sheet of chemiluminescence film would be exposed if necessary.  
 
 
Figure 2.15: Enhanced chemiluminescence (ECL). Indirect labelling. The nitrocellulose 
membrane was labelled with a primary antibody and a horseradish peroxidase (HRP) 
conjugated secondary antibody. HRP catalyzes the oxidation of luminal to its excited state and 
light is emitted and detected on film. Adapted from http://openwetware.org/wiki/Ima 
ge:ECL_Method.jpg (09/01/2014). 
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2.11.1. Stripping and reprobing nitrocellulose membranes 
A membrane may be stripped of its bound primary and secondary antibodies, in order 
to reprobe it with different antibodies. The membrane was placed in stripping buffer and 
incubated for 4 minutes at 37ºC in a shaker incubator. After washing at room 
temperature with X1 PBS-Tween 3 times for 10 minutes each, the membrane was 
blocked for 60 minutes using 5% blocking agent, and washed twice for 15 minutes with 
X1 PBS-Tween. A different primary antibody can then be added, following the 
procedure in section 2.10.1. 
2.12. Confocal microscopy 
Confocal microscopy is a technique used to visualise the interactions and location of 
different proteins within cells. This system of imaging was originally developed in 1955 
by Marvin Minsky. Confocal microscopy can create sharp images with very high spatial 
and temporal resolution that are far better than light or standard fluorescence 
microscopy. 
Conventional microscopes function by exposing the whole sample to light and 
recording the light emitted. In this imaging technique the image produced includes in 
focus and out-of-focus light emitted of the specimen, from above and below the focal 
plane. This results in a blurred image where focused light is overlapped with unfocused 
light. A confocal microscope can create sharp images of specimens by excluding out-
of-focus light in specimens which are thicker than the focal plane by using a spatial 
pinhole. This increases the micrograph contrast and enables reconstruction of three-
dimensional images. 
The confocal microscope uses two lenses to focus light from the focal point of one lens, 
through a pinhole aperture where the light is detected. This aperture can be controlled 
to cut out any light outside the focal plane (red light path in Figure 2.16). 
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Figure 2.16: Lens layout of a confocal microscope. Confocal microscope uses two lenses to 
focus light from the focal point of one lens to a pinhole where the light is then detected. This 
method sieves out-of-focus light eliminating unwanted noise to produce a high resolution image. 
 
The confocal microscope has the ability to reconstruct three dimensional images. It 
does this by taking multiple images of the sample through the microscope’s Z axis. This 
allows one to stack the images together (Z-stack) to create a revealing three 
dimensional representation of the sample. 
A confocal microscope works by scanning one or more focused beams of light, usually 
from a laser or arc-discharge source, across the specimen to create illumination. The 
laser beam passes through the microscope to the sample via a dichroic mirror and two 
motorised rotating mirrors. The motorised mirrors scan the laser beam over the 
sample. The light emitted is focused by two lenses, back in the direction of the original 
laser path, through a pinhole aperture and onto a photomultiplier tube (PMT) detector 
(Figure 2.17). The images collected from scanning the sample are processed by 
computer software into a two dimensional image. 
 
Focal point 
Screen with pinhole 
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Figure 2.17: Light path in a confocal microscope. The path of the laser (blue) as it is reflected 
off the dichroic mirror and then the rotating mirrors. This is then focused onto the specimen via 
the microscope lenses. The green line indicates the path of light emitted by the fluorescent label 
in the specimen, as it passes back in the direction of the laser through a pinhole, ridding of any 
undesired light, and onto a photomultiplier (PMT) detector. Adapted from http://www.physi 
cs.emory.edu/~weeks/lab/papers/ebbe05.pdf (14/01/2014). 
 
One of the great advantages of using a confocal microscope is that in spite of a 
relatively weak signal it is able to produce high quality images. It does so with the use 
of lasers and PMT detectors. The laser produces bright, low-divergent light that can be 
focused and collected with minimal light loss and the PMT detectors amplify the 
weakened signal. 
In this study the samples analysed with confocal imaging were immunolabelled with 
fluorochromes via direct or indirect immunofluorescence (Section 2.7.). Fluorescence is 
emitted from the fluorochrome that becomes excited when exposed to a laser beam of 
the correct wavelength. The confocal microscope is capable of distinguishing and 
filtering between different emission wavelengths which enables multiple labelling of 
molecules and/or structures of interest. 
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In this study the confocal microscope utilised was a Carl Zeiss LSM 510 META using a 
63x /1.4 Oil DIC Zeiss objective. The images were analysed using a Carl Zeiss LSM 
Image Browser software (Carl Zeiss, Inc). Cells were cultured on 8 well glass slides 
(Nunc Lab-TekTM Chamber SlideTM System) which were labelled via direct and/or 
indirect immunofluorescence. 
 
 
 
 
 
Figure 2.18: Nunc Lab-Tek
TM
 Chamber Slide
TM
 System. 8 well glass slides were used in this 
study for confocal imaging of RAW 264.7. Cells were cultured, stimulated and labelled directly 
on the slide. http://www.thermoscientific.com/en/product/nunc-lab-tek-ii-chamber-slide-
system.html (21-01-2014) 
 
2.12.1. Oregon Green-V and FITC-V conjugation 
In order to be able to visualise V recombinant proteins within the cells, they were 
labelled with Oregon-Green or FITC. 1mg of V recombinant protein was buffer 
exchanged into 0.1M NaHCO3, pH 8.3 using Pierce Slide-A-Lyser mini dialysis micro-
tubes.  
Following this, 5mg of Oregon Green (OG) or 20mg of FITC isomer was dissolved in 
500µl of DMSO, creating a solution of OG (10mg/ml) or FITC (40mg/ml). 500µl of 
recombinant protein (1mg/ml) was mixed with 250 µl of OG or FITC. The tube was 
sealed with parafilm, wrapped in aluminium foil and left to incubate away from light at 
120RPM and 37oC for 3 hours.  
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In order to separate the conjugated protein from the unconjugated OG/FITC, a 
Sephadex PD-10 column (GE Healthcare) was used. Prior to separating the 
conjugated protein, the Sephadex column was equilibrated with X1 PBS. The 
conjugated protein was added to the Sephadex column and allowed to run through the 
column by the use of gravity alone. This results in the bigger conjugated OG-
protein/FITC-protein separating itself from the smaller unconjugated OG/FITC and 
eluting from the column first. Therefore, the first coloured fraction that appeared from 
the column was OG-protein/FITC-protein, which was collected, wrapped in aluminium 
foil, protecting it from light, and then stored at 4ºC. 
2.12.2. Seeding procedures for confocal microscopy 
In this project, RAW 264.7 cells were grown on 8 well glass slides (Nunc Lab-TekTM 
Chamber SlideTM System) and both effect and colocalisation of V antigen with different 
receptors (TLR4, NLRP12 and NLRP3), pathways (Caspase p-20, MyD88, IRF3 and 
IRF7) and organelles (nucleus (TO-PRO) endosomes (EEA1)) were investigated.  
To investigate the effect of V antigen on TLR4 and MyD88, eight time points were used 
per stimulation: unstimulated (0 hour); 1 hour LPS, 1 hour V antigen; and 1 hour LPS 
followed by either 1, 2, 4 or 6 hour(s) of V antigen. The slides were divided up as 
shown in Figure 2.19 (left layout).  
To investigate the colocalisation of V antigen with the different receptors, pathways and 
organelles RAW 264.7 cells were incubated with either OG or FITC labelled V antigen. 
Four time points were used per stimulation: 10 minutes, 30 minutes, 1 hour and 2 
hours. The slides were divided up as shown in Figure 2.19 (right layout). 
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Figure 2.19: Layout of Lab-Tek
TM
 Chamber Slide
TM
 System. Cells were grown to confluency and 
stimulated. After fixing, the cells were incubated with primary antibody, washed and incubated 
with the corresponding secondary antibody. TO-PRO-3 iodine (Molecular Probes Invitrogen) 
was used as a nuclear stain. 
 
 
To prepare the slides, 400μl DMEM was added to each well. One flask of cells was 
trypsonised, 10,000 cells were added to each well, and the slides were incubated 
overnight, making sure that they did not reach 100% confluency before carrying on with 
the stimulations. Cells were counted using a hemocytometer (Section 2.3).  
The medium was aspirated from each well, and the 150μl was then added to each well. 
The cells were then stimulated. All aspirations and additions to the wells were made 
from the same corner, to minimise damage to the cells.  
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At each time point, the cells were fixed with 300μl 4% PFA for 15 minutes, washed 
twice with 400μl X1 PBS, and left in 400μl X1 PBS until the whole slide was ready.  
2.12.3. Labelling procedures for confocal microscopy 
Once ready, the 400μl was aspirated off and 150μl of PBS/0.02% BSA/0.02% 
NaN3/0.02% Saponin was added to each well. 3μl primary antibody was added to each 
well (Section 2.1.). The slides were left incubated overnight at room temperature. 
The following day the wells were washed two times with 400μl of PBS/0.02% 
BSA/0.02% NaN3/0.02% Saponin. 150μl of PBS/0.02% BSA/0.02% NaN3/0.02% 
Saponin was then added to each well. 5μl of the relevant secondary antibody was 
added to each well and incubated for 45 minutes in the dark at room temperature. The 
cells were then washed twice with 400μl PBS/0.02% BSA/0.02% NaN3/0.02% Saponin. 
2.12.3.1. Anti-fade treatment 
The well chambers and gasket were removed from the slide and the cells were treated 
with SlowFade Gold Antifade Reagent (Molecular Probes, Invitrogen). One drop of 
antifade reagent was placed in each well, and left for ten minutes. This reagent 
suppresses photobleaching and preserves the signal of the fluorescently labelled 
secondary antibody. A coverslip was then placed over the wells and any air bubbles 
were gently pushed out from underneath them. Excess antifade reagent was removed, 
and the cover slip was sealed down using two thin layers of clear nail varnish. 
Slides were then imaged using a Zeiss LSM 510 META confocal microscope under a 
63x / 1.4 Oil DIC objective, utilising the three fluorescent wavelengths of 488 (Argon – 
green), 543 (red) and 633 (blue). 
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2.13. Animal experimentation 
The testing on animals for scientific research can be traced back to the fourth century 
BCE in Greek writings. In the last few centuries animal testing has ranged from the 
demonstration of the germ theory by Louis Pasteur in the late nineteenth century, the 
discovery of classical conditioning by Ivan Pavlov, the exploration of space. Animal 
testing in the early twentieth century saw insulin isolated from dogs along with the 
development of modern anaesthetics, antibiotics and anticoagulants. More recently 
animal testing has enabled the development of vaccines and drugs to combat HIV. The 
ground braking cloning of Dolly the sheep in 1996 is the pinnacle of animal research 
which highlights the scientific advances that have been made, that will help humans 
and non-humans alike, which would have otherwise been impossible without animal 
testing. Although highly controversial, animal testing has undoubtedly improved and 
saved millions of lives throughout the world. 
Due to the controversial nature of animal testing many rules, guidelines and regulations 
have been put into place to protect animal welfare. Britain was relatively early in 
comparison to the rest of the world to put into practice the Britain Cruelty to Animals 
Act introduced in 1876, which was the first act that was concerned specifically with 
animal testing. Later the Animals (Scientific Procedures) Act 1986 (ASPA) was 
introduced, which has been modified but still is the basis of the ASPA to this day. 
2.13.1. Animal model selection 
Animal models used in animal testing include both non-vertebrates and vertebrates. 
Non-vertebrates include the widely used Drosophila melanogaster and Caenorhabditis 
elegans. Vertebrates include animals such as mice, rats guinea pigs, cats, dogs, fish, 
amphibians, larger domestic species such as pigs, goats, equines and primates 
including new and old world monkeys. 
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In the selection of a model organism for a specific experiment a number of factors have 
to be considered. Preliminary in vitro data should be used to help select the model. 
Animal models can come in a number of varieties where they can be tailored for a 
specific experiment. Animals can be out-bred, in-bred, mutants or transgenic. Out-bred 
animals (“stocks”) are from closed undefined genetic colonies. These have good 
fertility, large litter sizes, are easy to mate, have a good growth curve and are usually 
relatively cheap. Inbred mice (“strains”) are compromised in these factors. However, 
their benefit is that they are ~99% homozygous as a result of ≥20 generations of 
brother sister inbreeding. Mutant animals are an out-bred stock with a mutant gene 
these are tricky to breed and maintain. Dominant and recessive mutations can have a 
number of effects such as infertility and high birth mortality. Transgenic mice have had 
foreign DNA permanently incorporated into their genome resulting in the knock out 
(KO) of genes, for example. These mice often require high levels of maintenance, such 
as germ free environments if their immune system is compromised for example. 
In this study the out-bred CD-1 male mouse was selected as an animal model of 
sepsis. Yersinia pestis V antigen was tested for its ability to reduce inflammation and 
lethal shock in the murine model of sepsis, by protecting or potentially reversing the 
progression of lethal sepsis in mice.  
2.13.1.1. The CD-1 mouse 
In this study out-bred CD-1 male mice at 6-8 weeks were used as an animal model of 
sepsis as advised by Professor Mervyn Singer and Dr. Richard Hotchkiss who both 
have well established endotoxin CD-1 mouse models of sepsis. Mice were also 
selected for their good fertility, good growth curve, large litter size and the ease at 
which they can be bred. CD1 mice, which are an outbred stock, are most often used in 
research projects requiring vigorous, economically priced animals, but in which 
considerations of specific genotype are of lesser importance. In the current study we 
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wanted to assess the effect of V antigen on the outcome of sepsis, where the genetic 
genotype is of lesser importance. This would also be reflected in a human population of 
we were testing V antigen – there would have been variable genetic genotype – thus 
this model is ideal for testing this inhibitor. 
 
 
Figure 2.20: The CD-1 mouse. In this study the CD-1 mouse was selected as an animal model 
of sepsis. They have good fertility, a good growth curve, a large litter size and are easy to 
breed. http://www.biolasco.com.tw/Biolasco%20website%20English/SPF%20ra12.jpg (17/02/20 
10). 
 
LPS and V antigen were administered via intraperitoneal injection. 
2.13.2. Intraperitoneal injection 
Intraperitoneal (i.p) injection is the injection of a substance into the peritoneal cavity. 
This allows large amounts to be injected producing a massive and rapid systemic 
immune response. The procedure is relatively quick and easy which reduces any 
stress and damage that may be caused to the animal, reducing these factors increases 
result validity. 
The mouse is restrained so that its head was facing away and downward with its 
abdomen exposed (Figure 2.21), this allows the intestines to be under less pressure to 
reduce chance of internal damage. The needle is inserted, at a 30˚ angle, close to the 
midline on the animals right side horizontally in-line with the knees to a depth of 5mm 
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(Figure 2.21). Injection to the right side places the needle at the sight of the small 
intestines; again reducing risk of internal damage for the needle is less likely to hit 
smaller structures.  
 
 
Figure 2.21: Intraperitoneal (i.p.) injection to a mouse. The needle is inserted close to the 
midline on the animals right side horizontally in-line with the knees. http://www.procedureswith 
care.org.uk/wp-content/uploads/2010/07/DSC_2824.jpg (17/02/2014). 
 
2.13.3. Injected substance concentration determination 
The concentrations of substances to be injected were determined with preliminary 
experiments. In order to determine whether V antigen protects against septic shock, a 
mouse model had to be developed. The septic shock mouse model was designed to 
have 100% mortality at 24 hours post LPS administration. V antigen was tested to find 
optimum concentration for protection against LPS endotoxin induced septic shock. 
2.13.3.1. Determination of LPS concentration for sepsis model 
Male CD-1 mice (6-8 weeks) were randomly grouped (5-10 mice per group) and 
injected by intraperitoneal (i.p.) injection with different concentrations (50, 60, 70, 
80mg/Kg) of Escherichia coli 055 (E. coli 055) LPS (List Biological Laboratories) using 
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a sterile 1ml syringe (BD Plastipak™ (Becton Dickinson)) with a 25 GA1 0.5x25mm 
needle (BD Microlance™ 3 (Becton Dickinson)). The syringe was prepared with the 
correct volume of E. coli 055 LPS to be administered. The mouse was then restrained 
so that its head was facing away and downward with its abdomen exposed (Figure 
2.21). The needle was inserted, at a 30˚ angle, close to the midline on the animals right 
side horizontally in-line with the knees to a depth of 5mm (Figure 2.21). The needle 
was withdrawn and the mouse returned to the cage. 
Once the optimum concentration of LPS required to induce septic shock and death at 
24 hours was determined, it was kept constant throughout the in vivo inhibition studies. 
2.13.3.1.1. Induction of sepsis in the CD-1 mouse 
Intraperitoneal (i.p.) injection of LPS (60mg/Kg) was administered to the CD-1 mouse 
(male 6-8 weeks) using a sterile 1ml syringe (BD Plastipak™ (Becton Dickinson)) with 
a 25 GA1 0.5x25mm needle (BD Microlance™ 3 (Becton Dickinson)). The syringe was 
prepared with the correct volume of LPS, relative to mouse weight, to be administered. 
Death commenced at 24 hours. 
2.13.3.2. Determination of optimal V antigen concentration 
In order to determine the optimum concentration of V antigen (Kindly supplied by 
Professor R. Titball of the Ministry of Defence, Porton Down) that was needed to 
protect mice from LPS-induced septic shock, mice were administered different 
concentrations (500µg/Kg and 1000µg/Kg) of V antigen by i.p. injection 1 hour after 
LPS administration. Blood (50µl) was collected at certain time points after V antigen 
administration, over a 72 hour period, from the tail vein of mice (250µl of blood in total). 
The level of TNF-α and IL-1β in the serum was determined using a cytokine bead array 
system (CBA) (Becton Dickinson). 
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2.13.3.2.1. In vivo testing of V antigen 
Intraperitoneal (i.p.) injection of V antigen 500µg/Kg (Kindly supplied by Professor R. 
Titball of the Ministry of Defence, Porton Down)) was administered to the CD-1 mouse 
(male 6-8 weeks) using a sterile 1ml syringe (BD Plastipak™ (Becton Dickinson)) with 
a 25 GA1 0.5x25mm needle (BD Microlance™ 3 (Becton Dickinson)). The syringe was 
prepared with the correct volume of V antigen to be administered. The needle was 
withdrawn and the mouse returned to the cage. 
2.13.4. Cytokine analysis of blood samples 
Blood samples from mice were collected at different times before or after LPS 
administration and frozen until the cytokine assays were performed. The Becton 
Dickinson (Oxford, UK) Mouse Inflammation cytokine bead array (CBA) (Becton 
Dickinson) system was used in order to determine the level of TNF-α, IL-6, MCP-1 and 
IL12p70 according to the manufacturer’s instructions (Section 2.8.2.2). 
2.14. Statistical analysis 
Data were evaluated by analysis of variance (ANOVA) and the Dunnett multiple-
comparison test using the GraphPad Prism 5 program. Where appropriate (comparison 
of two groups only), two-tailed t tests were also performed. Statistical differences were 
considered significant at the level of p<0.05. Experiments were performed using 
triplicate samples and were performed twice or more to verify the results. 
With regards to the animal model and based on experimental experience with this 
model over several years we have calculated that we need a minimum group size of 8 
for statistical power. Using G*Power program freely available from the University of 
Dusseldorf website (http://www.psycho.uni-dusseldorf.de/abteilungen/aap/gpower3) 
(Faul et al., 2007) we calculate that this experiment had an actual power of over 90% 
(>0.9). If we assume that a similar level of variability will occur in any future 
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experiments and utilising the power value (>0.9) derived from our existing data we 
calculate that we shall need a minimum group size of 8 animals. 
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Results 
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3.1. V antigen purification 
In order to investigate the effect that V antigen might have on the innate immune 
response, recombinant versions of V antigen had to be produced. V antigen was 
cloned in Escherichia coli and kindly supplied to us by Professor Richard Titball of the 
Ministry of Defence, Porton Down. In order to purify the recombinant V, the E. coli 
strain had to be cultured in Luria broth and the protein isolated using affinity 
chromatography. 
Prior to investigating the effect on the innate immune system, the purity of V antigen 
had to be confirmed as well as to eliminate any traces of endotoxin from the purified 
proteins. 
3.1.1. Purification of V antigen 
In order to produce recombinant V antigen, the recombinant LcrV plasmid (pVG110) 
with a glutathione S-transferase (GST) tag was used which was kindly provided by 
Prof. Richard Titball (Chemical and Biological Defence Establishment, Porton Down, 
Salisbury, UK). The plasmid was transformed into E. coli BL21 cells as previously 
described by Carr et al. (1999). 
The cloning and expression of the gene was done by Prof. Titball and colleagues as 
described in Carr et al. 1999. Briefly, the lcrV gene (Genebank accession number 
AAA27641) was amplified by PCR from the chromosomal DNA of Y. pestis strain GB 
using 500pmol of primers (Cruachem, Strathclyde, UK) homologous to the 5’ and 3’ 
ends of the gene (the 5’ primer GATCGAATTC+GAGCCTACGAACAAAACCCA and 
the 3’ primer GGATCGTCGACTTA*CATAATTACCTCGTGTCA), respectively and 
cloned into pGEX-6P-2 (GE Healthcare) to make the recombinant plasmid, pVG110. 
E. coli BL21 cells containing the recombinant plasmid were cultured in Luria broth 
containing 100mg/ml ampicillin. Cultures were placed in a 37ºC rotary incubator at 
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120RPM until an A600 of 0.3 was achieved; cultures were then induced with 1mM 
isopropyl-β-D-thiogalactopyranoside (IPTG). Cultures were incubated for a further 6 
hours and harvested by centrifugation at 7000RPM for 30 minutes (Section 2.5.2). 
Harvested cells were resuspended in PBS and lysed by repeated freeze-thaw cycles. 
Crude cell extract was clarified by centrifugation at 2500RPM for 30 minutes and the 
supernatant added to glutathione Sepharose columns, previously equilibrated with 
PBS. Unbound material was washed off with PBS. Cleavage buffer (10ml) (50mM 
Tris/150mM NaCl/1mM EDTA/1mM DTT/0.01%) with PreScission™ Protease (150µl) 
was added to the column and incubated at room temperature for 3 hours. The column 
was then washed with more cleavage buffer (20ml) and the elution was collected 
(Section 2.5.5). 
The elution was concentrated and subsequently passed through a Profos EndoTrap® 
blue 10 to ensure there was no LPS in the final solution (Section 2.5.7.1). The HyCult 
LAL Chromogenic Endotoxin Quantitation Kit was used in order to measure the amount 
of endotoxin in the purified protein sample using the Limulus Amebocyte Lysate (LAL) 
assay, which was found to be none (Section 2.5.8). 
The preparations of purified rV were analysed by SDS-PAGE followed by Coomassie 
blue staining in order to verify its purity (Section 2.9.4). For Western blotting, the 
proteins were transferred onto a polyvinylidene difluoride (PVDF) membrane and 
detected using a V antigen specific monoclonal antibody (mouse anti-LcrV (Abcam)) at 
1:1000 dilution followed by a goat anti-mouse IgG horse-radish peroxidase conjugate 
at 1:2000 dilution. 
The molecular weight of the protein was determined by SDS-PAGE and was found to 
be 38 kDa, which is within the predicted molecular weight range of native V antigen 
(Figure 3.1). Although some lower molecular weight proteins were observed after 
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Coomassie staining (which could be V antigen fragments), the major band observed 
was the 37kDa V antigen. 
 
 
Figure 3.1: Coomassie blue stain for detection of purity of V antigen. 5µg of V antigen was 
analysed by SDS-PAGE and subsequently stained with Coomassie blue stain. Molecular weight 
markers were used to determine the correct position of the molecular weight of the bands 
indication presence of the desired protein.  
 
A strong band appeared around 37kDa, which suggests that there were no other 
proteins present except V antigen. In order to verify the identity of the 37kDa band 
observed with the Coomassie blue stain, a western blot was performed using an anti-V 
antigen specific antibody (Figure 3.2). It was shown that the band identified in the 
Coomassie blue stained gel, was indeed V antigen. Some minor band of lower and 
higher molecular weight appeared on the western blot and must represent fragments 
and aggregates of V antigen since they are recognised by the mAb specific for V 
antigen. 
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Figure 3.2: Western blots for detection of V antigen at different concentrations. Molecular 
weight markers were used to determine the correct position of the molecular weight of the 
bands indicating presence of the desired protein. The loading volumes in the wells were 5µg, 
10µg and 20µg, respectively, of the purified solution. 
 
3.1.2. Conclusions 
In order to investigate the effects of Y. pestis V antigen on human 
monocytes/macrophages, recombinant proteins had to be produced. Prof. Richard 
Titball kindly provided us with the recombinant LcrV plasmid (pVG110) with a gluthione 
S-transferase (GST) tag. The plasmid was transformed into E. coli BL21 cells as 
previously described by Carr et al. (1999). 
The LcrV protein was encoded with a glutathione S-transferase (GST) tag, thus it was 
straight forward to isolate the protein from the crude E. coli cell extract. LcrV 
recombinant proteins were isolated using glutathione Sepharose columns which have 
affinity for the GST tag, and subsequently eluted using PreScission™ Proteases. The 
eluted proteins were buffer-exchanged, concentrated and all traces of endotoxin 
V antigen 
45 kDa 
31 kDa 
21.5 kDa 
66.2 kDa 
97.4 kDa 
66.2 kDa 
97.4 kDa 
5µg 10µg 20µg 
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removed by passing the protein through Profos EndoTrap® blue 10 columns. In order 
to verify that all the endotoxin was removed, the Limulus Amebocyte Lysate (LAL) 
assay was used, which found no traces of endotoxin. 
The preparations of purified recombinant V antigen (rV) were analysed by SDS-PAGE 
followed by Coomassie blue staining. It was shown that the molecular weight of the 
protein was 37kDa, which was the predicted molecular weight of native V antigen. 
Some lower molecular weight proteins were observed after Coomassie staining (which 
could be V antigen fragments), the major band observed was the 37kDa V antigen. 
Western blotting also verified that the main protein band at 37kDa was V antigen, 
whereas smaller fragments also seemed to be present. 
The initial stage of this study was to generate and characterise recombinant V antigen. 
In order to investigate the effects of V antigen on the innate immune responses, 
recombinant protein that was pure and endotoxin free had to be produced. Once this 
was achieved the effects of this protein on the innate immune response was 
investigated. 
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3.2. Yersinia pestis V antigen induced immunomodulatory effects in THP-1 
cells 
Regulation of the innate immune system is important to keep the body in a healthy 
state. A loss of regulation or excessive stimulation of innate immunity can lead to a 
dangerous and often fatal symptoms. Septic shock is the purest example of this 
deregulation, where an overreaction of the host innate immune system lead to harmful 
symptoms. The search to pinpoint molecules that are able to modulate the innate 
immune responses is decisive in the successful development of a therapeutic 
intervention for sepsis.  
Yersinia pestis, the causative agent of the three main plague pandemics has been 
responsible for over 200 million deaths over several millennia. The bacterium has been 
so successful because it encodes several virulence factors, one of which is LcrV (V 
antigen). Y. pestis V antigen is a multifunctional protein that has been shown to exhibit 
immunomodulatory properties and essential in translocating other virulence factors into 
eukaryotic cells.  
It is the hypothesis of this study that this multifunctional protein modulates the innate 
immune responses to the bacterial component lipopolysaccharide (LPS), ultimately 
reversing the detrimental effects of sepsis associated inflammatory response. This 
study utilised monocytic (THP-1) (Section 2.2.2) cells to elucidate whether LcrV affects 
pattern recognition receptors (PRRs) and the subsequent inflammatory cytokine 
release. Firstly we investigated the effect of LPS on PRR expression and its capability 
of initiating an innate immune response in THP-1 cells. 
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3.2.1. Effect of LPS on TLR, CD14, NOD and NLRP expression in THP-1 
cells. 
In order to determine which PRRs are involved in the recognition of LPS, THP-1 cells 
were stimulated for 1, 2, 4 and 6 hours with 100ng/ml of E. coli LPS (Section 2.6). All 
stimulations were carried out in 25cm2 flasks. The receptors (TLR1, TLR2, TLR4, 
TLR6, TLR7, TLR9, NOD1, NOD2, NLRP1, NLRP3 and NLRP12) were labelled and 
their expression levels detected using indirect immunofluorescence (Section 2.7.2) and 
analysed by flow cytometry (Section 2.8). In addition the expression levels of CD14 
were also determined as it is a co-receptor of TLR4. Unstimulated cells were used as a 
control of THP-1 receptor expression levels prior to stimulation.  
 
Figure 3.3: PRR expression levels on THP-1 cells in response to 100ng/ml of LPS. Receptor 
expression levels of TLR1, TLR2, TLR4, TLR6, TLR7, TLR9, CD14, NOD1, NOD2, NLRP1, 
NLRP3 and NLRP12 on THP-1 cells stimulated with 100ng/ml of LPS for 1, 2, 4 and 6 hours. 
Unstimulated and isotype (-ve control) controls were performed. Cells were stimulated, fixed 
and labelled with a primary antibody against the receptor of interest, followed by an appropriate 
secondary antibody conjugated to FITC. Fluorescence was measured on a FACSCalibur
TM
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(Becton Dickinson), counting 10,000 cells per sample, not gated. The data is statistically 
significant (p<0.05). The data represents the mean of three independent experiments. 
 
LPS caused up-regulation of TLR2, TLR4, TLR6, TLR7, TLR9, CD14, NOD1, NOD2, 
NLRP3 and NLRP12 expressed on THP-1 cells (Figure 3.3). There was no up-
regulation of TLR1 and NLRP1 observed. In response to LPS, the receptors TLR2, 
TLR4 and co-receptor CD14 expression decayed over time with a maximum at 1 hour, 
possibly due to internalisation of the receptors. Likewise, NOD2, NLRP3 and NLRP12 
expression decayed over time with, a maximum at 1 hour. With regards to TLR6, TLR7 
and TLR9 expression, LPS induces up-regulation at 1 hour, the highest expression, 
followed by a downregulation at the 2 hour mark and a second increase of expression 
at 4 hours. A downregulation reoccurred by the 6 hours time-point, whose expression 
level was the lowest. Furthermore, after LPS stimulation, there is a marked increase in 
NOD1 expression after the first two hours, which tails off after 4 and 6 hours of 
stimulation. 
As expected, lipopolysaccharide has a broad effect on the expression levels of THP-1 
cells, up-regulating most pattern recognition receptors, either directly or indirectly by 
the secretion of cytokines. 
3.2.2. Effect of LcrV on TLR, CD14, NOD and NLRP expression in THP-1 
cells. 
In order to test the effect of Yersinia pestis V antigen has on the expression of different 
PRRs, THP-1 cells were stimulated for 1 hour with 100ng/ml of LPS and either pre- or 
post-incubated for 1 hour or 1, 2, 4 and 6 hours, respectively, with 50µg/ml of V 
antigen. All stimulations were carried out in 25cm2 flasks. The expression levels of 
TLR1, TLR2, TLR4, TLR6, TLR7, TLR9, CD14, NOD1, NOD2, NLRP1, NLRP3 and 
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NLRP12 were labelled and detected using indirect immunofluorescence (Section 2.7.2) 
and analysed by flow cytometry (Section 2.8). 
Initially, THP-1 cells were stimulated with 50µg/ml of V antigen (Figure 3.4). The 
expression levels of TLR2, TLR4, TLR6, TLR7, NOD1 and NLRP12 were inferior in 
comparison to THP-1 cells stimulated for 1 hour with LPS. In contrast, the expression 
levels of TLR9, CD14, NOD2, NLRP1 and NLRP3 were greater in response to V 
antigen. In particular, NOD2 showed a noticeable increase when cells were stimulated 
with V antigen in comparison to stimulation with LPS for 1 hour. TLR1 did not manifest 
an evident down or up-regulation. 
 
 
 
 
 
 
 
 
Figure 3.4: PRR expression levels on THP-1 cells stimulated for 1 hour with 50µg/ml of V 
antigen. Receptor expression levels of TLR1, TLR2, TLR4, TLR6, TLR7, TLR9, CD14, NOD1, 
NOD2, NLRP1, NLRP3 and NLRP12 on THP-1 cells stimulated for 1 hour with 50µg/ml of V 
antigen. Unstimulated and isotype (-ve control) controls were performed. Cells were stimulated, 
fixed and labelled with a primary antibody against the receptor of interest, followed by an 
appropriate secondary antibody conjugated to FITC. Fluorescence was measured on a 
FACSCalibur
TM
 (Becton Dickinson), counting 10,000 cells per sample, not gated. The data is 
statistically significant (p<0.05). The data represents the mean of three independent 
experiments. 
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Subsequently, THP-1 cells were pre-incubated with 50µg/ml of V antigen followed by 
stimulation with 100ng/ml of LPS (Figure 3.5). This pre-incubation caused up-regulation 
of TLR2, TLR6 and TLR7. In addition, NOD1, NOD2, NLRP1, NLRP3 and NLRP12 
expression levels also increased with pre-incubation with V antigen followed by a LPS 
stimulation. Furthermore, the TLR4 co-receptor CD14 also showed an increase in 
expression. After the pre-incubation with V and stimulation with LPS, TLR1 and TLR4 
showed no marked change in expression, whereas TLR9 showed a downregulation.  
 
 
Figure 3.5: PRR expression levels on THP-1 cells pre-incubated for 1 hour with 50µg/ml of V 
antigen and stimulated for 1 hour with 100ng/ml of LPS. Receptor expression levels of TLR1, 
TLR2, TLR4, TLR6, TLR7, TLR9, CD14, NOD1, NOD2, NLRP1, NLRP3 and NLRP12 on THP-1 
cells pre-incubated for 1 hour with 50µg/ml of V antigen and stimulated for 1 hour with 100ng/ml 
of LPS. Unstimulated and isotype (-ve control) controls were performed. Cells were stimulated, 
fixed and labelled with a primary antibody against the receptor of interest, followed by an 
appropriate secondary antibody conjugated to FITC. Fluorescence was measured on a 
FACSCalibur
TM
 (Becton Dickinson), counting 10,000 cells per sample, not gated. The data is 
statistically significant (p<0.05). The data represents the mean of three independent 
experiments. 
 
A comparison of TLR, CD14, NOD and NLRP receptor levels in monocytic cells (THP-1) when pre-incubated for 1
hour with 50g/ml of V Antigen and stimulated for 1 hour with 100ng/ml of LPS
-v
e 
co
nt
ro
l
TL
R
 1
TL
R
 2
TL
R
 4
TL
R
 6
TL
R
 7
TL
R
 9
C
D
14
N
O
D
 1
N
O
D
 2
N
LR
P 
1
N
LR
P 
3
N
LR
P 
12
0
5
10
15
20
25
Unstimulated LPS 1h 1h Pre-incubation
M
e
a
n
 f
lu
o
re
s
c
e
n
c
e
 i
n
te
n
s
it
y
132 
 
The following step was to examine what effect post-incubating THP-1 cells with V 
antigen, after stimulating them with LPS, has on the expression of the different PRRs 
(Figure 3.6).  
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Figure 3.6: PRR expression levels on THP-1 cells stimulated for 1 hour with 100ng/ml of LPS 
and post-incubated for 1, 2, 4 and 6 hours with 50µg/ml of V antigen. Receptor expression 
levels of TLR1, TLR2, TLR4, TLR6, TLR7, TLR9, CD14, NOD1, NOD2, NLRP1, NLRP3 and 
NLRP12 on THP-1 cells stimulated for 1 hour with 100ng/ml of LPS and post-incubated for 1, 2, 
4 and 6 hours with 50µg/ml of V antigen. Unstimulated and isotype (-ve control) controls were 
performed. Cells were stimulated, fixed and labelled with a primary antibody against the 
receptor of interest, followed by an appropriate secondary antibody conjugated to FITC. 
Fluorescence was measured on a FACSCalibur
TM
 (Becton Dickinson), counting 10,000 cells per 
sample, not gated. The data is statistically significant (p<0.05). The data represents the mean of 
three independent experiments. 
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TLR4 expression levels seem to downregulate in response to post-incubation with V 
antigen, with the lowest expression registered at 6 hour post-incubation. With regards 
to the receptors TLR6 and TLR7, they seem to have a similar trend of an initial 
increase of expression by the first hour of post-incubation followed by a drop in 
expression for the remaining time-points. The expression level of TLR2 in response to 
post-incubation with V antigen initially increased, with a maximum at 1 hour post-
incubation, which tails off for the remaining post-incubation time-points, noting that at 
the 4 and 6 hour post-incubation mark the expression levels are lower compared to the 
expression of TLR2 in response to LPS alone. 
At 1 hour post-incubation TLR9 expression level doubled, compared to cells stimulated 
solely with LPS. The following post-incubation time-points show a marked decrease in 
expression, where at 4 and 6 hours the expression level decreased to approximately 
the level observed in cells stimulated only with LPS. NLRP3 showed a similar trend to 
TLR9, where an initial surge in expression level was observed, followed by a decline in 
expression. It differed from the results obtained from TLR9 where at 4 and 6 hours the 
expression level of NLRP3 was higher compared to the one observed in cells 
stimulated with just with LPS. 
The TLR4 co-receptor CD14 and NOD1 expression levels increase after the first two 
post-incubation time-points, peaking at 2 hours post-incubation, which tails off after 4 
and 6 hours of post-incubation with V antigen. NLRP1 seems to have a similar 
response to post-incubation with V antigen as CD14 and NOD1, although a weak 
expression increase was observed. 
Finally, the expression levels of NOD2 and NLRP12 in response to post-incubation with 
V antigen induced an up-regulation for the first two hours post-incubation, the highest 
expression being at the second post-incubation mark, followed by a downregulation at 
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the 4 hour and a second increase of expression at 6 hours post-incubation with V 
antigen.  
3.2.3. Inflammatory immune responses triggered by Yersinia pestis V 
antigen 
As previously mentioned, one of the consequences of activation of TLRs is the 
expression of genes via NF-κB which, normally, is sequestered by unphosphorylated 
IκB. One of the most shared signalling pathways from TLR activation leads to the 
phosphorylation of IκB and consequently the release of NF-κB, which in turn lead to the 
production of inflammatory cytokines. Furthermore, also mentioned above, 
inflammasome sensor molecules, such as NODs and NLRPs, can activate caspase-1 
where its main role is to convert pro-IL-1β and pro-IL-18 into their bioactive cytokine IL-
1β and IL-18, respectively.  
3.2.3.1. NF-κB and caspase-1 activation in THP-1 cells in response to V 
antigen 
The protein complex NF-κB is the transcription factor that is involved in the cellular 
response to stress and, of particular interest to this work, presence of cytokines. The 
presence of phospho-IκB in the cell lysate indicates the transcription of pro-
inflammatory cytokines. Similarly, the presence of caspase-1 is an indicative of 
inflammasome activation, which also leads to a secretion in inflammatory cytokines. 
Western blotting was utilised in order to determine the presence of both phospho-IκBα 
and caspase-1 p-10. 
Since V antigen was shown to be able to modulate the expression of different PRRs, 
experiments were performed in order to test the hypothesis that V antigen is able to 
modulate NF-κB and caspase-1 activation in response to LPS.  
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3.2.3.1.1. Presence of phospho-IκBα and caspase-1 p10 in THP-1 cells in 
response to LPS 
Initially, in order to determine whether LPS can lead to NF-κB and caspase-1 
activation, THP-1 cells were stimulated for 1, 2, 4 and 6 hours with 100ng/ml LPS. The 
supernatant was collected, at the respective time-points, frozen and stored for later 
cytokine assays. The cells were lysed and the samples were separated by size via 
SDS-PAGE (Section 2.9) and transferred onto a membrane (Section 2.10.1), which 
was probed for phospho-IκBα or caspase-1 p-10, with their respective primary 
antibody, followed by the appropriate secondary antibody conjugated to horse-radish 
peroxidase (HRP). Membranes were imaged via enhanced chemiluminescence 
(Section 2.11). It was shown that LPS triggers NF-κB (Figure 3.11) and caspase-1 
(Figure 3.12). 
 
 
 
 
 
Figure 3.11: Western blot of phospho-IκBα from lysates of unstimulated THP-1 cells and those 
stimulated for 1, 2, 4 and 6 hours with 100ng/ml LPS. Lysates were separated by SDS-PAGE 
and transferred onto a nitrocellulose membrane. The membrane was probed with an antibody 
specific for phospho-IκBα followed by the appropriate secondary antibody conjugated to HRP. 
Enhanced chemiluminescence was used for detection. β-actin was used as a loading control. 
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Figure 3.12: Western blot of caspase-1 p10 from lysates of unstimulated THP-1 cells and those 
stimulated for 1, 2, 4 and 6 hours with 100ng/ml LPS. Lysates were separated by SDS-PAGE 
and transferred onto a nitrocellulose membrane. The membrane was probed with an antibody 
specific for caspase-1 p10 followed by the appropriate secondary antibody conjugated to HRP. 
Enhanced chemiluminescence was used for detection. β-actin was used as a loading control. 
 
3.2.3.1.2. Presence of phospho-IκBα and caspase-1 p10 in THP-1 cells in 
response to LPS pre- and post-incubated with V antigen 
Once it was established that LPS is able to trigger NF-κB signalling cascade and 
caspase-1 activation in THP-1 cells, whether V antigen was able to modulate this 
response was investigated. In order to do so, THP-1 cells were stimulated for 1 hour 
with 100ng/ml of LPS and either pre- or post-incubated for 1 hour or 1, 2, 4 and 6 
hours, respectively, with 50µg/ml of V antigen. The cells were lysed and the samples 
were separated by size via SDS-PAGE (Section 2.9) and transferred onto a membrane 
(Section 2.10.1), which was probed for phospho-IκBα or caspase p-10, with their 
respective primary antibody, followed by the appropriate secondary antibody 
conjugated to horse-radish peroxidase (HRP). Membranes were imaged via enhanced 
chemiluminescence (Section 2.11). 
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The results obtained from pre-incubating V antigen show that there is still some 
activation of NF-κB in response to LPS, however it appears to be slightly inhibited. On 
the other hand, the results obtained from cells stimulated with LPS and subsequently 
post-incubated with V antigen show that the activation of NF-κB is inhibited (Figure 
3.13). 
 
 
 
 
 
 
 
Figure 3.13: Western blot of phospho-IκBα from lysates of unstimulated THP-1 cells; stimulated 
for 2 and 4 hours with 100ng/ml LPS; stimulated for 1 hour with 50µg/ml of V antigen; pre-
incubated for 1 hour with 50µg/ml of V antigen and subsequently stimulated for 1 hour with 
100ng/ml LPS; and stimulated for 1 hour with 100ng/ml LPS and subsequently post-incubated 
for 1, 2, 4 and 6 hours with 50µg/ml of V antigen. Lysates were separated by SDS-PAGE and 
transferred onto a nitrocellulose membrane. The membrane was probed with an antibody 
specific for phospho-IκBα followed by the appropriate secondary antibody conjugated to HRP. 
Enhanced chemiluminescence was used for detection. β-actin was used as a loading control. 
 
Concerning caspase-1 activation, the results show that both pre- and post-incubations 
with V antigen result in a reduction of caspase-1. This reduction seems to gradually 
occur through the first three post-incubation time-points, with a maximum at the 4 hour 
post-incubation mark, and at the 6 hour mark it seems to re-increase caspase-1 
activation (Figure 3.14). 
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Figure 3.14: Western blot of caspase-1 p10 from lysates of unstimulated THP-1 cells; 
stimulated for 2 and 4 hours with 100ng/ml LPS; stimulated for 1 hour with 50µg/ml of V antigen; 
pre-incubated for 1 hour with 50µg/ml of V antigen and subsequently stimulated for 1 hour with 
100ng/ml LPS; and stimulated for 1 hour with 100ng/ml LPS and subsequently post-incubated 
for 1, 2, 4 and 6 hours with 50µg/ml of V antigen. Lysates were separated by SDS-PAGE and 
transferred onto a nitrocellulose membrane. The membrane was probed with an antibody 
specific for caspase-1 p10 followed by the appropriate secondary antibody conjugated to HRP. 
Enhanced chemiluminescence was used for detection. β-actin was used as a loading control. 
 
3.2.3.2. Cytokine secretion in THP-1 cells in response to V antigen 
Given that V antigen was found to modulate the expression of PRRs and the activation 
of both NF-κB and caspase-1 activation, the next step in this study was to examine the 
release of cytokines, the inflammatory mediators, caused by LPS and whether or not V 
antigen is able to modulate their secretion. Out of the inflammatory cytokines analysed 
(Interlukin-8 (IL-8), Interlukin-1β (IL-1β), Interlukin-6 (IL-6), Interlukin-10 (IL-10), Tumor 
Necrosis Factor (TNF) and Interlukin-12p70 (IL-12p70)), only the release of IL-1β, IL-6, 
IL-10 and TNF were significantly increased. 
THP-1 cells were stimulated for 1, 2, 4 and 6 hours with 100ng/ml of LPS as well as 
with different concentrations (50µg/ml and 100µg/ml) of V antigen. Additionally, THP-1 
cells were stimulated for 1 hour with 100ng/ml of LPS and either pre- or post-incubated 
for 1 hour or 1, 2, 4 and 6 hours, respectively, with 50µg/ml of V antigen. All 
stimulations were carried out in 25cm2 flasks. The supernatants were collected post 
β-actin 
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stimulations for cytokine analysis using the Human Inflammation BDTM Cytometric bead 
array kit (Section 2.8.2.2). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.15: Secretion of TNF in THP-1 cells in response to LPS, V antigen and pre- or post-
incubation with V antigen. THP-1 cells were stimulated with: 100ng/ml LPS for 1, 2, 4 and 6 
hours; 50µg/ml or 100µg/ml of V antigen for 1 hour; pre-incubated with 50µg/ml V antigen for 1 
hour and stimulated with 100ng/ml of LPS for 1 hour; or stimulated with 100ng/ml LPS for 1 
hour and post-incubated for 1, 2, 4 and 6 hours with 50µg/ml V antigen. The cytokines were 
measured in the cell supernatant using a flow cytometric cytokine bead array system (Becton 
Dickinson). Unstimulated controls were performed. The data is statistically significant (p<0.05). 
The data represents the mean of three independent experiments. 
 
 
As expected, it was shown that LPS stimulated the release of TNF. Its release 
increased over the first 4 hours and then decreased considerably at the 6 hour mark. It 
was also shown that V antigen on its own did not stimulate TNF secretion at any 
Level of TNF secretion in THP-1 cells
Un
st
im
ul
at
ed 1h 2h 4h 6h
g/
m
l

V 
So
lo
 5
0
g/
m
l

V 
So
lo
 1
00
1h
 V
 +
 1
h 
LP
S
1h
 LP
S +
 1
h 
V
1h
 LP
S +
 2
h 
V
1h
 LP
S +
 4
h 
V
1h
 LP
S +
 6
h 
V
0
50
100
150
200
LPS
Post-incubationPre-incV antigen
Le
ve
l o
f 
cy
to
ki
n
e
 s
e
cr
e
ti
o
n
 (
p
g/
m
l)
141 
 
concentration tested. TNF secretion was significantly down-regulated in response to 
pre- and post-incubation with V antigen (Figure 3.15). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.16: Secretion of IL-6 in THP-1 cells in response to LPS, V antigen and pre- or post-
incubation with V antigen. THP-1 cells were stimulated with: 100ng/ml LPS for 1, 2, 4 and 6 
hours; 50µg/ml or 100µg/ml of V antigen for 1 hour; pre-incubated with 50µg/ml V antigen for 1 
hour and stimulated with 100ng/ml of LPS for 1 hour; or stimulated with 100ng/ml LPS for 1 
hour and post-incubated for 1, 2, 4 and 6 hours with 50µg/ml V antigen. The cytokines were 
measured in the cell supernatant using a flow cytometric cytokine bead array system (Becton 
Dickinson). Unstimulated controls were performed. The data is statistically significant (p<0.05). 
The data represents the mean of three independent experiments. 
 
 
When THP-1 cells were stimulated with LPS they incrementally secreted IL-6, with a 
maximum at 6 hour stimulation. Both 50 and 100µg/ml of V antigen by itself did also 
stimulate IL-6 production, although not to the same extent as the 4 and 6 hour LPS 
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stimulation. The same can be said to THP-1 cells pre-incubated with V antigen. The 
first 3 post-incubation time-points with V antigen, the levels of IL-6 were much lower 
than the 4 and 6 hour LPS stimulation, although at the 6 hour post-incubation mark a 
acute increase in IL-6 secretion occurred (Figure 3.16). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.17: Secretion of IL-1β in THP-1 cells in response to LPS, V antigen and pre- or post-
incubation with V antigen. THP-1 cells were stimulated with: 100ng/ml LPS for 1, 2, 4 and 6 
hours; 50µg/ml or 100µg/ml of V antigen for 1 hour; pre-incubated with 50µg/ml V antigen for 1 
hour and stimulated with 100ng/ml of LPS for 1 hour; or stimulated with 100ng/ml LPS for 1 
hour and post-incubated for 1, 2, 4 and 6 hours with 50µg/ml V antigen. The cytokines were 
measured in the cell supernatant using a flow cytometric cytokine bead array system (Becton 
Dickinson). Unstimulated controls were performed. The data is statistically significant (p<0.05). 
The data represents the mean of three independent experiments. 
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antigen on its own stimulated IL-1β secretion. Both pre- and post-incubation with V 
antigen resulted in a general downregulation of the level of IL-1β. It seems that at the 6 
hour post-incubation time-point the level of IL-1β increases slightly compared to the 
previous time-points, although it still is a lower level than when cells are stimulated with 
LPS (Figure 3.17). 
 
 
 
 
 
 
 
 
 
 
Figure 3.18: Secretion of IL-10 in THP-1 cells in response to LPS, V antigen and pre- or post-
incubation with V antigen. THP-1 cells were stimulated with: 100ng/ml LPS for 1, 2, 4 and 6 
hours; 50µg/ml or 100µg/ml of V antigen for 1 hour; pre-incubated with 50µg/ml V antigen for 1 
hour and stimulated with 100ng/ml of LPS for 1 hour; or stimulated with 100ng/ml LPS for 1 
hour and post-incubated for 1, 2, 4 and 6 hours with 50µg/ml V antigen. The cytokines were 
measured in the cell supernatant using a flow cytometric cytokine bead array system (Becton 
Dickinson). Unstimulated controls were performed. The data is statistically significant (p<0.05). 
The data represents the mean of three independent experiments. 
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When THP-1 cells were stimulated with LPS they gradually secreted IL-10 in response 
to LPS, with a maximum at the 4 hour stimulation, followed by a downregulation at the 
6 hour mark. THP-1 cells stimulated with either 50 or 100µg/ml of V antigen by itself 
resulted in a slight IL-10 production. Pre-incubating THP-1 cells with V antigen resulted 
in a production of IL-10. The same cannot be said to THP-1 cells post-incubated with V 
antigen, as the production of IL-10 seemed to increase progressively through the time-
points with V antigen, where the secreted levels reached a maximum at the 6 hour 
post-incubation mark. 
3.2.4. Conclusion 
Yersinia pestis V antigen (LcrV) is a multifunctional protein and has been shown to 
exhibit immunomodulatory features and is essential in translocating other virulence 
factors into eukaryotic cells. One of the aims of this study was to investigate the effects 
of V antigen on innate immune responses. 
Initially, THP-1 cells were stimulated for 1, 2, 4 and 6 hours with 100ng/ml LPS and the 
expression levels of different PRRs were investigated. TLR2, TLR4, TLR6, TLR7, 
TLR9, CD14, NOD1, NOD2, NLRP3 and NLRP12 were all affected by the stimulation 
with LPS, either by direct interaction (CD14, TLR4) or by indirect interaction via the 
secretion of cytokines (all the other PRRs). In order to determine whether V antigen 
could immunomodulate innate immune responses, THP-1 cells were stimulated for 1 
hour with 50µg/ml of recombinant V antigen and the expression levels of the different 
PRRs were again examined. This showed a lesser expression level of TLR2, TLR4, 
TLR6, TLR7, NOD1 and NLRP12, and, on the other hand, the expression levels of 
TLR9, CD14, NOD2, NLRP1 and NLRP3 was greater in response to V antigen, in 
comparison with cells stimulated with LPS. This demonstrated that V antigen can affect 
the expression levels of PRRs. 
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Subsequently, THP-1 cells were stimulated for 1 hour with 100ng/ml of LPS and either 
pre- or post-incubated for 1 hour or 1, 2, 4 and 6 hours, respectively, with 50µg/ml of V 
antigen. Pre-incubating THP-1 cells with V antigen caused up-regulation of TLR2, 
TLR6, TLR7, CD14, NOD1, NOD2, NLRP1, NLRP3 and NLRP12. On the other hand, 
after the pre-incubation with V and stimulation with LPS, TLR1 and TLR4 showed no 
marked change in expression, whereas TLR9 showed a downregulation. Post-
incubating THP-1 cells with V antigen triggered downregulation of TLR2, TLR4, TLR6, 
TLR7. On the contrary, CD14, NOD1, NOD2, NLRP3 and NLRP12 expression levels 
seem to up-regulate. TLR9 showed an initial up-regulation, followed by a considerable 
down-regulation. There was no marked change in expression levels of TLR1 and 
NLRP1.  
Since our results showed that V antigen was able to modulate the expression of 
different PRRs in THP-1 cells, the next step was to test the hypothesis that V antigen is 
able to modulate NF-κB and caspase-1 activation, and as a consequence the release 
of inflammatory cytokines. Initially, we tested whether in out model cell system, the 
THP-1 cells could activate NF-κB and caspase-1, when stimulated with LPS. Our 
results showed that THP-1 cells do activate both NF-κB and caspase-1. Once it was 
established that LPS was able to trigger NF-κB signalling cascade and caspase-1, 
whether V antigen was able to modulate this response was investigated. Our results 
revealed that in THP-1 cells V antigen inhibited NF-κB activation. 
With reference to inflammatory cytokine release, V antigen seemed to inhibit 
completely TNF secretion. Similarly, IL-1β secretion levels seem to be inhibited in 
response to V antigen, although a very slight increase in secretion level was observed 
at the 6 hour post-incubation mark in THP-1 cells. In addition, cells IL-6 secretion 
seems to be inhibited in the first 3 post-incubation time-points and an acute increase 
occurred at the 6 post-incubation hour, whereas IL-10 cytokine production seemed to 
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be up-regulated in response to V antigen. It increased progressively through the time-
points reaching a maximum at the 6 hour post-incubation mark. 
Taken together our data suggests that V antigen is able to modulate not only the 
expression levels of different PRRs, but also inhibit the signalling pathways that lead to 
the secretion of pro-inflammatory cytokines. 
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3.3. Yersinia pestis V antigen induced immunomodulatory effects in RAW 
264.7 cells 
In this study we utilised human THP-1 cells and mouse RAW 264.7 cells before moving 
to our in vivo model. We utilised RAW 264.7 cells to further elucidate whether LcrV 
affects pattern recognition receptors (PRRs) and its capability of initiating an innate 
immune response and as a natural in vitro step before using our sepsis CD1 mouse 
model. 
3.3.1. Effect of LPS on TLR, CD14, NOD and NLRP expression in RAW 
264.7 cells. 
In order to determine which PRRs are involved in the recognition of LPS, RAW 264.7 
cells were stimulated for 1, 2, 4 and 6 hours with 100ng/ml (Section 2.6). All 
stimulations were carried out in 25cm2 flasks. The expression levels of the receptors 
(TLR1, TLR2, TLR4, TLR6, TLR7, TLR9, NOD1, NOD2, NLRP1, NLRP3 and NLRP12) 
were labelled and detected using indirect immunofluorescence (Section 2.7.2) and 
analysed by flow cytometry (Section 2.8). In addition the expression levels of CD14 
were also determined as it is a co-receptor of TLR4. Unstimulated cells were also used 
as a control of RAW 264.7 receptor expression levels prior to stimulation. 
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Figure 3.7: PRR expression levels on RAW 264.7 cells in response to 100ng/ml of LPS. 
Receptor expression levels of TLR1, TLR2, TLR4, TLR6, TLR7, TLR9, CD14, NOD1, NOD2, 
NLRP1, NLRP3 and NLRP12 on RAW 264.7 cells stimulated with 100ng/ml of LPS for 1, 2, 4 
and 6 hours. Unstimulated and isotype (-ve control) controls were performed. Cells were 
stimulated, fixed and labelled with a primary antibody against the receptor of interest, followed 
by an appropriate secondary antibody conjugated to FITC. Fluorescence was measured on a 
FACSCalibur
TM
 (Becton Dickinson), counting 10,000 cells per sample, not gated. The data is 
statistically significant (p<0.05). The data represents the mean of three independent 
experiments. 
 
In the case of TLRs and TLR-associated molecules, LPS caused up-regulation of 
TLR1, TLR2, TLR4, TLR6, TLR7, TLR9, CD14 expressed on RAW 264.7 cells (Figure 
3.3). For all TLRs, LPS stimulation induced up-regulation of the receptors at 1 hour, the 
highest expression, followed by a downregulation at the 2 hour, whereas the PRRs 
recovered by 4 hours. With regards to TLR9 and NOD2 expression, LPS induces up-
regulation at the first 2 hours, the second hour being the highest expression, followed 
by a downregulation at the 4 and 6 hour mark. An up-regulation was observed in the 
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TLR4 co-receptor CD14 and NOD1 in the first hour of stimulation with LPS. This was 
followed by a general decrease of expression for the remaining three time-points. 
In the case of NLRs, NLRP1, NLRP3 and NLRP12 remained virtually unchanged in 
response to LPS, whereas NOD1, NOD2 were found to be up-regulated within 1 hour 
and 2 hours of LPS stimulation, respectively, followed by a downregulation at 2 hours 
and 4 hours, respectively. 
As expected, lipopolysaccharide has a broad effect on the expression levels of RAW 
264.7 cells, up-regulating most pattern recognition receptors. 
3.3.2. Effect of LcrV on TLR, CD14, NOD and NLRP expression in RAW 
264.7 cells. 
In order to test the effect of Yersinia pestis V antigen has on the expression of different 
PRRs, RAW 264.7 cells were stimulated for 1 hour with 100ng/ml of LPS and either 
pre- or post-incubated for 1 hour or 1, 2, 4 and 6 hours, respectively, with 50µg/ml of V 
antigen. All stimulations were carried out in 25cm2 flasks. The expression levels of 
TLR1, TLR2, TLR4, TLR6, TLR7, TLR9, CD14, NOD1, NOD2, NLRP1, NLRP3 and 
NLRP12 were labelled and detected using indirect immunofluorescence (Section 2.7.2) 
and analysed by flow cytometry (Section 2.8). 
Firstly, RAW 264.7 cells were stimulated with 50µg/ml of V antigen (Figure 3.8). V 
antigen caused a general lowering of PRR expression. In response to V antigen TLR1, 
TLR2, TLR4, TLR6, TLR7, TLR9, CD14, NOD1, NOD2, NLRP3 and NLRP12 
expression levels lowered in comparison to RAW 264.7 cells stimulated for 1 hour with 
LPS. NLRP1 shows a slight decrease in its expression. 
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Figure 3.8: PRR expression levels on RAW 264.7 cells stimulated for 1 hour with 50µg/ml of V 
antigen. Receptor expression levels of TLR1, TLR2, TLR4, TLR6, TLR7, TLR9, CD14, NOD1, 
NOD2, NLRP1, NLRP3 and NLRP12 on RAW 264.7 cells stimulated for 1 hour with 50µg/ml of 
V antigen. Unstimulated and isotype (-ve control) controls were performed. Cells were 
stimulated, fixed and labelled with a primary antibody against the receptor of interest, followed 
by an appropriate secondary antibody conjugated to FITC. Fluorescence was measured on a 
FACSCalibur
TM
 (Becton Dickinson), counting 10,000 cells per sample, not gated. The data is 
statistically significant (p<0.05). The data represents the mean of three independent 
experiments. 
 
Subsequently, RAW 264.7 cells were pre-incubated for 1 hour with 50µg/ml of V 
antigen and stimulated for 1 hour with 100ng/ml of LPS (Figure 3.5). This pre-
incubation caused a downregulation of TLR1, TLR2, TLR4, TLR6, TLR7, TLR9, CD14 
and NOD1. TLR1, TLR2, TLR4 and TLR6 expression levels decreased below the 
levels seen in unstimulated cells, i.e. basal expression levels found naturally in RAW 
264.7 cells. In addition, TLR7, CD14 and NOD1 expression levels downregulated 
considerably, decreasing almost to the same expression level as unstimulated cells. 
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In contrast, the expression level of NOD2 seems not to change compared to cells 
stimulated solely with LPS. Furthermore, NLRP1, NLRP3 and NLRP12 showed an 
increase in expression, more prominently observed in NLRP12 expression level.  
 
 
 
 
 
 
 
 
Figure 3.9: PRR expression levels on RAW 264.7 cells pre-incubated for 1 hour with 50µg/ml of 
V antigen and stimulated for 1 hour with 100ng/ml of LPS. Receptor expression levels of TLR1, 
TLR2, TLR4, TLR6, TLR7, TLR9, CD14, NOD1, NOD2, NLRP1, NLRP3 and NLRP12 on RAW 
264.7 cells pre-incubated for 1 hour with 50µg/ml of V antigen and stimulated for 1 hour with 
100ng/ml of LPS. Unstimulated and isotype (-ve control) controls were performed. Cells were 
stimulated, fixed and labelled with a primary antibody against the receptor of interest, followed 
by an appropriate secondary antibody conjugated to FITC. Fluorescence was measured on a 
FACSCalibur
TM
 (Becton Dickinson), counting 10,000 cells per sample, not gated. The data is 
statistically significant (p<0.05). The data represents the mean of three independent 
experiments. 
 
The following step was to examine what effect post-incubating RAW 264.7 cells with V 
antigen, after stimulating them with LPS, has on the expression of the different PRRs 
(Figure 3.10).  
A comparison of TLR, CD14, NOD and NLRP receptor levels in macrofage (RAW 264.7) cells when pre-incubated for 1 hour with 50g/ml
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Figure 3.10: PRR expression levels on RAW 264.7 cells stimulated for 1 hour with 100ng/ml of 
LPS and post-incubated for 1, 2, 4 and 6 hours with 50µg/ml of V antigen. Receptor expression 
levels of TLR1, TLR2, TLR4, TLR6, TLR7, TLR9, CD14, NOD1, NOD2, NLRP1, NLRP3 and 
NLRP12 on RAW 264.7 cells stimulated for 1 hour with 100ng/ml of LPS and post-incubated for 
1, 2, 4 and 6 hours with 50µg/ml of V antigen. Unstimulated and isotype (-ve control) controls 
were performed. Cells were stimulated, fixed and labelled with a primary antibody against the 
receptor of interest, followed by an appropriate secondary antibody conjugated to FITC. 
Fluorescence was measured on a FACSCalibur
TM
 (Becton Dickinson), counting 10,000 cells per 
sample, not gated. The data is statistically significant (p<0.05). The data represents the mean of 
three independent experiments. 
 
When RAW 264.7 cells were stimulated with LPS and post-incubated with V antigen, 
all the PRRs investigated seemed to decrease expression levels, in comparison with 
cells stimulated with only with LPS. The PRRs that stand out the most in this 
downregulation due to post-incubation with V antigen are TLR2, TLR4, TLR6, TLR7, 
TLR9, CD14 and NOD1. The expression levels of these receptors seem to ultimately 
reduce to a lower level compared to unstimulated cells. Although, not as predominantly 
as the previously mentioned PRRs, NOD2, NLRP3 and NLRP3 expression levels also 
A comparison of TLR, CD14, NOD and NLRP receptor levels in macrofage (RAW 264.7) cells when stimulated for 1 hour with 100ng/ml of LPS and
post-incubated with 50g/ml of V antigen
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seem to reduce down to as low or lower than the expression level seen in unstimulated 
cells. In contrast, TLR1 and NLRP1, in particular the later one, V antigen seems not to 
have an effect. 
3.3.3. NF-κB and caspase-1 activation in RAW 264.7 cells in response to V 
antigen 
In this study we also utilised RAW 264.7 cells to further elucidate whether V antigen 
could modulate NF-κB and caspase-1 activation in response to LPS, and consequently 
the secretion of inflammatory cytokines. 
Experiments were performed in RAW 264.7 cells order to test the hypothesis that V 
antigen is able to modulate NF-κB and caspase-1 activation in response to LPS. The 
presence of phospho-IκB in the cell lysate indicates the transcription of pro-
inflammatory cytokines. Similarly, the presence of caspase-1 is an indicative of 
inflammasome activation, which also leads to a secretion in inflammatory cytokines. 
Western blotting was utilised in order to determine the presence of both phospho-IκBα 
and caspase-1 p-10. 
3.3.3.1 Presence of phospho-IκBα and caspase-1 p10 in RAW 264.7 cells 
in response to LPS 
Initially, in order to determine whether LPS can lead to NF-κB and caspase-1 
activation, RAW 264.7 cells were stimulated for 1, 2, 4 and 6 hours with 100ng/ml LPS. 
The supernatant was collected, at the respective time-points, frozen and stored for later 
cytokine assays. The cells were lysed and the samples were separated by size via 
SDS-PAGE (Section 2.9) and transferred onto a membrane (Section 2.10.1), which 
was probed for phospho-IκBα or caspase-1 p-10, with their respective primary 
antibody, followed by the appropriate secondary antibody conjugated to horse-radish 
peroxidase (HRP). Membranes were imaged via enhanced chemiluminescence 
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(Section 2.11). It was shown that LPS could trigger NF-κB (Figure 3.19) and caspase-1 
(Figure 3.20). 
 
 
 
 
 
 
Figure 3.19: Western blot of phospho-IκBα from lysates of unstimulated RAW 264.7 cells and 
those stimulated for 1, 2, 4 and 6 hours with 100ng/ml LPS. Lysates were separated by SDS-
PAGE and transferred onto a nitrocellulose membrane. The membrane was probed with an 
antibody specific for phospho-IκBα followed by the appropriate secondary antibody conjugated 
to HRP. Enhanced chemiluminescence was used for detection. β-actin was used as a loading 
control. 
 
 
 
 
 
 
 
 
Figure 3.20: Western blot of caspase-1 p10 from lysates of unstimulated RAW 264.7 cells and 
those stimulated for 1, 2, 4 and 6 hours with 100ng/ml LPS. Lysates were separated by SDS-
PAGE and transferred onto a nitrocellulose membrane. The membrane was probed with an 
antibody specific for caspase-1 p10 followed by the appropriate secondary antibody conjugated 
to HRP. Enhanced chemiluminescence was used for detection. β-actin was used as a loading 
control. 
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3.3.3.2. Presence of phospho-IκBα and caspase-1 p10 in RAW 264.7 cells 
in response to LPS pre- and post-incubated with V antigen 
Once it was established that LPS is able to trigger NF-κB signalling cascade and 
caspase-1 activation in RAW 264.7 cells, whether V antigen was able to modulate this 
response was investigated. In order to do so, RAW 264.7 cells were stimulated for 1 
hour with 100ng/ml of LPS and either pre- or post-incubated for 1 hour or 1, 2, 4 and 6 
hours, respectively, with 50µg/ml of V antigen. The cells were lysed and the samples 
were separated by size via SDS-PAGE (Section 2.9) and transferred onto a membrane 
(Section 2.10.1), which was probed for phospho-IκBα or caspase p-10, with their 
respective primary antibody, followed by the appropriate secondary antibody 
conjugated to horse-radish peroxidase (HRP). Membranes were imaged via enhanced 
chemiluminescence (Section 2.11). 
The results obtained from pre- and post-incubating with V antigen show that there is a 
still some activation of NF-κB in response to LPS, however it appears to be slightly 
inhibited. Although post-incubating with V antigen initially seems to show some NF-κB 
activation, when it hits the 4 hour and 6 hour post-incubation mark it seems to be 
inhibited (Figure 3.21). 
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Figure 3.21: Western blot of phospho-IκBα from lysates of unstimulated RAW 264.7 cells; 
stimulated for 2 and 4 hours with 100ng/ml LPS; stimulated for 1 hour with 50µg/ml of V antigen; 
pre-incubated for 1 hour with 50µg/ml of V antigen and subsequently stimulated for 1 hour with 
100ng/ml LPS; and stimulated for 1 hour with 100ng/ml LPS and subsequently post-incubated 
for 1, 2, 4 and 6 hours with 50µg/ml of V antigen. Lysates were separated by SDS-PAGE and 
transferred onto a nitrocellulose membrane. The membrane was probed with an antibody 
specific for phospho-IκBα followed by the appropriate secondary antibody conjugated to HRP. 
Enhanced chemiluminescence was used for detection. β-actin was used as a loading control. 
 
Concerning caspase-1 activation, the results show that pre-incubation with V antigen 
seems not to have an effect on caspase-1 activation. On the contrary and post-
incubating with V antigen results on a reduction of caspase-1. This reduction seems to 
gradually occur through the four post-incubation time-points, most prominent at 4 hour 
post-incubation (Figure 3.22). 
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Figure 3.22: Western blot of caspase-1 p10 from lysates of unstimulated RAW 264.7 cells; 
stimulated for 2 and 4 hours with 100ng/ml LPS; stimulated for 1 hour with 50µg/ml of V antigen; 
stimulated for 1 hour with 50µg/ml of V antigen; pre-incubated for 1 hour with 50µg/ml of V 
antigen and subsequently stimulated for 1 hour with 100ng/ml LPS; and stimulated for 1 hour 
with 100ng/ml LPS and subsequently post-incubated for 1, 2, 4 and 6 hours with 50µg/ml of V 
antigen. Lysates were separated by SDS-PAGE and transferred onto a nitrocellulose 
membrane. The membrane was probed with an antibody specific for caspase-1 p10 followed by 
the appropriate secondary antibody conjugated to HRP. Enhanced chemiluminescence was 
used for detection. β-actin was used as a loading control. 
 
3.3.3.3. Cytokine secretion in RAW 264.7 cells in response to V antigen 
Given that V antigen was found to modulate the expression of PRRs and the activation 
of both NF-κB and caspase-1 activation, the next step in this study was to examine the 
release of cytokines, the inflammatory mediators, caused by LPS and whether or not V 
antigen is able to modulate their secretion. Out of the inflammatory cytokines analysed 
(Interlukin-8 (IL-8), Interlukin-1β (IL-1β), Interlukin-6 (IL-6), Interlukin-10 (IL-10), Tumor 
Necrosis Factor (TNF) and Interlukin-12p70 (IL-12p70)), only the release of IL-1β, IL-6, 
IL-10 and TNF were significantly increased. 
RAW 264.7 cells were stimulated for 1, 2, 4 and 6 hours with 100ng/ml of LPS as well 
as with 50µg/ml of V antigen for 1 hour. Additionally, RAW 264.7 cells were stimulated 
for 1 hour with 100ng/ml of LPS and either pre- or post-incubated for 1 hour or 1, 2, 4 
and 6 hours, respectively, with 50µg/ml of V antigen. All stimulations were carried out in 
β-actin 
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25cm2 flasks. The supernatants were collected post stimulations for cytokine analysis 
using the Human Inflammation BDTM Cytometric bead array kit (Section 2.8.2.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.23: Secretion of TNF in RAW 264.7 cells in response to LPS, V antigen and pre- or 
post-incubation with V antigen. RAW 264.7 cells were stimulated with: 100ng/ml LPS for 1, 2, 4 
and 6 hours; 50µg/ml of V antigen for 1 hour; pre-incubated with 50µg/ml V antigen for 1 hour 
and stimulated with 100ng/ml of LPS for 1 hour; or stimulated with 100ng/ml LPS for 1 hour and 
post-incubated for 1, 2, 4 and 6 hours with 50µg/ml V antigen. The cytokines were measured in 
the cell supernatant using a flow cytometric cytokine bead array system (Becton Dickinson). 
Unstimulated controls were performed. The data is statistically significant (p<0.05). The data 
represents the mean of three independent experiments. 
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As expected, it was shown that LPS stimulated the release of TNF. Its release 
increased over the first 4 hours and then decreased at the 6 hour mark. It was shown 
that V antigen on its own did not stimulate TNF secretion. TNF secretion was 
significantly down-regulated in response to pre- and post-incubation with V antigen, 
reaching unstimulated levels (Figure 3.23). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.24: Secretion of IL-6 in RAW 264.7 cells in response to LPS, V antigen and pre- or 
post-incubation with V antigen. RAW 264.7 cells were stimulated with: 100ng/ml LPS for 1, 2, 4 
and 6 hours; 50µg/ml of V antigen for 1 hour; pre-incubated with 50µg/ml V antigen for 1 hour 
and stimulated with 100ng/ml of LPS for 1 hour; or stimulated with 100ng/ml LPS for 1 hour and 
post-incubated for 1, 2, 4 and 6 hours with 50µg/ml V antigen. The cytokines were measured in 
the cell supernatant using a flow cytometric cytokine bead array system (Becton Dickinson). 
Unstimulated controls were performed. The data is statistically significant (p<0.05). The data 
represents the mean of three independent experiments. 
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When RAW 264.7 cells were stimulated with LPS, our results showed an increase in 
levels of IL-6, with a maximum by the 4 hour mark, followed by a decrease in secretion 
at the 6 hour time-point. When cells were stimulated with 50µg/ml of V antigen by itself 
our results showed no change in IL-6 production in comparison with unstimulated cells. 
The same can be said to THP-1 cells pre-incubated with V antigen. The first 2 post-
incubation time-points with V antigen showed that the levels of IL-6 were alike with the 
levels of unstimulated cells. Our results showed a slight increase in IL-10 secretion 
when cells were post-incubated with V antigen for 4 and 6 hours compared to 
unstimulated cells, although much lower levels compared with cells stimulated with 
LPS (Figure 3.24). 
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Figure 3.25: Secretion of IL-1β in RAW 264.7 cells in response to LPS, V antigen and pre- or 
post-incubation with V antigen. RAW 264.7 cells were stimulated with: 100ng/ml LPS for 1, 2, 4 
and 6 hours; 50µg/ml of V antigen for 1 hour; pre-incubated with 50µg/ml V antigen for 1 hour 
and stimulated with 100ng/ml of LPS for 1 hour; or stimulated with 100ng/ml LPS for 1 hour and 
post-incubated for 1, 2, 4 and 6 hours with 50µg/ml V antigen. The cytokines were measured in 
the cell supernatant using a flow cytometric cytokine bead array system (Becton Dickinson). 
Unstimulated controls were performed. The data is statistically significant (p<0.05). The data 
represents the mean of three independent experiments. 
 
Our results show that when RAW 264.7 cells were stimulated with LPS the levels of IL-
1β increased. With regards to cells stimulated solely with V antigen and pre or post-
incubated with V, the levels of IL-1β are lower compared to the levels seen in 
unstimulated cells (Figure 3.25). 
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Figure 3.26: Secretion of IL-10 in RAW 264.7 cells in response to LPS, V antigen and pre- or 
post-incubation with V antigen. RAW 264.7 cells were stimulated with: 100ng/ml LPS for 1, 2, 4 
and 6 hours; 50µg/ml of V antigen for 1 hour; pre-incubated with 50µg/ml V antigen for 1 hour 
and stimulated with 100ng/ml of LPS for 1 hour; or stimulated with 100ng/ml LPS for 1 hour and 
post-incubated for 1, 2, 4 and 6 hours with 50µg/ml V antigen. The cytokines were measured in 
the cell supernatant using a flow cytometric cytokine bead array system (Becton Dickinson). 
Unstimulated controls were performed. The data is statistically significant (p<0.05). The data 
represents the mean of three independent experiments. 
 
When RAW 264.7 cells were stimulated with LPS they gradually secreted IL-10 in 
response to LPS, with a maximum at the 4 hour stimulation, followed by a 
downregulation at the 6 hour mark. RAW 264.7 cells stimulated with V antigen by itself 
did not result in IL-10 production. Similarly, pre-incubating THP-1 cells with V antigen 
did not result in a production of IL-10. The first two post-incubation time-points showed 
no increase in IL-10 production, whereas 4 and 6 hour post-incubation with V antigen 
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showed a slight increase in IL-10 production, although only matching the levels seen in 
cells stimulated with LPS for 1 hour (Figure 3.26). 
3.3.4. Conclusion 
In addition to THP-1 cells, RAW 264.7 cells were also utilised in order to elucidate the 
effects of V antigen on the innate immune responses. Experiments with a similar 
sequential layout to THP-1 were used to investigate the effects of V antigen on RAW 
264.7 cell PRRs. In RAW 264.7 cells, LPS caused up-regulation of TLR1, TLR2, TLR4, 
TLR6, TLR7, TLR9, CD14, NOD1 and NOD2. Moreover, but not as acute, NLRP1, 
NLRP3 and NLRP12 expression levels increased in response to LPS. When RAW 
264.7 cells were stimulated with V antigen TLR1, TLR2, TLR4, TLR6, TLR7, TLR9, 
CD14, NOD1, NOD2, NLRP3 and NLRP12 expression levels were lowered in 
comparison with cells stimulated just with LPS. NLRP1 showed a slight decrease in its 
expression level in response to V antigen. 
When RAW 264.7 were pre-incubated with V antigen, the expression levels of TLR1, 
TLR2, TLR4, TLR6, TLR7, TLR9, CD14 and NOD1 lowered. In contrast, the expression 
level of NOD2 did not seem change and NLRP1, NLRP3 and NLRP12 showed a very 
slight increase in expression, more prominently observed in NLRP12 expression level. 
Post-incubating RAW cells with V antigen caused a downregulation of TLR1, TLR2, 
TLR4, TLR6, TLR7, TLR9, CD14, NOD1, NOD2, NLRP1, NLRP3 and NLRP12 – an 
overall decrease in expression levels, across the four post-incubation time-points, of all 
PRRs investigated in this study. 
Since our results showed that V antigen was able to modulate the expression of 
different PRRs in RAW 264.7 cells the next step was to test the hypothesis that V 
antigen is able to modulate NF-κB and caspase-1 activation, and as a consequence 
the release of inflammatory cytokines. 
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Initially, we tested if both THP-1 and RAW 264.7 cells when stimulated with LPS would 
activate NF-κB and caspase-1. Our results showed that both cell types do activate both 
NF-κB and caspase-1. Once it was established that LPS was able to trigger NF-κB 
signalling cascade and caspase-1, whether V antigen was able to modulate this 
response was investigated. Our results revealed that RAW 264.7 cells V antigen 
slightly inhibited NF-κB activation and gradually decreased caspase-1 activation over 
time. 
With reference to inflammatory cytokine release, V antigen seemed to inhibit 
completely TNF secretion in both cell types. Similarly, IL-1β secretion levels seem to be 
inhibited in RAW 264.7 cells in response to V antigen. IL-6 levels seem to be 
downregulated down to basal levels in RAW 264.7 cells in response to V antigen. In 
the case of IL-10 RAW 264.7 cells showed no increase in IL-10 production in the first 
two post-incubation time-points, whereas 4 and 6 hour post-incubation with V antigen 
showed a slight increase in IL-10 production, although only matching the levels seen in 
cells stimulated with LPS for 1 hour. 
Overall our data suggests that V antigen is able to modulate PRR expression as well 
as inhibit signalling cascades and pro-inflammatory cytokine secretion in RAW 264.7 
cells. When compared to THP-1 cells the results are similar, but rather more 
pronounced inhibition is seen in RAW 264.7 cells. 
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3.4. Functional domain of V antigen 
Previous studies have shown that, not only the entire, but also small regions of Yersinia 
pestis V antigen can provide protection against the plague. It has been suggested that 
Y. pestis V antigen contains a number of protective epitopes that are located in a 
central region between amino acids (a.a.) 135 and 275 (Hill et al., 1997). Vernazza et 
al. (2009) aimed to identify the minimum protective fraction of Y. pestis V antigen that 
could provide protection against plague. In order to do so, they generated small regions 
of the V antigen, residing between the central a.a. 135-275 fragment.  
In order to investigate the functional domain of V antigen that is responsible for the 
immunomodulatory effects we observed, V antigen fractions had to be produced. V 
antigen fractions were cloned in E. coli and kindly supplied to us by Dr. Claire 
Vernazza, Ministry of Defence, Porton Down. In order to purify the V antigen fractions, 
the E. coli strain had to be cultured in Luria broth and the protein isolated using affinity 
chromatography. 
V antigen fragments were selected according to previous studies performed by 
Vernazza et al. (2009) (Table 2.2). In this study the V antigen fragments selected were 
V1, V3, V4 and V5. 
Fragment Deletion type Amino acids 
V1 - 135-275 
V2 N-terminal 168-275 
V3 N-terminal 175-275 
V4 C-terminal 135-268 
V5 C-terminal 135-262 
V6 Internal 135-275 Δ218-234 
 
Table 2.5: V antigen fragments. In this study the V antigen fragments selected were V1, V3, V4 
and V5 (highlighted). Adapted from Vernazza et al. (2009). 
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3.4.1. Purification of V antigen fractions V1, V3, V4 and V5 
In order to produce V antigen fractions (V1, V3, V4 and V5), the recombinant protein 
plasmids (pGEX6P-1) with a glutathione S-transferase (GST) tag was used which was 
kindly provided by Dr. Claire Vernazza (Defence Science and Technology Laboratory, 
Porton Down, Salisbury, UK). The plasmids were transformed into E. coli BL21 cells as 
previously described by Carr et al. (1999). 
The cloning and expression of the genes was done by Claire Vernazza and colleagues 
as described in Vernazza et al. (2009). Briefly, the lcrV fragments gene was amplified 
by PCR from the chromosomal DNA of Y. pestis strain GB. Primers: 135 5’ 
CGGATCCATTTTGAAAGTGATTGTTG 3’, 175 3’ CGGATCCATTAAGCATCTGTCT- 
AGTA 5’, 262 5’ CGTCGACTCAATCTTTATTATAAGAG 3’, 268 5’ CGTCGACTCAG- 
TGAGATAATTCATTA 3’, 275 5’ CGTCGACTCAATCCGAGCAGGTGGTG 3’ were 
cloned into a pGEX6P-1 (GE Healthcare) to make the recombinant plasmids, pGEX6P-
1. 
E. coli BL21 cells containing the recombinant plasmid were cultured in Luria broth 
containing 100mg/ml ampicillin. Cultures were placed in a 37ºC rotary incubator at 
120RPM until an A600 of 0.3 was achieved; cultures were then induced with 1mM 
isopropyl-β-D-thiogalactopyranoside (IPTG). Cultures were incubated for a further 6 
hours and harvested by centrifugation at 7000RPM for 30 minutes (Section 2.5.2). 
Harvested cells were resuspended in PBS and lysed by repeated freeze-thaw cycles. 
Crude cell extract was clarified by centrifugation at 2500RPM for 30 minutes and the 
supernatant added to glutathione Sepharose columns, previously equilibrated with 
PBS. Unbound material was washed off with PBS. Cleavage buffer (10ml) (50mM 
Tris/150mM NaCl/1mM EDTA/1mM DTT/0.01%) with PreScission™ Protease (150µl) 
was added to the column and incubated at room temperature for 3 hours. The column 
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was then washed with more cleavage buffer (20ml) and the elution was collected 
(Section 2.5.5). 
The elution was concentrated and subsequently passed through a Profos EndoTrap® 
blue 10 to ensure there was no LPS in the final solution (Section 2.5.7.1). The HyCult 
LAL Chromogenic Endotoxin Quantitation Kit was used in order to measure the amount 
of endotoxin in the purified protein sample using the Limulus Amebocyte Lysate (LAL) 
assay, which was found to be none (Section 2.5.8). 
3.4.2. Effects of V antigen fractions on innate immune signalling 
As previously mentioned, one of the consequences of activation of TLRs is the 
expression of genes via NF-κB which, normally, is sequestered by unphosphorylated 
IκB. One of the most common signalling pathways from TLR activation leads to the 
phosphorylation of IκB and consequently the release of NF-κB, which in turn lead to the 
production of inflammatory cytokines. Furthermore, also mentioned above, 
inflammasome sensor molecules, such as NODs and NLRPs, can activate caspase-1 
where its main role is to convert pro-IL-1β and pro-IL-18 into their bioactive cytokine IL-
1β and IL-18, respectively.  
The protein complex NF-κB is the transcription factor that is involved in the cellular 
response to stress and, of particular interest to this work, presence of cytokines. The 
presence of phospho-IκB in the cell lysate indicates the transcription of pro-
inflammatory cytokines. Similarly, the presence of caspase-1 p10 is an indicative of 
inflammasome activation, which also leads to a secretion in inflammatory cytokines. 
Western blotting was utilised in order to determine the presence of both phospho-IκBα 
and caspase-1 p-10. 
In order to determine whether V antigen fractions were able to modulate this response 
RAW 264.7 cells were stimulated for 1, 2, 4 and 6 hours with 100ng/ml LPS or 
stimulated for 1 hour with 100ng/ml of LPS and then post-incubated for 1, 2, 4 and 6 
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hours with the different fractions. The supernatant was collected, at the respective 
time-points, frozen and stored for later cytokine assays. The cells were lysed and the 
samples were separated by size via SDS-PAGE (Section 2.9) and transferred onto a 
membrane (Section 2.10.1), which was probed for phospho-IκBα or caspase p-10, with 
their respective primary antibody, followed by the appropriate secondary antibody 
conjugated to horse-radish peroxidase (HRP). Membranes were imaged via enhanced 
chemiluminescence (Section 2.11).  
In this study, out of the six fragments that possibly could confer protection, proposed by 
Vernazza et al. (2009), four were chosen – V1, V3, V4 and V5 (Figure 3.27). V1 was 
selected because it has been previously shown to be protective against plague, V3 due 
to a N-terminal deletion whereas V4 and V5 a C-terminal deletion type. 
 
Figure 3.27: Schematic representation of V antigen and its fragments V1, V2, V3, V4, V5 and 
V6. In this study, the fragments selected were V1 (a.a. 135-275), V3 (a.a. 175-275), V4 (a.a. 
135-268) and V5 (135-262). 
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The results obtained from post-incubating RAW 264.7 cells with V1 fraction show that 
there is a minor activation of NF-κB in response to LPS, however it appears to majorly 
inhibited compared to cells stimulated solely with LPS. At the 6 hour post-incubation 
NF-κB activation seems to increase somewhat (Figure 3.28). Post-incubating RAW 
264.7 cells with V1 fraction show that there is a total inhibition of caspase-1 activation 
(Figure 3.29). 
 
 
 
 
 
 
 
 
Figure 3.28: Western blot of phospho-IκBα from lysates of unstimulated RAW 264.7 cells and 
those stimulated for 1, 2, 4 and 6 hours with 100ng/ml LPS; stimulated with for 1 hour with 
50µg/ml of fragment V1; and stimulated for 1 hour with 100ng/ml LPS and subsequently post-
incubated for 1, 2, 4 and 6 hours with 50µg/ml of fragment V1. Lysates were separated by SDS-
PAGE and transferred onto a nitrocellulose membrane. The membrane was probed with an 
antibody specific for phospho-IκBα followed by the appropriate secondary antibody conjugated 
to HRP. Enhanced chemiluminescence was used for detection. β-actin was used as a loading 
control. 
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Figure 3.29: Western blot of caspase-1 p10 from lysates of unstimulated RAW 264.7 cells and 
those stimulated for 1, 2, 4 and 6 hours with 100ng/ml LPS; stimulated with for 1 hour with 
50µg/ml of fragment V1; and stimulated for 1 hour with 100ng/ml LPS and subsequently post-
incubated for 1, 2, 4 and 6 hours with 50µg/ml of fragment V1. Lysates were separated by SDS-
PAGE and transferred onto a nitrocellulose membrane. The membrane was probed with an 
antibody specific for caspase-1 p10 followed by the appropriate secondary antibody conjugated 
to HRP. Enhanced chemiluminescence was used for detection. β-actin was used as a loading 
control. 
 
Concerning V3 fraction, the results show that post-incubations result on a small 
inhibition of NF-κB compared to RAW 264.7 cells stimulated with just LPS. This 
inhibition seems to gradually occur through the first three post-incubation time-points, 
with a considerable surge in NF-κB at the 6 hour mark (Figure 3.30). With regards to 
caspase-1 activation, V3 seems to downregulate its activation at the first hour of post-
incubation and at the second hour it caspase-1 activation seems to increase. A re-
inhibition seems to occur for the remaining post-incubation time-points (Figure 3.31). 
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Figure 3.30: Western blot of phospho-IκBα from lysates of unstimulated RAW 264.7 cells and 
those stimulated for 1, 2, 4 and 6 hours with 100ng/ml LPS; stimulated with for 1 hour with 
50µg/ml of fragment V3; and stimulated for 1 hour with 100ng/ml LPS and subsequently post-
incubated for 1, 2, 4 and 6 hours with 50µg/ml of fragment V3. Lysates were separated by SDS-
PAGE and transferred onto a nitrocellulose membrane. The membrane was probed with an 
antibody specific for phospho-IκBα followed by the appropriate secondary antibody conjugated 
to HRP. Enhanced chemiluminescence was used for detection. β-actin was used as a loading 
control. 
 
 
 
 
 
 
 
 
Figure 3.31: Western blot of caspase-1 p10 from lysates of unstimulated RAW 264.7 cells and 
those stimulated for 1, 2, 4 and 6 hours with 100ng/ml LPS; stimulated with for 1 hour with 
50µg/ml of fragment V3; and stimulated for 1 hour with 100ng/ml LPS and subsequently post-
incubated for 1, 2, 4 and 6 hours with 50µg/ml of fragment V3. Lysates were separated by SDS-
PAGE and transferred onto a nitrocellulose membrane. The membrane was probed with an 
antibody specific for caspase-1 p10 followed by the appropriate secondary antibody conjugated 
to HRP. Enhanced chemiluminescence was used for detection. β-actin was used as a loading 
control. 
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The results obtained from post-incubating RAW 264.7 cells with V4 fraction show that 
there is a total inhibition of NF-κB activation (Figure 3.32). Likewise, post-incubating 
RAW 264.7 cells with V1 fraction show that there is a complete inhibition of caspase-1 
activation (Figure 3.33). 
 
 
 
 
 
Figure 3.32: Western blot of phospho-IκBα from lysates of unstimulated RAW 264.7 cells and 
those stimulated for 1, 2, 4 and 6 hours with 100ng/ml LPS; stimulated with for 1 hour with 
50µg/ml of fragment V4; and stimulated for 1 hour with 100ng/ml LPS and subsequently post-
incubated for 1, 2, 4 and 6 hours with 50µg/ml of fragment V4. Lysates were separated by SDS-
PAGE and transferred onto a nitrocellulose membrane. The membrane was probed with an 
antibody specific for phospho-IκBα followed by the appropriate secondary antibody conjugated 
to HRP. Enhanced chemiluminescence was used for detection. β-actin was used as a loading 
control. 
 
 
 
 
 
 
 
Figure 3.33: Western blot of caspase-1 p10 from lysates of unstimulated RAW 264.7 cells and 
those stimulated for 1, 2, 4 and 6 hours with 100ng/ml LPS; stimulated with for 1 hour with 
50µg/ml of fragment V4; and stimulated for 1 hour with 100ng/ml LPS and subsequently post-
incubated for 1, 2, 4 and 6 hours with 50µg/ml of fragment V4. Lysates were separated by SDS-
PAGE and transferred onto a nitrocellulose membrane. The membrane was probed with an 
antibody specific for caspase-1 p10 followed by the appropriate secondary antibody conjugated 
to HRP. Enhanced chemiluminescence was used for detection. β-actin was used as a loading 
control. 
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Regarding the V5 fraction, the results show that post-incubation seems to 
predominantly inhibit NF-κB activation (Figure 3.34). In the same way, V5 fraction 
seems to have the same effect on caspase-1 activation, as it seems to entirely 
downregulate it (Figure 3.35). 
 
 
 
 
 
Figure 3.34: Western blot of phospho-IκBα from lysates of unstimulated RAW 264.7 cells and 
those stimulated for 1, 2, 4 and 6 hours with 100ng/ml LPS; stimulated with for 1 hour with 
50µg/ml of fragment V5; and stimulated for 1 hour with 100ng/ml LPS and subsequently post-
incubated for 1, 2, 4 and 6 hours with 50µg/ml of fragment V5. Lysates were separated by SDS-
PAGE and transferred onto a nitrocellulose membrane. The membrane was probed with an 
antibody specific for phospho-IκBα followed by the appropriate secondary antibody conjugated 
to HRP. Enhanced chemiluminescence was used for detection. β-actin was used as a loading 
control. 
 
 
 
 
 
 
 
Figure 3.35: Western blot of caspase-1 p10 from lysates of unstimulated RAW 264.7 cells and 
those stimulated for 1, 2, 4 and 6 hours with 100ng/ml LPS; stimulated with for 1 hour with 
50µg/ml of fragment V5; and stimulated for 1 hour with 100ng/ml LPS and subsequently post-
incubated for 1, 2, 4 and 6 hours with 50µg/ml of fragment V5. Lysates were separated by SDS-
PAGE and transferred onto a nitrocellulose membrane. The membrane was probed with an 
antibody specific for caspase-1 p10 followed by the appropriate secondary antibody conjugated 
to HRP. Enhanced chemiluminescence was used for detection. β-actin was used as a loading 
control. 
β-actin 
β-actin 
174 
 
Unstim 
Pre-incubation 
V1 V3 V4 V5 
LPS 
1h 2h 4h 6h 
In this study we also utilised pre-incubated RAW 264.7 cells with the different V 
fractions to further elucidate the effect they have in NF-κB and caspase-1 activation in 
response to LPS. It seems that pre-incubating RAW264.7 cells with the different V 
fractions has an overall NF-κB inhibitory effect. It is more noticeable in V1 then V4 and 
V5. V3 seems to also have an inhibitory effect on NF-κB activation, although not as V1, 
V4 or V5 (Figure 3.36). With regards to caspase-1 activation, V1 appears to have the 
highest effect in inhibiting it. On the other hand, V3, V4 and V5, appear to slightly inhibit 
caspase-1 activation, but not to the same extent as V1 (Figure 3.37). 
 
 
 
 
 
Figure 3.36: Western blot of phospho-IκBα from lysates of unstimulated RAW 264.7 cells and 
those stimulated for 1, 2, 4 and 6 hours with 100ng/ml LPS; and pre-incubated for 1 hour with 
50µg/ml of fragments V1, V3, V4 or V5 and subsequently stimulated for 1 hour with 100ng/ml of 
LPS. Lysates were separated by SDS-PAGE and transferred onto a nitrocellulose membrane. 
The membrane was probed with an antibody specific for phospho-IκBα followed by the 
appropriate secondary antibody conjugated to HRP. Enhanced chemiluminescence was used 
for detection. β-actin was used as a loading control. 
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Figure 3.37: Western blot of caspase-1 p10 from lysates of unstimulated RAW 264.7 cells and 
those stimulated for 1, 2, 4 and 6 hours with 100ng/ml LPS; and pre-incubated for 1 hour with 
50µg/ml of fragments V1, V3, V4 or V5 and subsequently stimulated for 1 hour with 100ng/ml of 
LPS. Lysates were separated by SDS-PAGE and transferred onto a nitrocellulose membrane. 
The membrane was probed with an antibody specific for caspase-1 p10 followed by the 
appropriate secondary antibody conjugated to HRP. Enhanced chemiluminescence was used 
for detection. β-actin was used as a loading control. 
 
3.4.3. Cytokine secretion in RAW 264.7 cells in response to V antigen 
fractions 
Our results show that V antigen fractions had an effect on the activation of both NF-κB 
and caspase-1 activation. The following step in this study was to examine the release 
of cytokines, the inflammatory mediators, caused by LPS and whether or not the 
different V antigen fractions were able to modulate their secretion. Out of the 
inflammatory cytokines analysed (Interlukin-8 (IL-8), Interlukin-1β (IL-1β), Interlukin-6 
(IL-6), Interlukin-10 (IL-10), Tumor Necrosis Factor (TNF) and Interlukin-12p70 (IL-
12p70)), only the release of IL-1β, IL-6, IL-10 and TNF were significantly increased. 
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3.4.3.1. Cytokine secretion in RAW 264.7 cells in response to V1 
RAW 264.7 cells were stimulated for 1, 2, 4 and 6 hours with 100ng/ml of LPS as well 
as with 50µg/ml of the V1 for 1 hour. Additionally, RAW 264.7 cells were stimulated for 
1 hour with 100ng/ml of LPS and either pre- or post-incubated for 1 hour or 1, 2, 4 and 
6 hours, respectively, with 50µg/ml of the V1. All stimulations were carried out in 25cm2 
flasks. The supernatants were collected post stimulations for cytokine analysis using 
the Human Inflammation BDTM Cytometric bead array kit (Section 2.8.2.2). 
Out of the inflammatory cytokines analysed, only the release of TNF, IL-6, IL-1β and IL-
10 were significantly increased in response to V1. 
As expected, it was shown that LPS stimulated the release of TNF. Its release 
increased over the first 4 hours and then decreased at the 6 hour mark. It was shown 
that V1 on its own did not stimulate TNF secretion. TNF secretion was significantly 
down-regulated in response to pre- and post-incubation with V1 fraction, reaching as 
little as unstimulated levels (Figure 3.38).  
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Figure 3.38: Secretion of TNF in RAW 264.7 cells in response to LPS, V1 and pre- or post-
incubation with V1. RAW 264.7 cells were stimulated with: 100ng/ml LPS for 1, 2, 4 and 6 
hours; 50µg/ml of V1 for 1 hour; pre-incubated with 50µg/ml V1 for 1 hour and stimulated with 
100ng/ml of LPS for 1 hour; or stimulated with 100ng/ml LPS for 1 hour and post-incubated for 
1, 2, 4 and 6 hours with 50µg/ml V1. The cytokines were measured in the cell supernatant using 
a flow cytometric cytokine bead array system (Becton Dickinson). Unstimulated controls were 
performed. The data is statistically significant (p<0.05). The data represents the mean of three 
independent experiments. 
 
Our results showed that LPS stimulated the release of IL-6. Its release increased over 
the first 4 hours and then slightly lowered at the 6 hour mark. It was shown that V1 on 
its own did not stimulate IL-6 secretion. IL-6 secretion was significantly dampened in 
response to pre- and post-incubation with V1 fraction, reaching as little as unstimulated 
levels (Figure 3.39).  
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Figure 3.39: Secretion of IL-6 in RAW 264.7 cells in response to LPS, V1 and pre- or post-
incubation with V1. RAW 264.7 cells were stimulated with: 100ng/ml LPS for 1, 2, 4 and 6 
hours; 50µg/ml of V1 for 1 hour; pre-incubated with 50µg/ml V1 for 1 hour and stimulated with 
100ng/ml of LPS for 1 hour; or stimulated with 100ng/ml LPS for 1 hour and post-incubated for 
1, 2, 4 and 6 hours with 50µg/ml V1. The cytokines were measured in the cell supernatant using 
a flow cytometric cytokine bead array system (Becton Dickinson). Unstimulated controls were 
performed. The data is statistically significant (p<0.05). The data represents the mean of three 
independent experiments. 
 
As anticipated, it was shown that LPS stimulated the release of IL-1β. Its release 
increased over the first 4 hours and then lowered at the 6 hour mark. It was shown that 
V1 by itself did not stimulate IL-1β secretion. IL-1β secretion was reduced in response 
to pre- and post-incubation with V1 fraction, reaching as little as unstimulated levels 
(Figure 3.40). 
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Figure 3.40: Secretion of IL-1β in RAW 264.7 cells in response to LPS, V1 and pre- or post-
incubation with V1. RAW 264.7 cells were stimulated with: 100ng/ml LPS for 1, 2, 4 and 6 
hours; 50µg/ml of V1 for 1 hour; pre-incubated with 50µg/ml V1 for 1 hour and stimulated with 
100ng/ml of LPS for 1 hour; or stimulated with 100ng/ml LPS for 1 hour and post-incubated for 
1, 2, 4 and 6 hours with 50µg/ml V1. The cytokines were measured in the cell supernatant using 
a flow cytometric cytokine bead array system (Becton Dickinson). Unstimulated controls were 
performed. The data is statistically significant (p<0.05). The data represents the mean of three 
independent experiments. 
 
Our results showed that LPS stimulated the release of IL-10. Its release increased over 
the first 4 hours and then lowered at the 6 hour mark. It was shown that V1 by itself did 
not stimulate IL-10 secretion. IL-10 secretion was reduced in response to pre- and the 
first two post-incubation time-points with V1 fraction, reaching as little as unstimulated 
levels. Our results showed a slight increase in IL-10 secretion when cells were post-
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incubated with V1 for 4 and 6 hours compared to unstimulated cells, although much 
lower levels compared with cells stimulated with LPS (Figure 3.41). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.41: Secretion of IL-10 in RAW 264.7 cells in response to LPS, V1 and pre- or post-
incubation with V1. RAW 264.7 cells were stimulated with: 100ng/ml LPS for 1, 2, 4 and 6 
hours; 50µg/ml of V1 for 1 hour; pre-incubated with 50µg/ml V1 for 1 hour and stimulated with 
100ng/ml of LPS for 1 hour; or stimulated with 100ng/ml LPS for 1 hour and post-incubated for 
1, 2, 4 and 6 hours with 50µg/ml V1. The cytokines were measured in the cell supernatant using 
a flow cytometric cytokine bead array system (Becton Dickinson). Unstimulated controls were 
performed. The data is statistically significant (p<0.05). The data represents the mean of three 
independent experiments. 
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3.4.3.2. Cytokine secretion in RAW 264.7 cells in response to V3 
RAW 264.7 cells were stimulated for 1, 2, 4 and 6 hours with 100ng/ml of LPS as well 
as with 50µg/ml of the V1 for 1 hour. Additionally, RAW 264.7 cells were stimulated for 
1 hour with 100ng/ml of LPS and either pre- or post-incubated for 1 hour or 1, 2, 4 and 
6 hours, respectively, with 50µg/ml of the V1. All stimulations were carried out in 25cm2 
flasks. The supernatants were collected post stimulations for cytokine analysis using 
the Human Inflammation BDTM Cytometric bead array kit (Section 2.8.2.2). 
Out of the inflammatory cytokines analysed, only the release of TNF, IL-6, IL-1β and IL-
10 were significantly increased in response to V3. 
As predicted, our results show that LPS stimulated the release of TNF. Its release 
increased over the first 4 hours and then lowered at the 6 hour mark. It was shown that 
V3 by itself did not stimulate TNF secretion. Our results showed a slight increase in 
TNF secretion when cells were pre- or post-incubated with V3 compared to 
unstimulated cells, although with lower levels compared with cells stimulated with LPS 
(Figure 3.42). 
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Figure 3.42: Secretion of TNF in RAW 264.7 cells in response to LPS, V3 and pre- or post-
incubation with V3. RAW 264.7 cells were stimulated with: 100ng/ml LPS for 1, 2, 4 and 6 
hours; 50µg/ml of V3 for 1 hour; pre-incubated with 50µg/ml V3 for 1 hour and stimulated with 
100ng/ml of LPS for 1 hour; or stimulated with 100ng/ml LPS for 1 hour and post-incubated for 
1, 2, 4 and 6 hours with 50µg/ml V3. The cytokines were measured in the cell supernatant using 
a flow cytometric cytokine bead array system (Becton Dickinson). Unstimulated controls were 
performed. The data is statistically significant (p<0.05). The data represents the mean of three 
independent experiments. 
 
Our results demonstrated that LPS stimulated the release of IL-6. Its release increased 
over the first 4 hours and then lowered at the 6 hour mark. It was shown that V3 by 
itself did not stimulate TNF secretion. Our results showed a slight increase in TNF 
secretion when cells were pre- or post-incubated with V3 compared to unstimulated 
cells, although with lower levels compared with cells stimulated with LPS (Figure 3.43). 
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Figure 3.43: Secretion of IL-6 in RAW 264.7 cells in response to LPS, V3 and pre- or post-
incubation with V3. RAW 264.7 cells were stimulated with: 100ng/ml LPS for 1, 2, 4 and 6 
hours; 50µg/ml of V3 for 1 hour; pre-incubated with 50µg/ml V3 for 1 hour and stimulated with 
100ng/ml of LPS for 1 hour; or stimulated with 100ng/ml LPS for 1 hour and post-incubated for 
1, 2, 4 and 6 hours with 50µg/ml V3. The cytokines were measured in the cell supernatant using 
a flow cytometric cytokine bead array system (Becton Dickinson). Unstimulated controls were 
performed. The data is statistically significant (p<0.05). The data represents the mean of three 
independent experiments. 
 
As predicted, LPS stimulated the release of IL-1β in RAW 264.7 cells. Its release 
increased over the first 4 hours and then lowered at the 6 hour mark. It was shown that 
V3 by itself did not stimulate IL-1β secretion. Our results showed a slight increase in 
TNF secretion when cells were pre- or post-incubated with V3 compared to 
unstimulated cells, although with lower levels compared with cells stimulated with LPS 
(Figure 3.44). 
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Figure 3.44: Secretion of IL-1β in RAW 264.7 cells in response to LPS, V3 and pre- or post-
incubation with V3. RAW 264.7 cells were stimulated with: 100ng/ml LPS for 1, 2, 4 and 6 
hours; 50µg/ml of V3 for 1 hour; pre-incubated with 50µg/ml V3 for 1 hour and stimulated with 
100ng/ml of LPS for 1 hour; or stimulated with 100ng/ml LPS for 1 hour and post-incubated for 
1, 2, 4 and 6 hours with 50µg/ml V3. The cytokines were measured in the cell supernatant using 
a flow cytometric cytokine bead array system (Becton Dickinson). Unstimulated controls were 
performed. The data is statistically significant (p<0.05). The data represents the mean of three 
independent experiments. 
 
Our results showed that LPS stimulated the release of IL-10. Its release increased over 
the first 4 hours and then lowered at the 6 hour mark. It was shown that V3 by itself did 
not stimulate IL-10 secretion. Our results showed an increase in IL-10 secretion when 
cells were pre- or post-incubated for 1, 2 and 4 hours with V3 compared to 
unstimulated cells, although with lower levels compared with cells stimulated with LPS. 
When RAW 264.7 cells were post-incubated for 6 hours with V3 the levels of IL-10 
U
ns
tim
ul
at
ed 1
h 2h 4h 6h
g/
m
l

V
3 
S
ol
o 
50
1h
 V
3 
+ 
1h
 L
P
S
1h
 L
P
S
 +
 1
h 
V
3
1h
 L
P
S
 +
 2
h 
V
3
1h
 L
P
S
 +
 4
h 
V
3
1h
 L
P
S
 +
 6
h 
V
3
0
500
1000
1500
2000 LPS
Post-incubation
Pre-incV antigen
Levels of IL-1  in RAW 264.7 cells
Le
ve
l o
f 
cy
to
ki
n
e
 s
e
cr
e
ti
o
n
 (
p
g/
m
l)
185 
 
increased to higher levels compared to cells stimulated with LPS with 1 hour (Figure 
3.45). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.45: Secretion of IL-10 in RAW 264.7 cells in response to LPS, V3 and pre- or post-
incubation with V3. RAW 264.7 cells were stimulated with: 100ng/ml LPS for 1, 2, 4 and 6 
hours; 50µg/ml of V3 for 1 hour; pre-incubated with 50µg/ml V3 for 1 hour and stimulated with 
100ng/ml of LPS for 1 hour; or stimulated with 100ng/ml LPS for 1 hour and post-incubated for 
1, 2, 4 and 6 hours with 50µg/ml V3. The cytokines were measured in the cell supernatant using 
a flow cytometric cytokine bead array system (Becton Dickinson). Unstimulated controls were 
performed. The data is statistically significant (p<0.05). The data represents the mean of three 
independent experiments. 
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3.4.3.3. Cytokine secretion in RAW 264.7 cells in response to V4 
RAW 264.7 cells were stimulated for 1, 2, 4 and 6 hours with 100ng/ml of LPS as well 
as with 50µg/ml of the V1 for 1 hour. Additionally, RAW 264.7 cells were stimulated for 
1 hour with 100ng/ml of LPS and either pre- or post-incubated for 1 hour or 1, 2, 4 and 
6 hours, respectively, with 50µg/ml of the V1. All stimulations were carried out in 25cm2 
flasks. The supernatants were collected post stimulations for cytokine analysis using 
the Human Inflammation BDTM Cytometric bead array kit (Section 2.8.2.2). 
Out of the inflammatory cytokines analysed, only the release of TNF, IL-6, IL-1β and IL-
10 were significantly increased in response to V4. 
As foreseen, our results show that LPS stimulated the release of TNF. Its release 
increased over the first 4 hours and then lowered at the 6 hour mark. It was shown that 
V4 by itself did not stimulate TNF secretion. TNF secretion was significantly down-
regulated in response to pre- and 1 hour post-incubation with V4 fraction, reaching as 
little as unstimulated levels. Our results showed a slight increase in TNF secretion 
when cells were post-incubated for 2, 4 and 6 hours with V4 compared to unstimulated 
cells, although with lower levels compared with cells stimulated with LPS (Figure 3.46). 
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Figure 3.46: Secretion of TNF in RAW 264.7 cells in response to LPS, V4 and pre- or post-
incubation with V4. RAW 264.7 cells were stimulated with: 100ng/ml LPS for 1, 2, 4 and 6 
hours; 50µg/ml of V4 for 1 hour; pre-incubated with 50µg/ml V4 for 1 hour and stimulated with 
100ng/ml of LPS for 1 hour; or stimulated with 100ng/ml LPS for 1 hour and post-incubated for 
1, 2, 4 and 6 hours with 50µg/ml V4. The cytokines were measured in the cell supernatant using 
a flow cytometric cytokine bead array system (Becton Dickinson). Unstimulated controls were 
performed. The data is statistically significant (p<0.05). The data represents the mean of three 
independent experiments. 
 
Our results show that LPS stimulated the release of IL-6 inflammatory cytokine. Its 
release increased over the first 4 hours and then lowered at the 6 hour mark. It was 
shown that V4 by itself did not stimulate IL-6 secretion. IL-6 secretion was significantly 
down-regulated in response to pre- and 1 hour post-incubation with V4 fraction, 
reaching as little as unstimulated levels. Our results showed a slight increase in IL-6 
secretion when cells were post-incubated for 2, 4 and 6 hours with V4 compared to 
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unstimulated cells, although with lower levels compared with cells stimulated with LPS 
(Figure 3.47). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.47: Secretion of IL-6 in RAW 264.7 cells in response to LPS, V4 and pre- or post-
incubation with V4. RAW 264.7 cells were stimulated with: 100ng/ml LPS for 1, 2, 4 and 6 
hours; 50µg/ml of V4 for 1 hour; pre-incubated with 50µg/ml V4 for 1 hour and stimulated with 
100ng/ml of LPS for 1 hour; or stimulated with 100ng/ml LPS for 1 hour and post-incubated for 
1, 2, 4 and 6 hours with 50µg/ml V4. The cytokines were measured in the cell supernatant using 
a flow cytometric cytokine bead array system (Becton Dickinson). Unstimulated controls were 
performed. The data is statistically significant (p<0.05). The data represents the mean of three 
independent experiments. 
 
As anticipated, LPS resulted in the release of IL-1β inflammatory cytokine. Its release 
increased over the first 4 hours and then lowered at the 6 hour mark. It was shown that 
V4 by itself did not stimulate IL-1β secretion. IL-1β secretion was significantly down-
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regulated in response to pre- and 1 hour post-incubation with V4 fraction, reaching as 
little as unstimulated levels. Our results showed a slight increase in IL-1β secretion 
when cells were post-incubated for 2, 4 and 6 hours with V4 compared to unstimulated 
cells, although with lower levels compared with cells stimulated with LPS (Figure 3.48). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.48: Secretion of IL-1β in RAW 264.7 cells in response to LPS, V4 and pre- or post-
incubation with V4. RAW 264.7 cells were stimulated with: 100ng/ml LPS for 1, 2, 4 and 6 
hours; 50µg/ml of V4 for 1 hour; pre-incubated with 50µg/ml V4 for 1 hour and stimulated with 
100ng/ml of LPS for 1 hour; or stimulated with 100ng/ml LPS for 1 hour and post-incubated for 
1, 2, 4 and 6 hours with 50µg/ml V4. The cytokines were measured in the cell supernatant using 
a flow cytometric cytokine bead array system (Becton Dickinson). Unstimulated controls were 
performed. The data is statistically significant (p<0.05). The data represents the mean of three 
independent experiments. 
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Our results show that LPS stimulated the release of IL-10 inflammatory cytokine. Its 
release increased over the first 4 hours and then lowered at the 6 hour mark. It was 
shown that V4 by itself did not stimulate IL-10 secretion. IL-10 secretion was 
significantly down-regulated in response to pre-, 1 and 2 hours post-incubation with V4 
fraction, reaching as little as unstimulated levels. Our results showed a slight increase 
in IL-10 secretion when cells were post-incubated for 4 and 6 hours with V4 compared 
to unstimulated cells, although with lower levels compared with cells stimulated with 
LPS (Figure 3.49). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.49: Secretion of IL-10 in RAW 264.7 cells in response to LPS, V4 and pre- or post-
incubation with V4. RAW 264.7 cells were stimulated with: 100ng/ml LPS for 1, 2, 4 and 6 
hours; 50µg/ml of V4 for 1 hour; pre-incubated with 50µg/ml V4 for 1 hour and stimulated with 
100ng/ml of LPS for 1 hour; or stimulated with 100ng/ml LPS for 1 hour and post-incubated for 
1, 2, 4 and 6 hours with 50µg/ml V4. The cytokines were measured in the cell supernatant using 
a flow cytometric cytokine bead array system (Becton Dickinson). Unstimulated controls were 
performed. The data is statistically significant (p<0.05). The data represents the mean of three 
independent experiments. 
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3.4.3.4. Cytokine secretion in RAW 264.7 cells in response to V5 
RAW 264.7 cells were stimulated for 1, 2, 4 and 6 hours with 100ng/ml of LPS as well 
as with 50µg/ml of the V1 for 1 hour. Additionally, RAW 264.7 cells were stimulated for 
1 hour with 100ng/ml of LPS and either pre- or post-incubated for 1 hour or 1, 2, 4 and 
6 hours, respectively, with 50µg/ml of the V1. All stimulations were carried out in 25cm2 
flasks. The supernatants were collected post stimulations for cytokine analysis using 
the Human Inflammation BDTM Cytometric bead array kit (Section 2.8.2.2). 
Out of the inflammatory cytokines analysed, only the release of TNF, IL-6, IL-1β and IL-
10 were significantly increased in response to V5. 
As expected, our results show that LPS stimulated the release of TNF. Its release 
increased over the first 4 hours and then lowered at the 6 hour mark. It was shown that 
V5 by itself did not stimulate TNF secretion. Our results showed a slight increase in 
TNF secretion when cells were pre- or post-incubated with V5 compared to 
unstimulated cells, although with lower levels compared with cells stimulated with LPS 
(Figure 3.50). 
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Figure 3.50: Secretion of TNF in RAW 264.7 cells in response to LPS, V5 and pre- or post-
incubation with V5. RAW 264.7 cells were stimulated with: 100ng/ml LPS for 1, 2, 4 and 6 
hours; 50µg/ml of V5 for 1 hour; pre-incubated with 50µg/ml V5 for 1 hour and stimulated with 
100ng/ml of LPS for 1 hour; or stimulated with 100ng/ml LPS for 1 hour and post-incubated for 
1, 2, 4 and 6 hours with 50µg/ml V5. The cytokines were measured in the cell supernatant using 
a flow cytometric cytokine bead array system (Becton Dickinson). Unstimulated controls were 
performed. The data is statistically significant (p<0.05). The data represents the mean of three 
independent experiments. 
 
Our results show that LPS stimulated the release of Il-6. Its release increased over the 
first 4 hours and then lowered at the 6 hour mark. It was shown that V5 by itself did not 
stimulate IL-6 secretion. Our results showed a slight increase in IL-6 secretion when 
cells were pre- or post-incubated with V5 compared to unstimulated cells, although with 
lower levels compared with cells stimulated with LPS (Figure 3.51). 
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Figure 3.51: Secretion of IL-6 in RAW 264.7 cells in response to LPS, V5 and pre- or post-
incubation with V5. RAW 264.7 cells were stimulated with: 100ng/ml LPS for 1, 2, 4 and 6 
hours; 50µg/ml of V5 for 1 hour; pre-incubated with 50µg/ml V5 for 1 hour and stimulated with 
100ng/ml of LPS for 1 hour; or stimulated with 100ng/ml LPS for 1 hour and post-incubated for 
1, 2, 4 and 6 hours with 50µg/ml V5. The cytokines were measured in the cell supernatant using 
a flow cytometric cytokine bead array system (Becton Dickinson). Unstimulated controls were 
performed. The data is statistically significant (p<0.05). The data represents the mean of three 
independent experiments. 
 
As foreseen, LPS stimulated the release of IL-6 in RAW 264.7. Its release increased 
over the first 4 hours and then lowered at the 6 hour mark. It was shown that V5 by 
itself did not stimulate IL-1β secretion. Our results showed a slight increase in IL-1β 
secretion when cells were pre- or post-incubated with V5 compared to unstimulated 
cells, although with lower levels compared with cells stimulated with LPS (Figure 3.52). 
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Figure 3.52: Secretion of IL-1β in RAW 264.7 cells in response to LPS, V5 and pre- or post-
incubation with V5. RAW 264.7 cells were stimulated with: 100ng/ml LPS for 1, 2, 4 and 6 
hours; 50µg/ml of V5 for 1 hour; pre-incubated with 50µg/ml V5 for 1 hour and stimulated with 
100ng/ml of LPS for 1 hour; or stimulated with 100ng/ml LPS for 1 hour and post-incubated for 
1, 2, 4 and 6 hours with 50µg/ml V5. The cytokines were measured in the cell supernatant using 
a flow cytometric cytokine bead array system (Becton Dickinson). Unstimulated controls were 
performed. The data is statistically significant (p<0.05). The data represents the mean of three 
independent experiments. 
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IL-1β secretion compared to unstimulated cells, although with lower levels compared 
with cells stimulated with LPS (Figure 3.53). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.52: Secretion of IL-10 in RAW 264.7 cells in response to LPS, V5 and pre- or post-
incubation with V5. RAW 264.7 cells were stimulated with: 100ng/ml LPS for 1, 2, 4 and 6 
hours; 50µg/ml of V5 for 1 hour; pre-incubated with 50µg/ml V5 for 1 hour and stimulated with 
100ng/ml of LPS for 1 hour; or stimulated with 100ng/ml LPS for 1 hour and post-incubated for 
1, 2, 4 and 6 hours with 50µg/ml V5. The cytokines were measured in the cell supernatant using 
a flow cytometric cytokine bead array system (Becton Dickinson). Unstimulated controls were 
performed. The data is statistically significant (p<0.05). The data represents the mean of three 
independent experiments. 
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3.4.4. Conclusion 
Previous studies have shown that, not only the entire, but also small regions of Yersinia 
pestis V antigen can provide protection against the plague. It has been suggested that 
Y. pestis V antigen contains a number of protective fragments that are located in a 
central region between amino acids (a.a.) 135 and 275 (Hill et al., 1997). Vernazza et 
al. (2009) aimed to identify the minimum protective fraction of Y. pestis V antigen that 
could provide protection against plague. In order to do so, they generated small regions 
of the V antigen, residing between the central a.a. 135-275 fragment.  
In order to investigate the functional domain of V antigen that was responsible for the 
immunomodulatory effects that we observed, V antigen fractions had to be produced. V 
antigen fractions were cloned in E. coli, cultured in Luria broth and the protein isolated 
using affinity chromatography. In this study, out of the six fragments that possibly could 
confer protection, proposed by Vernazza et al. (2009), four were chosen – V1, V3, V4 
and V5. V1 was selected because it has been previously shown to be protective 
against plague, V3 due to a N-terminal deletion whereas V4 and V5 a C-terminal 
deletion type. 
Initially, we tested if RAW 264.7 cells when stimulated with LPS would activate NF-κB 
and caspase-1. Our results showed that both cell types do activate both NF-κB and 
caspase-1. 
Once it was established that LPS was able to trigger NF-κB signalling cascade and 
caspase-1 p-10, whether the different V antigen fractions were able to modulate this 
response was investigated. Our results revealed in RAW 264.7 cells V1, V4 and V5 
inhibited NF-κB and caspase-1 activation over time. V3 fraction was able to decrease 
NF-κB and caspase-1 activation, but not to the same extent as the other fractions. 
The next step was to evaluate the inflammatory cytokine release and if the different 
fractions had an effect in the levels secreted by RAW 264.7 cells. Out of the 
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inflammatory cytokines analysed (IL-8, IL-1β,IL-6, IL-10, TNF and IL-12p70), only the 
release of IL-1β, IL-6, IL-10 and TNF were significantly increased in response to LPS. 
Our results show V1, V3, V4 and V5 can inhibit the production of TNF, IL-6, IL-1β and 
IL-10 inflammatory cytokines. The highest reduction of cytokine release was seen on 
V1 followed by V4, V5 and last V3, therefore the functional domain of V antigen 
responsible for the effects that we have observed lies within the amino acids 135-275. 
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3.5. Intracellular trafficking and targeting of exogenous V antigen 
The innate immune system has an essential role in recognising a range of invading 
pathogens and is responsible to mount an inflammatory response in order to remove 
them in a fast and efficient manner. It employs germ-lined encoded receptors, termed 
pattern recognition receptors (PRRs), which are able to recognise molecular 
“signatures” that exist on pathogens. These PRRs are expressed on immune cells and 
are able to distinguish a great variety of microbial ligands, including ones from Gram-
negative and positive bacteria. A tight regulation of the innate immune system is key to 
keep the body alive. The loss of regulation or overstimulation of innate immunity can 
lead to detrimental and often-fatal symptoms. Septic shock is a prime example of a 
condition that reflects this overreaction of the hosts innate immune system, where 
bacterial components cause the over secretion of cytokines, which trigger a chain of 
damaging events that cause this condition. This study concerned with the effects of V 
antigen has in the innate immune system. It is becoming apparent that the presence of 
V antigen may have the effect of altering cellular response to LPS. 
Our data has shown that V antigen interferes with PRRs, ultimately leading to a 
modified cellular response. The next step in this study was to use confocal microscopy 
to check whether V antigen from Y. pestis associates with PRRs, signalling molecules 
and cellular organelles. 
3.5.1. Intracellular effect of V antigen on TLR4 and MyD88 
To investigate the effect of V antigen on TLR4 and MyD88, RAW 264.7 cells were 
grown on 8 well glass slides (Section 2.12.2) and indirect immunofluorescence (Section 
2.7.2) was used to label RAW 264.7 cells. Slides were viewed using a Zeiss LSM 510 
META confocal microscope under a 63x / 1.4 Oil DIC objective, utilising the three 
fluorescent wavelengths of 488 (Argon – green), 543 (red) and 633 (blue) (Section 
2.12.3.1). RAW cells were stimulated in eight time-points: unstimulated (0 hour); 1 hour 
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LPS, 1 hour V antigen; and 1 hour LPS followed by either 1, 2, 4 or 6 hour(s) of V 
antigen. The cells were subsequently fixed and labelled for TO-PRO (blue (nuclear 
stain)), TLR4 (green (FITC)) and MyD88 (red (Cy3)) (Figure 3.53). 
In unstimulated RAW 264.7 cells, TLR4 and MyD88 did not to co-localise. On the other 
hand, upon LPS stimulation, TLR4 did co-localise with MyD88. Similarly to 
unstimulated, when RAW 264.7 cells were incubated for 1 hour with V antigen TLR4 
and MyD88 did not co-localise.  
When RAW 264.7 cells were post-incubated with V antigen, TLR4 and MyD88 did co-
localise in the first two post-incubation time-points. In contrast, when RAW 264.7 cells 
were post-incubated for 4 and 6 hours, TLR4 and MyD88 did not associate. An 
interesting result occurred at the 2 hour post-incubation mark, where MyD88 seems to 
cluster. 
 
 
 
 
 
 
 
 
 
 
200 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Unstimulated 
LPS 1h 
V antigen 1h 
LPS 1h + V 1h 
1h 1h 
LPS 1h + V 2h 
1h 
LPS 1h + V 4h 
1h 
LPS 1h + V 6h 
1h 
TLR4 MyD88 Topro Merged 
LPS 7h 
201 
 
Figure 3.53: Intracellular effect of V antigen on TLR4 (green (FITC)) and MyD88 (red (Cy3)) in 
RAW 264.7 cells. TO-PRO (blue) was used to stain the nucleus. RAW 264.7 were either 
unstimulated or stimulated for 1 and 7 hour with 100ng/ml of LPS; incubated for 1 hour with 
50µg/ml of V antigen; or stimulated for 1 hour with 100ng/ml of LPS followed by a post-
incubation with 50µg/ml of V antigen for 1, 2, 4 or 6 hour(s). The cells were subsequently fixed 
and labelled via indirect immunofluorescence. The images are representative from a number of 
independent experiments. The cells were imaged using a Carl Zeiss LSM 510 META confocal 
microscope, used in conjunction with Zeiss LSM software. Scale bar, 10µm. 
 
3.5.2. V antigen co-localisation with TLR4 and MyD88 over time 
In order to determine if V antigen associates with TLR4 or MyD88, RAW 264.7 cells 
were grown on 8 well glass slides (Section 2.12.2) and indirect immunofluorescence 
(Section 2.7.2) was used to label RAW 264.7 cells. Cells were incubated with V antigen 
conjugated to Oregon Green (V-OG) for 10 minutes, 30 minutes, 1 hour and 2 hours 
(Section 2.12.1). Following stimulation with V-OG the cells were fixed and labelled for 
TLR4 and MyD88 with a specific antibody and the appropriate secondary antibody 
conjugated with Cy5 (blue) and Cy3 (red), respectively (Figure 3.54). Slides were 
viewed using a Zeiss LSM 510 META confocal microscope under a 63x / 1.4 Oil DIC 
objective, utilising the three fluorescent wavelengths of 488 (Argon – green), 543 (red) 
and 633 (blue) (Section 2.12.3.1). 
The first thing that can be said about the results obtained is that V antigen is 
internalised within 10 minutes. Also at this time point it seems that V antigen is co-
localising with MyD88. It also seems to associate with TLR4 but not as much as it does 
with MyD88. Similarly, V antigen seems to co-localise with MyD88 and, to a lesser 
extent with TLR4 throughout the remaining incubation time-points. 
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Figure 3.54: V antigen co-localisation with TLR4 and MyD88. RAW 264.7 were incubated with 
V antigen conjugated with Oregon green (V-OG) for 10 minutes, 30 minutes, 1 hour and 2 
hours. The cells were subsequently fixed and labelled via indirect immunofluorescence for TLR4 
(blue (Cy5)) and MyD88 (red (Cy3)). The cells were imaged using a Carl Zeiss LSM 510 META 
confocal microscope, used in conjunction with Zeiss LSM software. The images are 
representative from a number of independent experiments. Scale bar, 10µm. 
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3.5.3. V antigen co-localisation with caspase-1 and NLRP12 over time 
In order to determine if V antigen associates with caspase-1 or NLRP12, RAW 264.7 
cells were grown on 8 well glass slides (Section 2.12.2) and indirect 
immunofluorescence (Section 2.7.2) was used to label RAW 264.7 cells. Cells were 
incubated with V antigen conjugated to Oregon Green (V-OG) for 10 minutes, 30 
minutes, 1 hour and 2 hours (Section 2.12.1). Following stimulation with V-OG the cells 
were fixed and labelled for caspase-1 p20 and NLRP12 with a specific antibody and 
the appropriate secondary antibody conjugated with and Cy5 (blue) and Cy3 (red), 
respectively (Figure 3.55). Slides were viewed using a Zeiss LSM 510 META confocal 
microscope under a 63x / 1.4 Oil DIC objective, utilising the three fluorescent 
wavelengths of 488 (Argon – green), 543 (red) and 633 (blue) (Section 2.12.3.1). 
Confocal microscopy revealed that that V antigen is internalised within 10 minutes. At 
this time point it seems that V antigen does not associate with either NLRP12 or 
caspase-1. V antigen only seems to start co-localising with NLRP12 after 30 minutes of 
incubation. The subsequent incubation time-points show that V antigen is strongly co-
localising with NLRP12. On the contrary, V antigen does not seem to associate with 
caspase-1 through the incubation time-points. 
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Figure 3.55: V antigen co-localisation with caspase-1 and NLRP12. RAW 264.7 were incubated 
with V antigen conjugated with Oregon green (V-OG) for 10 minutes, 30 minutes, 1 hour and 2 
hours. The cells were subsequently fixed and labelled via indirect immunofluorescence for 
caspase-1 p20 (blue (Cy5)) and NLRP12 (red (Cy3)). The cells were imaged using a Carl Zeiss 
LSM 510 META confocal microscope, used in conjunction with Zeiss LSM software. The images 
are representative from a number of independent experiments. Scale bar, 10µm. 
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3.5.4. Intracellular co-localisation of V antigen with IRF-7 and IRF3 
In this study we also utilised RAW 264.7 cells to see whether V antigen would 
associate IFN regulatory factor 7 (IRF7) and IRF3. Both these regulatory factors are 
part of the MyD88-independent pathway, which translocate to the nucleous and initiate 
transcription of IFN and IFN-inducible genes in order to induce type-I IFN expression. 
In order to determine if V antigen associates with IRF7 and IRF3, RAW 264.7 cells 
were grown on 8 well glass slides (Section 2.12.2) and indirect immunofluorescence 
(Section 2.7.2) was used to label RAW 264.7 cells. Cells were incubated with V antigen 
conjugated to FITC for 10 minutes (Section 2.12.1). Following stimulation with V-FITC 
the cells were fixed and labelled for IRF7 and IRF3 with a specific antibody and the 
appropriate secondary antibody conjugated with and Cy5 (blue) and Alexa fluor 633 
(red), respectively (Figure 3.56). Slides were viewed using a Zeiss LSM 510 META 
confocal microscope under a 63x / 1.4 Oil DIC objective, utilising the three fluorescent 
wavelengths of 488 (Argon – green), 543 (red) and 633 (blue) (Section 2.12.3.1). 
Confocal microscopy revealed that that V antigen strongly associates with both IRF7 
and IRF3. This shows that V antigen might not only be modulating the MyD88-
dependent but also the MyD88-independent pathway. 
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Figure 3.56: V antigen co-localisation with IRF-7 and IRF-3. RAW 264.7 were incubated with V 
antigen conjugated FITC (V-FITC) for 10 minutes. The cells were subsequently fixed and 
labelled via indirect immunofluorescence for IRF-7 (blue (Cy5)) and IRF-3 (red (Alexa 633)). 
The cells were imaged using a Carl Zeiss LSM 510 META confocal microscope, used in 
conjunction with Zeiss LSM software. The images are representative from a number of 
independent experiments. Scale bar, 10µm. 
 
3.5.5. Intracellular co-localisation of V antigen with EEA1 and NLRP3 
In order to determine whether V antigen was internalised and where it was being 
targeted to within the cell, confocal microscopy was utilised. 
RAW 264.7 were incubated with V antigen conjugated to FITC (V-FITC) for 10 minutes, 
30 minutes, 1 hour and 2 hours. Following stimulation with V-FITC the cells were fixed 
and the endosomes were labelled with an antibody against EEA1, a protein within the 
early endosomes, and the appropriate secondary antibody conjugated with Cy5 (blue) 
(Figure 3.57). In addition, NLRP3 was labelled with a specific antibody and the 
appropriate secondary antibody conjugated to Cy3 (red). Slides were viewed using a 
Zeiss LSM 510 META confocal microscope under a 63x / 1.4 Oil DIC objective, utilising 
the three fluorescent wavelengths of 488 (Argon – green), 543 (red) and 633 (blue) 
(Section 2.12.3.1). 
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It was shown that when RAW 264.7 cells were incubated with V antigen, within 
minutes, it associated with EEA1, showing that V antigen might be concentrated in 
endosomes. Similarly, V antigen was shown that it does co-localise with NLRP3. The 
remaining incubation time-points show that V antigen co-localises with both EEA1 and 
NLRP3. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.57: V antigen co-localisation with EEA1 and NLRP3. RAW 264.7 were incubated with 
V antigen conjugated FITC (V-FITC) for 10 minutes, 30 minutes, 1 hour and 2 hours. The cells 
were subsequently fixed and labelled via indirect immunofluorescence for EEA1 (blue (Cy5)) 
and NLRP3 (red (Cy3)). The cells were imaged using a Carl Zeiss LSM 510 META confocal 
microscope, used in conjunction with Zeiss LSM software. The images are representative from 
a number of independent experiments. Scale bar, 10µm. 
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3.5.6. Conclusion 
V antigen has been shown to associate with TLRs and to modulate their signalling, 
ultimately altering the cytokine secretion. Confocal microscopy was used in order to 
test the effect of V antigen on TLR4 and MyD88 in response to LPS. It was shown that 
unstimulated cells and cells incubated for 1 hour with V antigen did not activate TLR4 
or MyD88. On the other hand, when RAW 264.7 cells were stimulated with LPS, both 
TLR4 and MyD88 showed, as expected, activation and co-localisation. Interestingly, 
when cells were stimulated with LPS and post-incubated with V antigen our results 
show that the first two post-incubation periods there is still activation and co-localisation 
of both TLR4 and MyD88, but by the 4 and 6 post-incubation time-point, TLR4 and 
MyD88 co-localisation seems to be inhibited. 
Our results show that there is an influx of V antigen right from the 10 minute mark. 
Additionally, confocal microscopy was also used in order to test V antigen 
colocalisation with TLR4, NLRP3 and NLRP12 over a 2 hour period. It seems that V 
antigen is co-localising with NLRP3 and NLRP12 straight from within 10 minutes of 
stimulation and throughout the 2 hours. Similarly, but to a lesser extent, V antigen does 
co-localise with TLR4.  
Signalling molecules, such as MyD88, IRF3 and IRF7 were also tested to elucidate 
whether or not there is an association with V antigen. Our results show that both 
MyD88 and IRFs co-localised with V antigen, demonstrating that not only V antigen 
interacts with the dependent (MyD88) but also independent (IRF3 and IRF7) pathways. 
Caspase-1 also seems to interact with V antigen, but not excessively. 
Finally, cells were incubated with V antigen and labelled for EEA1, a protein within the 
early endosomes. Our results show that V antigen associates with EEA1, which shows 
that it might be concentrated within endosomes. 
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3.6. Yersinia pestis V antigen as a therapeutic intervention for sepsis 
Sepsis is the leading cause for all hospitalised patients and the leading cause in death 
in non-coronary intense care units (ICUs). It also remains an important cause of 
childhood morbidity and mortality (Alberti et al., 2003, Martin et al., 2003). Despite the 
availability of potent antibiotics to which the bacteria are highly sensitive, the overall 
mortality rate is higher than 30%. 
It is now widely accepted that the over-reaction of the host occurs at the level of the 
innate immune system and is directly linked to the recognition of bacterial cell wall 
components, such as lipopolysaccharide (LPS) from Gram-negative bacteria. On entry 
to the bloodstream, bacteria and their products (principally LPS) trigger an intense 
inflammatory process which results in a loss of regulation of the innate immune system. 
This loss of regulation or excessive stimulation of innate immunity can lead to a 
dangerous and often fatal symptoms. Septic shock is the purest example of this 
deregulation, where an overreaction of the host innate immune system lead to harmful 
symptoms. The search to pinpoint molecules that are able to modulate the innate 
immune responses is decisive in the successful development of a therapeutic 
intervention for sepsis. 
As already mentioned, currently therapy is limited to anti-infectives and supportive 
care. These approaches only give the body time to recover, but do not treat the cause 
of the problem. Our group has been working in trying to identify possible inhibitors of 
the “sensing apparatus” in order to dampen the host’s inflammatory response. In this 
study we tested the effects of the virulence factor from a bacterium, Yersinia pestis V 
antigen (LcrV) on LPS-induced responses. V antigen is a multifunctional protein that 
has been shown to have immunomodulatory features (Derewenda et al., 2004, Fields 
et al., 1999, Leary et al., 1995, Pettersson et al., 1999). Y. pestis, the causative agent 
of the three main plague pandemics has been responsible for over 200 million deaths. 
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The bacterium has been so successful because it encodes several virulence factors, 
one of which is V antigen. In this part of the study, we investigated whether this protein 
was able to inhibit LPS responses in vivo using a mouse model of sepsis. 
3.6.1. Determination of LPS concentration needed to induce septic shock 
In order to determine the optimum concentration of LPS that is needed to induce septic 
shock, male CD-1 out-bred mice (6-8 weeks) were randomly grouped (10 mice per 
group) and injected by intraperitoneal (i.p.) (Section 2.13.2) injection with different 
concentrations (50, 60, 70 and 80 mg/Kg) of E. coli LPS using a sterile 1ml syringe (BD 
PlastipakTM) with a 25 GA1 0.5x25mm needle (BD MicrolanceTM 3). Since our mouse 
model of sepsis takes place over 72 hours, the suitability of each LPS concentration 
was determined by its ability to induce septic shock and death with 24 hours from LPS 
administration. 
LPS-induced death was observed for LPS of 60, 70 and 80mg/Kg. When 50mg/Kg was 
administered 100% survival at 24 hours was recorded. Our data showed that 60mg/Kg 
of LPS was sufficient in order to induce septic shock and death by 24 hours (Figure 
3.58), thus it was decided to use this concentration in all future experiments.  
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Figure 3.58: Determination of LPS concentration needed to induce septic shock. Male CD-1 
mice (6-8 weeks) were randomly grouped (10 mice per group) and injected intraperitoneal (i.p.) 
injection with different concentrations (50, 60, 70, 80mg/Kg) of E. coli LPS. Mortality was 
determined over a 72 period. Data points are from three independent experiments. 
 
3.6.2. Determination of optimal V antigen concentration  
In order to determine the optimum concentration of V antigen that is needed to protect 
mice from LPS-induced septic shock, male CD-1 out-bred mice (6-8 weeks) were 
randomly grouped (10 mice per group) and injected by intraperitoneal (i.p.) (Section 
2.13.2) injection with different concentrations (500µg/Kg and 1mg/Kg) of V antigen 1 
hour after LPS administration. A sterile 1ml syringe (BD PlastipakTM) with a 25 GA1 
0.5x25mm needle (BD MicrolanceTM 3) was used. Since our mouse model of sepsis 
takes place over 72 hours, the suitability of each V antigen concentration was 
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determined by its ability to protect mice from septic shock and death with 24 hours from 
LPS administration. 
Protection from LPS-induced death was observed for V antigen of 500µg/Kg. Our data 
showed that 500µg/Kg of V antigen was sufficient in order to protect mice from LPS-
induced septic shock and death by 24 hours (Figure 3.59), thus it was decided to use 
this concentration in all future experiments.  
 
 
 
 
 
 
 
Figure 3.59: Determination of V antigen concentration needed to protect mice from LPS-
induced septic shock. Male CD-1 mice (6-8 weeks) were randomly grouped (10 mice per group) 
and injected intraperitoneal (i.p.) injection with different concentrations (500µg/Kg and 1mg/Kg) 
of V antigen 1 hour after LPS stimualtion. Mortality was determined over a 72 period. Data 
points are from three independent experiments. 
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3.6.3. Pre-treatment with V antigen improves survival in response to LPS 
In order to determine whether V antigen is able to protect the mice if they are pre-
treated with V antigen prior to LPS administration, in vivo experiments were employed. 
For these studies, male CD-1 out-bred mice (6-8 weeks) were randomly grouped (10 
mice per group) and injected by intraperitoneal (i.p.) (Section 2.13.2) injection with 
different 60mg/Kg of E. coli LPS, which was previously shown to be sufficient to induce 
shock within 24 hours. Improved survival of animals and inhibition of cytokines 
secretion was used in order to determine efficacy. It was shown that V antigen was 
able to improve survival up to 72.5% when administered 1 hour to LPS administration 
(Figure 3.60). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.60: Pre-treatment with V antigen improves survival in response to LPS. Male CD-1 
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(i.p.) injection with V antigen 0.5mg/Kg 1 hour prior to 60mg/Kg E. coli LPS administration. 
Survival was determined over a 72 period. Data points are from three independent experiments. 
 
3.6.4. Pre-treatment with V antigen inhibits inflammatory responses in 
vivo 
Blood (250µl) was collected at time-points 0, 2, 4, 6, 8 and 12 hours from the tail vain of 
the mice. Inflammatory cytokine levels, of TNF and IL-1β, in the serum were 
determined using a cytokine bead array (CBA) (Becton Dickinson). It was shown that 
LPS induced an inflammatory response, reaching its highest at 2 hours following LPS 
administration (Figure 3.61). Pre-treatment of mice with 0.5mg/Kg V antigen 1 hour 
prior to the LPS administration revealed that it almost halved the amount of TNF 
(Figure 3.61, top) as well as IL-1β (Figure 61, bottom). 
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Figure 3.61: Analysis of inflammatory parameters during fatal sepsis. Male CD-1 mice (6-8 
weeks) were randomly grouped (10 mice per group) and injected intraperitoneal (i.p.) injection 
with V antigen 0.5mg/Kg 1 hour prior to 60mg/Kg E. coli LPS administration. 250µl of tail vein 
blood were taken from CD-1 mice at 0, 2, 4, 6, 8 and 12 hours. The level of TNF (top) and IL-1β 
(bottom) in the serum was determined using a cytokine bead array (CBA) system obtained from 
Becton Dickinson. Data points are from three independent experiments. 
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3.6.5. Post-treatment with V antigen improves survival in response to LPS 
If V antigen is to be used as a therapeutic intervention, it would be administered after 
the bacterial infection has presented itself. Therefore, in order to determine whether V 
antigen is able to protect the mice following LPS administration in vivo experiments 
were employed. For these studies, male CD-1 out-bred mice (6-8 weeks) were 
randomly grouped (10 mice per group) and injected by intraperitoneal (i.p.) (Section 
2.13.2) injection with different 60mg/Kg of E. coli LPS, which was previously shown to 
be sufficient to induce shock within 24 hours. V antigen (0.5 mg/Kg) was administered 
by i.p. injection at different time points (1, 2, 4 and 6 hours) following LPS 
administration. Improved survival of animals and inhibition of cytokine secretion was 
used in order to determine efficacy. It was shown that V antigen was able to improve 
survival up to 80% even when treatment was postponed for up to 6 hours (Figure 3.62). 
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Figure 3.62: Post-treatment with V antigen improves survival in response to LPS. Male CD-1 
mice (6-8 weeks) were randomly grouped (10 mice per group) and injected via intraperitoneal 
(i.p.) injection with V antigen 0.5mg/Kg at different time points (1, 2, 4 and 6 hours) following 
60mg/Kg E. coli LPS administration. Survival was determined over a 72 period. Data points are 
from three independent experiments. 
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3.6.6. Post-treatment with V antigen inhibits inflammatory responses in 
vivo 
In order for V antigen to be used therapeutically for the treatment of sepsis, it has to 
show efficacy when administered after LPS treatment. In order to test the efficacy of 
LcrV in treating sepsis following LPS administration, Blood (250µl) was collected at 
time-points 0, 2, 4, 6, 8 and 12 hours from the tail vain of the mice. Inflammatory 
cytokine levels, of TNF and IL-1β, in the serum were determined using a cytokine bead 
array (CBA) (Becton Dickinson). It was shown V antigen was able to able to inhibit 
inflammatory responses even if the mice were treated 6 hours following LPS treatment 
(Figure 3.63). In particular it was shown to be more effective when administered 4-6 
hours after LPS treatment, where the TNF (Figure 3.63, top) and IL-1β (Figure 3.63, 
bottom) levels were reduced by almost 80% when compared to the mice treated with 
LPS alone. 
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Figure 3.63: Analysis of inflammatory parameters during fatal sepsis. Male CD-1 mice (6-8 
weeks) were randomly grouped (10 mice per group) and injected intraperitoneal (i.p.) injection 
with V antigen 0.5mg/Kg 1 hour following to 60mg/Kg E. coli LPS administration. 250µl of tail 
vein blood were taken from CD-1 mice at 0, 2, 4, 6, 8 and 12 hours. The level of TNF (top) and 
IL-1β (bottom) in the serum was determined using a cytokine bead array (CBA) system obtained 
from Becton Dickinson. Data points are from three independent experiments. 
 
3.6.7. Conclusion 
Sepsis is an area of unmet clinical need and thus there are very few new products that 
are reaching the market. At the moment there is no treatment for the disease, except 
antibiotics, which can kill the bacterium but do not neutralise its LPS and the only new 
product that has been licensed in the last few years in order to reduce mortality in 
severe sepsis is recombinant activated Protein C or Xigris – which targets the 
coagulation cascade and has since been withdrawn from the market for having low 
efficacy as well as multiple side-effects. 
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In this study we decided to test the efficacy of V antigen treatment both as a 
prophylactic intervention as well as a therapeutic treatment for sepsis. We have utilized 
a mouse model of sepsis where we induce death by LPS. When we tested V antigen’s 
prophylactic properties by pre-incubating the mice with 0.5 mg/animal we found that V 
antigen could improve survival by 70% and reduce pro-inflammatory cytokines TNF-a 
and IL-1β by almost half the amount.  
Most importantly when we tested V antigen’s therapeutic potential, we treated animals 
at 2, 4, 6 and 8 hour post administration of LPS. V antigen was shown to dramatically 
increase the survival of the mice to 80% even when they were treated 6 hours post 
infection. Interestingly it was shown that the longer the treatment was postponed the 
better, as the 4 and 6 h post-treatment gave us the best survival rates.  
As expected the pro-inflammatory response was also significantly decreased, as 
shown by the levels of TNF and IL-1β observed. 
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Discussion 
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Sepsis is a clinical disorder that is an often-fatal systemic inflammatory response to 
bacterial infection. This medical condition is paradoxical, seeing as the system that has 
evolved to protect the host against microbial infection is fundamentally responsible for 
injury and damage to the host. Bacterial products, like lipopolysaccharide (LPS), which 
are recognised by the host lead to an oversecretion of inflammatory cytokines that 
have a detrimental effect to the host. 
Patients with severe sepsis and septic shock manifest striking heterogeneity including 
age, underlying diseases, diverse microbial etiology, local infection site and genetic 
makeup. This problem remains a major hurdle which makes the discovery of new 
therapies for severe sepsis and septic shock especially difficult. Over the past 4 
decades, the outcome for septic patients has improved significantly, and yet this 
improvement is almost solely due to advances in the supportive care given to critically 
ill patients and the use of antimicrobial agents (Suffredini and Munford, 2011). Over the 
years, great effort and expenditure has gone in order to develop new treatments to 
reverse the harmful and often terminal effects seen on septic patients. With the 
exception of a short-lived drug, no new treatments have been developed. 
Sepsis is not only the leading cause of death in non-coronary intensive care units 
(ICUs) but also one of the most common causes of morbidity and mortality for all 
hospitalised patients (Alberti et al., 2003, Martin et al., 2003). Seen that there is no 
current therapy for sepsis and this condition has a mortality rate higher than 30% and is 
responsible for more than 750,000 and 30,000 annual cases in USA and England, 
Wales and Northern Ireland, respectively, it is crucial to identify molecules that are able 
to modulate the host response to bacterial infection (Angus et al., 2001, Harrison et al., 
2006, Martin et al., 2003, Padkin et al., 2003).  
Yersinia pestis, the aetiological agent of the plague, is a bacterium responsible for 
hundreds of millions of deaths throughout history. It invades the mammalian body, 
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often through a flea bite, and proceeds to create a fulminating disease that, more often 
than not, tends to kill the host within a matter of days. It is so successful because Y. 
pestis possesses several plasmids that encode virulence factors that modulate the host 
immune system. V antigen, also known as LcrV, is one of these virulence factors and it 
is encoded by the lcrV gene in the pCD1/pYV plasmid. This 326-residue, 37kDa 
soluble protein has many functions, from being critical for gene regulation within the 
bacterium and for translocating other virulence factors (Yops) into host cells 
(Derewenda et al., 2004, Fields et al., 1999, Pettersson et al., 1999), to having 
immunomodulatory properties of its own, such as inhibiting the production TNF-α and 
IFN-γ inflammatory cytokines (Leary et al., 1995). 
In this study, the effect that Yersinia pestis V antigen and V antigen fractions have on 
the innate immune system was investigated, with emphasis on PRRs, signalling 
pathways and ultimately cytokine secretion.  
The innate immune system is the host’s quick response mechanism against invasive 
pathogens. It does so through many mechanisms but the most intricate function of the 
innate immune system involves pattern recognition receptors (PRRs), which are able to 
recognise certain pathogen-associated molecular patterns (PAMPs) that are present on 
all pathogens. Toll-like receptors (TLRs) and NOD-like receptors (NLRs) are part of the 
PRR family and are responsible for the detection of a range of PAMPs, such as cell 
wall components like lipopolysaccharide (LPS) from Gram-negative bacteria to viral 
DNA or single stranded RNA. PAMP recognition through PRRs causes the activation of 
intracellular signalling pathways that ultimately cause the release of inflammatory 
mediators such as TNF, IL-1β and IL-6 (Kawai and Akira, 2011, Kumar et al., 2011). 
The field of TLR research is relatively new with the first human Toll being discovered in 
1997 by Medzhitov and Janeway. Our knowledge of the role that PRRs have in 
pathogen recognition and disease has been expanding as throughout the years, 
making them exciting targets for new therapeutics.  
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PRR activation typically triggers a signalling cascade that results in differences in gene 
expression and secretion of inflammatory mediators, such as cytokines, to promote the 
appropriate response against the detected pathogens. Some pathogens, however, 
such as Yersinia pestis, are capable of subverting these mechanisms for their own 
survival and proliferation. This study was interested in the ability that Y. pestis V 
antigen and V antigen fractions have in modulating the innate immune system. 
In order to determine the effects of V antigen and V antigen fractions on the innate 
immune responses, initially the recombinant proteins were generated. The recombinant 
LcrV plasmids (pVG110) with a glutathione S-transferase (GST) were kindly provided 
by Professor Richard Titball (Chemical and Biological Defence Establishment, Porton 
Down, Salisbury, UK) and transformed into E. coli BL21 cells as previously described 
by (Carr et al., 1999). In order to produce V antigen fractions (V1, V3, V4 and V5), the 
recombinant protein plasmid (pGEX6P-1), again with a glutathione S-transferase (GST) 
tag, were kindly provided by Dr. Claire Vernazza (Defence Science and Technology 
Laboratory, Porton Down, Salisbury, UK). The plasmids were transformed into E. coli 
BL21 cells as previously described by (Carr et al., 1999). 
After purification using affinity chromatography, both V antigen and V antigen fractions 
were passed through a Profos Endotrap® blue 10 (Hycult Biotechnology) to ensure 
there was no LPS in the final solution. This was verified using the Limulus Amebocyte 
Lysate (LAL) assay), which did not detect any traces of LPS in the purified 
preparations. 
In the present study we investigated the effects of V antigen have on PRR expression, 
signalling pathways and cytokine release in THP-1 and RAW 264.7 cells. 
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4.1. Effects of V antigen in innate immune responses 
Having shown that recombinant V antigen was free of contaminants, its effect in innate 
immune responses was investigated. This study utilised human monocytic leukemia 
(THP-1) and mouse leukaemic monocyte macrophage (RAW 264.7) cells to elucidate 
PRR expression, signalling pathways and inflammatory cytokine release in response to 
LPS, and if V antigen was able to modulate the response. Initially we investigated PRR 
expression in response to LPS via indirect immunofluorescence and flow cytometry. It 
was shown that LPS caused up-regulation of TLR2, TLR4, TLR6, TLR7, TLR9, CD14, 
NOD1, NOD2, NLRP3 and NLRP12 expression on THP-1 cells. Increased TLR1 and 
NLRP1 expression was not observed in any stimulation. Augmented TLR, CD14, NOD 
and NLRP expression has previously been observed in response to LPS (Akira et al., 
2006, An et al., 2002, Kawai and Akira, 2009, Mao et al., 2013, Raetz and Whitfield, 
2002, Takahashi et al., 2006). Results from RAW 264.7 cell line show that LPS caused 
up-regulation in expression of TLR1, TLR2, TLR4, TLR6, TLR7, TLR9, CD14, NOD1, 
NOD2, NLRP3 and NLRP12. 
When investigating what effect V antigen had on PRR expression in THP-1 and RAW 
264.7 cells it was found that V antigen was able to modulate the expression of PRRs in 
both cell types. In particular, V antigen seemed to induce a general downregulation of 
all PRRs tested in RAW 264.7 cells. In the case of THP-1 cells V antigen seemed to 
downregulate most PRRs with the exception of TLR9, CD14, NOD2, NLRP1 and 
NLRP3, where an up-regulation was observed.  
The current findings are in contrast to the studies of Sharma et al. (Sharma et al., 2005, 
Sharma et al., 2004) and Reithmeier-Rost et al. (2004) where they observed no 
difference in TLR4 and an up-regulation of TLR2 and TLR6 in the former and no 
difference in TLR2 and TLR4 expression following V antigen stimulation in the later 
study. Differences observed between the different studies could be due to the fact that 
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the Sharma et al. study was performed in Balb/c mice peritoneal macrophages 
whereas this study was performed in human monocytic leukemia (THP-1) and mouse 
leukaemic monocyte macrophage (RAW 264.7) and they were observing effects after 
12 hour stimulation. In the case of Reithmeier-Rost et al. study, the strain of Yersinia 
was completely different, as they used Y. enterocolitica O8 rLcrV, whereas in this study 
Y. pestis LcrV was used. It has been previously shown that LcrV from Y. enterocolitica 
and LcrV from Y. pestis can have different effects from each other (Abramov et al., 
2007, Reithmeier-Rost et al., 2004, Sing et al., 2002a). 
Having shown that stimulating cells solely with V antigen modulates PRR expression in 
both cell types, the next step was to investigate whether pre- or post-incubating with V 
antigen can alter the innate immune response of THP-1 and RAW 264.7 cells in 
response to LPS. 
It was found that pre-incubating THP-1 cells with V antigen followed by LPS stimulation 
resulted in a up-regulation of TLR2, TLR6, TLR7, CD14, NOD1, NOD2, NLRP1, 
NLRP3, NLRP12 expression. There was no change in TLR4 and a small 
downregulation in TLR9 expression. On the contrary, when RAW 264.7 cells were pre-
incubated with V antigen TLR1, TLR2, TLR4, TLR6, TLR7, TLR9, CD14 and NOD1 
expression decreased. There was no change in NLRP1 and NOD2 expression where 
as a slight increase in NLRP3 and NLRP12 was seen.  
When THP-1 cells were post-incubated with V antigen there was a reduction on TLR2, 
TLR4, TLR6 and TLR7 expression. On the other hand, TLR9, CD14, NOD1, NOD2, 
NLRP1, NLRP3 and NLRP12 expression levels seem to increase. Our results show a 
different outcome in PRR expression levels when RAW 264.7 cells are post-incubated 
with V antigen - every PRR investigated in this study seem to reduce its expression in 
response to V antigen. This disparity between the two cell types might be because 
monocytes (THP-1 cells) are released into the circulation where they migrate into most 
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tissues, due to growth factors, inflammatory cytokines and microbial products, they 
differentiate into mature macrophages (RAW 264.7 cells). The main function of 
monocytes is to replenish the levels of circulating macrophages, whereas mature 
macrophages have a more active role in immune activities such as phagocytosis and 
immune suppression (Murray and Wynn, 2011, Shi and Pamer, 2011). Perhaps 
Yersinia pestis V antigen has evolved to immunosuppress certain cell types such as 
macrophages rather than monocytes, which may pose a more direct threat to Y. pestis 
survival and proliferation.  
Having shown the effect of V antigen on PRR expression, the next step was to 
determine how this protein influenced NF-κB and caspase-1 activation in response to 
LPS. This was assayed by either pre- or post-incubating with V antigen and measuring 
the intracellular concentration of phosphorylated IκB and caspase p-10. Our results in 
THP-1 cells show that V antigen inhibits phosphorylation of IκB, therefore NF-κB. 
Additionally our results show a reduction in caspase-1 p-10, thus caspase-1 activity. In 
RAW 264.7 cells, our results demonstrated that V antigen reduces both 
phosphorylation of IκB and caspase-1 p-10, therefore NF-κB and caspase-1 activity, 
respectively. These findings are in agreement with the study of Sodhi et al. (2004), 
where they have also observed NF-κB inactivation in response to V antigen. 
Given that V antigen was found to modulate the expression of PRRs and the activation 
of both NF-κB and caspase-1 activation, the next step in this study was to examine the 
release of cytokines, the inflammatory mediators, caused by LPS and whether or not V 
antigen was able to modulate their secretion. Inflammatory cytokines were measured in 
the cell supernatant using flow cytometry coupled with cytokine bead array system. 
Cytokine analysis of THP-1 and RAW cells in response to LPS gave notable increase 
in TNF, IL-6, IL-1β and IL-10 in comparison to unstimulated cells. When it was 
investigated whether V antigen was able to trigger any cytokine secretion on its own, 
our results showed no marked difference in cytokine secretion levels. 
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Pre- or post-incubating V antigen in response to LPS was also tested. It was shown 
that in both THP-1 and RAW 264.7 cells pre-incubation with V had little or no effect on 
the release of cytokines.  
When THP-1 cells were post-incubated with V antigen TNF and IL-1β levels seemed to 
be completely inhibited. IL-6 secretion seems to be inhibited in the first 3 post-
incubation time-points and an acute increase occurred at the 6 post-incubation hour. 
This might be due to the fact that V antigen is no longer effective after 6 hours of LPS 
stimulation, or more specifically that it is not able to combat the huge amount of IL-6 
that was accumulated 6 hours after LPS challenge. IL-10 cytokine production seemed 
to be up-regulated in response to V antigen. It increased progressively through the 
time-points reaching a maximum at the 6 hour post-incubation mark. This finding is in 
agreement with the study of Reithmeier-Rost et al. (2004) and (Sharma et al., 2005), 
suggesting that V antigen is able to trigger anti-inflammatory cytokine production and 
thus immunosuppress the innate immune response. 
Our RAW 264.7 cells show that pre- or post-incubating with V antigen resulted in a 
downregulation of TNF, IL-6, IL-1β and IL-10 in comparison with cells stimulated with 
LPS alone. 
Overall our data suggests that V antigen is able to modulate PRR expression as well 
as inhibit signalling cascades and pro-inflammatory cytokine secretion in RAW 264.7 
cells. When compared to THP-1 cells the results are similar, but rather more 
pronounced inhibition is seen in RAW 264.7 cells. 
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4.2. Effects of V antigen fragments in innate immune responses 
Previous studies have shown that, not only the entire, but also small regions of Yersinia 
pestis V antigen can provide protection against the plague. It has been suggested that 
Y. pestis V antigen contains a number of protective epitopes that are located in a 
central region between amino acids (a.a.) 135 and 275 (Hill et al., 1997). In this study, 
out of the six fragments that possibly could confer protection, proposed by Vernazza et 
al. (2009), four were chosen – V1, V3, V4 and V5. V1 was selected because it had 
been previously shown to be protective against plague, V3 due to a N-terminal deletion 
whereas V4 and V5 a C-terminal deletion type. In order to determine the efficacy of the 
different V antigen fractions, NF-κB and caspase-1 activation and the cytokine 
secretion was investigated.  
Initially, we tested if RAW 264.7 cells would activate NF-κB and caspase-1 when 
stimulated with LPS. Our results showed that both cell types do activate both NF-κB 
and caspase-1. 
Once it was established that LPS was able to trigger the NF-κB signalling cascade and 
caspase-1 p-10, whether the different V antigen fractions were able to modulate this 
response was investigated. Our results revealed in RAW 264.7 cells V1, V4 and V5 
inhibited NF-κB and caspase-1 activation over time. V3 fraction was able to decrease 
NF-κB and caspase-1 activation, but not to the same extent as the other fractions. 
The next step was to evaluate the inflammatory cytokine release and if the different 
fractions had an effect in the levels secreted by RAW 264.7 cells. Cytokine analysis of 
RAW 264.7 cells in response to LPS gave notable increase in TNF, IL-6, IL-1β and IL-
10 in comparison to unstimulated cells. Our results show V1, V3, V4 and V5 can inhibit 
the production of TNF, IL-6, IL-1β and IL-10 inflammatory cytokines. The highest 
reduction of cytokine release was seen with V1 followed by V4, V5 and last V3, 
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therefore the functional domain of V antigen responsible for the effects that we have 
observed lies within the amino acids 135-275. 
Out of the fragments analysed, V3 seemed to have the least immunosuppressive 
properties. This might suggest that residues within a.a. 135-175 are important for the 
stability of the epitope, which results in a lower immunomodulation capability. 
 
 
Figure 4.1: Schematic representation of V antigen and its fragments V1, V2, V3, V4, V5 and 
V6. In this study, the fragments selected were V1 (a.a. 135-275), V3 (a.a. 175-275), V4 (a.a. 
135-268) and V5 (135-262). a.a. 135-175 (in red) might be important for the stability of the 
epitope. 
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4.3. Intracellular trafficking and targeting of exogenous V antigen 
The innate immune system has an essential role in recognising molecular “signatures” 
of invading pathogens. It does so through a range of receptors which are tailored to 
recognise different molecular ligands. This study was concerned with the effects of V 
antigen has in the innate immune system. It is becoming apparent that the presence of 
V antigen may have the effect of altering cellular response to LPS. 
Our data has shown that V antigen interferes with PRRs, ultimately leading to a 
modified cellular response. Thus we proceeded to employ triple label confocal 
microscopy in order to image whether V antigen from Y. pestis associates with PRRs, 
signalling molecules and cellular organelles. In order to track V antigen within the cell, it 
was conjugated to a fluorescent tag – Oregon Green (OG) or FITC. 
Confocal microscopy was used in order to test the effect of V antigen on TLR4 and 
MyD88 in response to LPS.  
 It was shown that unstimulated cells and cells incubated with V antigen by itself did not 
activate TLR4 or MyD88. On the other hand, when RAW 264.7 cells were stimulated 
with LPS, both TLR4 and MyD88 showed, as expected, activation and co-localisation. 
When cells were stimulated with LPS and post-incubated with V antigen our results 
show that in the first two post-incubation periods there is still activation and co-
localisation of both TLR4 and MyD88, but by the 4 and 6 post-incubation time-point, 
TLR4 and MyD88 co-localisation seems to be inhibited. Interestingly, at the 2 hour 
post-incubation mark, MyD88 seems to cluster with each other. These results might 
suggested that V antigen is interfering with the normal function of MyD88, which would 
result in an interference with subsequent downstream signalling.  
Additionally, confocal microscopy was also used in order to test V antigen 
colocalisation with TLR4, NLRP3 and NLRP12. Our results show that that V antigen is 
co-localising with NLRP3 and NLRP12 immediately within 10 minutes of stimulation 
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and throughout the 2 hours. These results seem to be in agreement with Vladimer et al. 
(2012) where both NLRP3 and NLRP12 were linked to the recognition of Yersinia 
pestis. This co-localisation might result in the prevention of the assembly of the 
inflammasome complex, resulting in the inhibition of IL-1β seen in this study. 
The co-localisation of MyD88, IRF3 and IRF7 with V antigen were also investigated.. 
Our results show that both MyD88 and IRFs co-localised with V antigen, demonstrating 
that V antigen not only interacts with the dependent (MyD88) but also independent 
(IRF3 and IRF7) pathways. This might be linked to the fact that V antigen might be 
meddling with both dependent and independent pathways, resulting in the inhibition of 
inflammatory cytokines as seen above. 
Finally, cells were incubated with V antigen and labelled for EEA1, a protein within the 
early endosomes. Our results show that V antigen associates with EEA1, which shows 
that it might be concentrated within endosomes. This might be linked to the 
internalization route that V antigen follows when it is internalized within the cell. 
4.4. Yersinia pestis V antigen as a therapeutic intervention for sepsis 
Throughout this study it has been shown that V antigen is able to modulate the innate 
immune responses in response to LPS. In particular, V antigen has shown to reduce 
dramatically the main pro-inflammatory cytokines – TNF and IL-1β. It is widely 
accepted that the onset of sepsis results from an over-reaction of the host that occurs 
at the level of the innate immune system and is directly linked to the recognition of 
bacterial cell wall components, such as lipopolysaccharide (LPS) from Gram-negative 
bacteria. Thus the reduction in this excessive production of pro-inflammatory cytokines 
might be the key to a possible therapeutic intervention. 
It is hypothesised that the modulation of this immune response could have a 
therapeutic potential. We went on to explore the blocking of the endogenous and 
microbial sensing apparatus in vivo to determine the beneficial effects of V antigen as a 
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prophylactic and also therapeutic intervention in the reversing of the detrimental 
outcomes septic patients portray. A male CD-1 mouse model of sepsis was used to 
test whether or not V antigen is able to prevent the over-expression of pro-inflammatory 
cytokines, as a result of sepsis, and ultimately survival.  
Intraperitoneal (i.p.) injection of V antigen was found to be very effective at decreasing 
mortality in CD-1 male mice. Mice pre-treated with V antigen improved survival by 70% 
over the 72 hours. V antigen was most effective at preventing septic shock when mice 
were post-treated with the protein, where 80% survival was observed at 72 hours. 
Interestingly it was shown that the longer the treatment was postponed the better, as 
the 4 and 6 h post-treatment gave us the best survival rates, this might be due to the 
fact that V antigen has more time to have its full immunomodulatory effect. The blood 
concentrations of TNF and IL-1β were all reduced after mice were pre- or post-treated 
with V antigen in comparison to those that were not. A possible mechanism for the 
modulatory effect of V antigen on inflammatory response both in vitro and in vivo might 
be on its ability to disrupt the MyD88 adaptor molecule disruption, resulting on a direct 
interference of the downstream signalling. 
Adult CD1 outbred mice have been extensively in order to study the development of 
early septic-shock syndrome that causes high mortality (Doi et al., 2009, Dominguez-
Punaro Mde et al., 2008, Rodriguez et al., 2009, Wang et al., 2003, Zager et al., 2003). 
Several different interventions have been tested on the CD1 sepsis model in order to 
assess whether they can improve survival or tissue injury, but none of the interventions 
have demonstrated the extent of improved survival as well as the inhibition of cytokines 
that we have shown (in the same model). Interventions that have been tried include 
treatment with anti-hypercholestromic agents, such as Cerivastatin (Ando et al., 2000), 
blockade of receptors such as A2B adenosine receptor blockade (Belikoff et al., 2011), 
CXCR2 (Ness et al., 2003) or high mobility group box protein-1 (HMGB1) 
(Leelahavanichkul et al., 2011) as well as using Androstenediol (androst-5-ene-
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3β,17βdiol; 5-AED), a natural adrenal steroid (Nicoletti et al., 2010) – none of these 
interventions showed the promise that V antigen has shown with almost 80% 
improvement in survival and almost complete inhibition of pro-inflammatory cytokines. 
These findings are very exciting, since they demonstrate that V antigen could be used 
effectively as a prophylactic intervention against sepsis and other inflammatory 
conditions, but most importantly it can be used in the future as a therapeutic 
intervention for the cytokine storm observed in patients with sepsis. 
4.5. Concluding remarks 
Sepsis is a medical condition that stems from a multi-system disorder resulting in a loss 
of homeostasis which in turn results in multi-organ failure and a high chance of death. It 
is an area of unmet clinical need and thus there are very few new products that are 
reaching the market. It is imperative to seek out new therapeutic interventions in order 
to modify this severe outcome.  
V antigen can clearly modulate the innate immune response. Throughout this study we 
have shown the capability of this protein to modulate PRR expression, signalling 
pathways, cytokine secretion and in vivo survival. 
Our data show for the first time that V antigen can inhibit the production of TNF and IL-
1β which are crucial on the onset of sepsis. Of a greater magnitude, our in vivo data 
show an impressive 80% reduction in mortality when mice are treated with V antigen. 
This protein should unquestionably be further investigated as a possible therapeutic 
intervention for sepsis and future studies should focus on testing not only the whole V 
antigen protein, but peptides encoding the functional domain of V as a therapeutic 
intervention not only for sepsis but for other inflammatory conditions as well. 
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